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Abstract
Claspin is a large, acidic, DNA binding protein required for the ATR mediated
activation of Chk1 in response to DNA replication stress. Upon checkpoint
activation Claspin is phosphorylated which allows binding to Chk1. This binding
in turn promotes the phosphorylation and activation of Chk1 by ATR. Although
these findings have led to the designation of Claspin as a mediator protein in the
activation of Chk1, the broader biological functions of Claspin have not been
extensively explored at the cellular level, in part due to the lack of a genetically
tractable system in which to study Claspin function.
The purpose of this study was to use reverse genetics in order to generate a
Claspin knock-out cell line with which study Claspin function at the cellular
level. This was to be achieved by exploiting the recombinogenic vertebrate
DT40 cell line, a pre B-cell line of chicken origin. The chicken homologue of
Claspin was successfully isolated and characterised. The chicken Claspin
orthologue shares 56% identity with human Claspin and the overall domain
structure of Claspin appears to be conserved based on sequence comparison.
This information facilitated the construction of gene targeting vectors to disrupt
Claspin expression in the DT40 cell line. One allele of Claspin was successfully
targeted. Despite multiple attempts at disrupting the remaining allele
homozygous Claspin knock-out cells were not obtained. This strongly indicates
that Claspin is essential for the viability of DT40 cells. In order to circumvent
this lethality, efforts were made to conditionally express Claspin in the
hemizygous background to facilitate the generation of a conditional knock-out
cell line. These efforts proved unsuccessful.
Other studies using a polyclonal antibody raised against Claspin investigated
phosphorylation of the protein under various stress conditions. Data is
presented which shows that phosphorylation of Claspin in response to replication
stress is dependent on Chk1 kinase activity. However results from an in vitro
kinase assay suggest that Chk1 itself does not directly phosphorylate Claspin. In
addition it is also shown that Claspin is phosphorylated following inhibition of
protein synthesis. Using specific kinase inhibitors against p38, JNK and mTOR,
protein kinases known to be activated during protein synthesis inhibition, theiii
involvement of these kinases in mediating this response was ruled out. The
significance of this observation is yet to be determined.
Overall the work presented here provides evidence that a conditional DT40
knock-out cell line will be a valuable tool in revealing novel functions of Claspin
once a successful rescue of lethality is achieved.
Keywords: Claspin; Chk1; ATR; DT40 knock-out; Phosphorylation; Gene
targeting; DNA Replication; Protein synthesis.iv
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1.1. The DNA Damage response
Damaged lipids, proteins and RNA can be degraded and re-synthesised. However
damage to DNA is more serious. The information required to re-synthesise RNA,
proteins and indirectly lipids is contained within DNA and if this information gets
corrupted, through the introduction of mutations for example, it can drastically
affect the normal functioning of the cell. Therefore due to the critical
importance of protecting DNA from mutation multiple pathways have evolved in
order to prevent damage to the DNA or to sense when the DNA is damaged and
then signal this to both the cell cycle machinery and to the DNA repair
machinery. These processes are described below.
1.1.1. DNA Damage sensing and signalling
DNA damage signalling encompasses a complex set of co-ordinated events that
occur upon damage to the DNA, replication stress and in response to shortened
telomeres. Two kinases play a central role in this process; ATM and ATR
(Abraham, 2001). Classically these kinases were thought to be activated
following DNA double strand breaks and replication stress respectively, but it has
now become clear that there is considerable cross talk between the two
pathways as illustrated in Figure 1.1 (Cuadrado et al, 2006; Yoo et al, 2007; Yoo
et al, 2009).
ATR is activated by tracts of single stranded DNA (ssDNA) such as are found at
the replication fork if the DNA polymerase and the replicative helicase become
uncoupled. ssDNA generated through the process of DNA repair can also lead to
the activation of ATR. ssDNA rapidly becomes coated with the ssDNA binding
protein RPA and this complex recruits the ATR kinase via its binding partner
ATRIP (Ball et al, 2005; Namiki & Zou, 2006). Independently a complex with a
similar structure to PCNA, the processivity factor for DNA replication, is loaded
onto DNA by the Rad17-RFC complex. This complex is made up of the Rad9-
Rad1-Hus1 proteins. Stimulation of ATR kinase activity is brought about by the
recruitment of another factor called TopBP1. TopBP1 has been shown to contain
a domain that greatly stimulates ATR kinase activity – the ATR activation domain
(Kumagai et al, 2006). TopBP1 is recruited through binding to the Rad9 subunitConor Larkin Chapter 1 16
Figure 1.1 ATM/ATR Signalling
A) Single stranded DNA is generated at replication forks or through the process of DNA repair such
as the resection of DNA DSBs. DNA DSB’s can directly lead to the activation of ATM. B) RPA is
recruited to this single stranded DNA which in turn leads to the recruitment of ATR via its ATRIP
subunit. The Rad9-Rad1-Hus1 complex is loaded onto the DNA by the Rad17-RFC complex. C)
TopBP1 which stimulates ATR kinase activity is recruited via the Rad9 subunit of the 9-1-1
complex. ATM stimulates ATR kinase activity by phosphorylating TopBP1 which promotes the
ATR-TopBP1 interaction. Active ATR then phosphorylates its downstream targets.Conor Larkin Chapter 1 17
of the 9-1-1 complex (Lee et al, 2007). TopBP1 is phosphorylated by ATR
following replication stress and by ATM following DNA DSBs which further
promotes the ATR-TopBP1 interaction leading to enhanced activation of ATR.
The Nbs1 subunit of the MRN complex facilitates this ATM mediated
phosphorylation of TopBP1 (Yoo et al, 2009). Once activated ATR then
phosphorylates its target proteins on SQ/TQ sites in order to transmit the signal
to the downstream effector proteins. An important target of ATR is the Chk1
protein kinase. ATR phosphorylates Chk1 which increases its kinase activity
allowing it to phosphorylate its down stream targets in order to control cell
cycle progression. Claspin functions in this process by binding to Chk1 and
facilitating the phosphorylation of Chk1 by ATR (Chini & Chen, 2004; Cimprich &
Cortez, 2008; Shiotani & Zou, 2009). (See sections 1.2 and 1.3 for the discussion
on Chk1 activation and Claspin function respectively)
ATM is activated following DNA DSBs. The exact mechanism of ATM activation by
DNA damage is not yet completely understood but it is thought to require the
MRN complex, changes to the chromatin structure and post translational
modifications including phosphorylation and acetlyation (Bakkenist & Kastan,
2003; Sun et al, 2007). One model proposes that ATM exists as an inactive
homodimer which dissociates upon activation due to autophosphorylation at
S1981 to release active ATM monomers (Bakkenist & Kastan, 2003). The validity
of this model has been challenged however with the observation that mice
bearing a mutation at the equivalent mATM site behave as WT mice with no
defects in mATM activation (Daniel et al, 2008; Pellegrini et al, 2006). The down
stream targets of ATM overlap significantly with those of ATR and influence the
processes of cell cycle progression and DNA repair (Lavin & Kozlov, 2007).
In addition to the core signalling molecules described above other proteins,
which have been termed mediators or adaptors, have been implicated in the
DNA damage response. MDC1, 53BP1, MCPH1, Nbs1 and Brca1 each have
functions in ensuring optimal signalling following DNA damage. All of these
proteins contain BRCT domains which are phospho-peptide binding motifs.
Other domains present in these proteins include FHA domains (in MDC1 – binds
phospho-threonine peptides) and Tudor domains (53BP1 – binds methylated
histones). One of the earliest signalling events to occur following DNA damage is
the phosphorylation of the C-terminal tail of the variant Histone H2AX. ThisConor Larkin Chapter 1 18
serves as a molecular beacon to attract the adaptor proteins to the site of
damage leading to a concentration of DNA damage signalling and repair proteins
in nuclear foci (Mohammad & Yaffe, 2009).
1.1.2. Cell cycle checkpoints
1.1.2.1. Overview
Damaging DNA per se does not automatically result in a mutation. For example
an undetected mis-paired base within a gene will only become a mutation once
the cell passes undergoes DNA replication during S phase. In this instance one
daughter cell will inherit the correct copy of the gene where as the other cell
will get the mutated copy of the gene. Similarly gross changes at the
chromosome level only become mutations once the cell has passed through
mitosis. Such mutations can be chromosome rearrangements or even the loss of
portions of or entire chromosomes. Given the vulnerability of both S phase and
mitosis with regards to mutation of the genome it is not surprising that elaborate
mechanisms are in place to either prevent entry into or halt the progression of
these phases of the cell cycle.
1.1.2.2. G1/S
Before committing to DNA replication the cell must ensure that there is no
damage present in its DNA. Cells damaged before entry into S phase display two
responses – an immediate response through the inhibition of Cyclin dependent
kinases and a later response due to the accumulation of Cdk inhibitors e.g. p21
induced through the activation of p53. ATM is activated in G1 phase of the cell
cycle where it phosphorylates p53 leading to its stabilisation. p53 in turn
induces the transcription of p21 which inhibits Cdk’s and inhibits S phase. At the
same time but with a quicker response ATM phosphorylates Chk2 which
phosphorylates and inhibits Cdc25A also leading to an inhibition of Cyclin
dependent kinases (Bartek & Lukas, 2001).
1.1.2.3. S phase
Checkpoint responses in S phase can be broadly divided into three different
categories. Inhibition of DNA synthesis, for example through nucleotide pool
imbalance or by direct damage to the replicating DNA, leads to the activation ofConor Larkin Chapter 1 19
the Replication checkpoint which serves to protect the process of replication
itself (Bartek et al, 2004). It does this by inhibiting the activation of late firing
origins and stabilising stalled forks in order to facilitate the resumption of DNA
synthesis when the conditions are once again favourable (Branzei & Foiani, 2009;
Feijoo et al, 2001). The S-M checkpoint on the other hand prevents entry into
mitosis in the presence of incompletely replicated DNA. Much less is known
about what the molecular signal that activates the S-M checkpoint is, but it has
been speculated to arise from viable replication forks. Chk1 plays a major role
in orchestrating all of these responses (Broderick & Nasheuer, 2009; Kumagai et
al, 1998; Zachos et al, 2005).
1.1.2.4. G2-M
Prevention from entry into mitosis in the presence of damaged DNA is carried
out by the G2-M checkpoint. Through the activation of the ATM/ATR kinases the
down-stream kinase Chk1 is phosphorylated and activated leading to inhibition
of Cdk1-cyclin B. This is mediated through the phosphorylation and inhibition of
the Cdc25 phosphatases which are required to activate Cdk1-Cyclin B to allow
mitosis to proceed. Other kinases such as p38 have also been implicated in
carrying out this function. A transcriptional programme regulated by p53 and
Brca1 can also contribute to sustaining G2-M arrest (Kastan & Bartek, 2004).
1.1.2.5. Mitosis
Cells activate the Spindle Assembly checkpoint in order to prevent loss of
chromosomes during mitosis. Until all chromosomes are attached to two
microtubules from opposite poles of the cell an inhibitory signal preventing the
activation of the Anaphase promoting complex (APC), which is required to
progress through mitosis, is maintained. Once this signal is shut off the APC
becomes active leading to the degradation of key proteins, such as Cyclin B and
Separase, which facilitates mitotic exit (Tanaka & Hirota, 2009). Whether a
pathway exists that responds to DNA damage during mitosis is still unclear
(Mikhailov et al, 2002; Skoufias et al, 2004).Conor Larkin Chapter 1 20
1.1.3. DNA repair
1.1.3.1. Overview
The repair of damaged DNA and the activation of cell cycle checkpoints
following DNA damage are intimately linked and essentially interdependent
(Lazzaro et al, 2009). Many of the signals that activate the cell cycle checkpoint
machinery are generated through the repair of damaged DNA, but DNA repair is
in turn stimulated and facilitated through the activation of checkpoint signalling
(Goodarzi et al, 2008; Sorensen et al, 2005). Indeed many proteins involved in
the DNA damage response have functions in both the repair of DNA and
checkpoint signalling e.g. Brca1, MRN complex, RPA etc.
DNA damage can arise from both endogenous and exogenous factors. Within the
cell errors in replication and damage from the by products of metabolism e.g.
reactive oxygen species can lead to DNA structural aberration. External sources
of damage include UV light, ionising irradiation and environmental toxins and
mutagens. These types of damage can lead to a variety of different lesions that
include chemical modification of individual nucleotides, inter and intrastrand
crosslinks and single and double strand breaks.
To counteract the deleterious effects of damaged DNA multiple DNA repair
pathways have evolved. Some damaged DNA can be directly repaired through
the action of specialised enzymes e.g. MGMT (Verbeek et al, 2008). Other
damage can be by-passed and repaired later through the action of by-pass
polymerases (Guo et al, 2009). Other lesions if left un-repaired would have
more drastic effects on the cell for example DNA strand breaks. A brief
overview of some of the main details of these pathways follows.
1.1.3.2. Repair of DNA double strand breaks
DNA double strand breaks (DSBs) represent a particular difficulty for the cell.
Unlike with other forms of damage an un-repaired DSB can lead to the loss of a
large amount of genetic information and incorrectly repaired breaks can result
in mutations which lead to disease (Hartlerode & Scully, 2009). Double strand
breaks are repaired in two ways – either faithfully by the process of homologous
recombination (HR) or through error-prone mechanisms such as non-homologousConor Larkin Chapter 1 21
end joining (NHEJ) or micro-homology mediated end joining (MMEJ). The
proteins involved in these pathways (especially for HR and NHEJ) have been
described and much of the mechanistic detail of how they function has been
elucidated (Lieber, 2008; Sung & Klein, 2006).
Briefly the process of NHEJ simply results in the ligation of two broken DNA
ends. The double strand breaks are recognised by the Ku70/80 heterodimer
complex. This complex then serves to recruit the proteins necessary to mediate
the repair of the broken end. DNA-PKcs in complex with an endonuclease
Artemis binds to Ku.  In addition DNA polymerases λ and μ are also recruited.  
The nuclease activity of the DNA-PKcs-Artemis is stimulated by binding to Ku and
this together with the activity of the polymerases prepares the broken DNA end
for ligation. The ligation step is carried out by the XLF/Xrcc4/DNA ligase IV
complex which due to its flexible nature can re-join imperfect ends leading to
the re-formation of the phosphodiester backbone (Downs & Jackson, 2004;
Lieber, 2008). A similar but less characterised process called microhomology
mediated end joining (MMEJ) requires some resection to reveal regions of
microhomology that facilitate annealing of the broken ends and re-ligation of
the break (McVey & Lee, 2008).
Whereas non-homologous end joining often leads to mutations at the ligation
site the process of homologous recombination results in the high-fidelity repair
of DNA DSBs breaks. This process occurs in S phase and in G2 phase once a sister
chromatid, which serves as a template for repair, has been generated. In
homologous recombination the DSB is recognised by the Mre11/Rad50/Nbs1
(MRN) complex. The exonuclease activity of the Mre11 subunit and probably the
activity of other nucleases and factors (e.g. Exo1, CtIP) lead to the generation of
single stranded resected DNA. Then, through the action of the RAD52 epistasis
group of proteins, this stretch of ssDNA finds its homologous sequence in its
sister chromatid and a joint DNA structure is formed which is resolved by the
action of polymerases, helicases and nucleases to restore the original DNA
sequence (San Filippo et al, 2008).
It must be remembered however that this process does not occur on free DNA
but rather in the context of chromatin. Great advances in our understanding of
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made. Phosphorylation, methylation and ubiquitination of chromatin all play a
major role in orchestrating the recruitment of both DNA damage signalling and
repair factors to the sites of DNA damage (Lisby & Rothstein, 2009).
1.1.3.3. Nucleotide/Base Excision and Mismatch Repair
Nucleotide and Base Excision repair are required to remove bulky lesions and
damaged bases from the DNA respectively whereas mismatch repair serves to
correct mismatched bases that arise from errors in replication or by mutagenic
bases. Nucleotide excision repair recognises and repairs bulky lesions such as
pyrimidine dimers and cyclobutane adducts. These lesions are recognised and
processed by the Xeroderma pigmentosa family of proteins XPA-G and other
factors including ERCC1, TFIIH and CSA/B proteins. Nucleotide excision repair
can act globally (GG-NER) or coupled with transcription (TC-NER). In both cases
the nucleotide lesion is recognised, the double strand helix is unwound and the
damaged piece of DNA is removed. The gap is then filled in and religated (de
Laat et al, 1999). Base excision repair removes damaged bases by the action of
specific glycosylases that remove specific damaged bases e.g. UNG removes
uracil from DNA and Ogg1 removes 8-oxoguanine lesions from DNA. The resulting
AP (apurinic/apyrimidinic) site is recognised by AP endonuclease which nicks the
DNA allowing removal of the damaged nucleotides and resynthesis and ligation
by Polβ and DNA Ligase I or DNA Ligase III/Xrcc1 (Fortini et al, 2003). 
Mismatch repair corrects errors of replication if bases are incorrectly paired or if
nucleotides are deleted or inserted. This process in vertebrate cells relies on
the activity of the orthologues of the MutS and MutL found in bacteria. MutS
recognises the mismatched DNA and recruits MutL. MutL then stimulates MutS to
recruit the rest of the proteins involved in repairing the mismatch e.g. Exo1,
DNA polymerase δ/ε and DNA Ligase 1 (Jiricny, 2006). 
Overall these repair pathways serve to prevent single base pair mutations
through out the genome. Loss of these pathways is said to lead to a mutator
phenotype which can greatly increase genome instability, a process intimately
linked with cancer (Loeb et al, 2008). Indeed mutations in some of the proteins
involved in these pathways can lead to cancer predisposition syndromes.
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damage signalling resulting in impaired signalling down the cell cycle checkpoint
arm of the DNA damage response (Cejka et al, 2003; O'Brien & Brown, 2006).
1.2. Regulation of Chk1 Kinase Activity
Chk1 was first reported in the yeast Schizosaccharomyces pombe over 15 years
ago (Walworth et al, 1993). Over subsequent years it has become clear that
Chk1 plays a vital role in the response to DNA damage. It was discovered that
spChk1 could phosphorylate and activate the kinase spWee1 which in turn
phosphorylates and inactivates the mitotic CDK in pombe, spCdc2 (O'Connell et
al, 1997; Rhind et al, 1997). Simultaneously it inactivates the spCdc25
phosphatase, which is required to remove the inhibitory phosphorylation on
spCdc2 (Furnari et al, 1997). In combination, this leads to an inhibition of the
spCdc2 kinase and a halt in cell cycle progression. This same pathway appears
to be conserved in vertebrates with vertebrate Chk1 also playing the major role
in the G2-M checkpoint through the maintenance of the inhibitory
phosphorylation on Cdk1 (Lee et al, 2001; Peng et al, 1997; Sanchez et al, 1997).
In contrast with the situation in yeast however it is vertebrate Chk1 and not
Chk2 (orthologue of spCds1) that is activated during replication stress and
required to mediate S phase checkpoint responses (Feijoo et al, 2001; Zachos et
al, 2005). As for the G2-M checkpoint the S phase checkpoint may also be
enforced through the inhibition of Cyclin dependent kinases via the inhibition of
Cdc25 (Mailand et al, 2000). However it also appears that intrinsic signals,
distinct from checkpoint signalling, may also exist during S phase which prevent
replicating cells from entering mitosis (Oehler, 2008; Rao & Johnson, 1970). The
validity of this model has also been challenged recently due to the observation
that Cdk2 (the S phase Cdk) activity actually increases in S phase following DNA
damage (Bourke et al, 2009).
Given the importance of Chk1 in the response to DNA damage it is therefore not
surprising that the regulation of this kinase might be complex. Purified full-
length Chk1 from insect cells possesses intrinsic kinase activity (Jackson et al,
2000) and the kinase domain of human Chk1 is in a relatively open conformation,
potentially not requiring any additional modifications to adopt the structure of
an active kinase (Chen et al, 2000). However in the cellular context, the kinase
activity is repressed. This repression is mediated by C-terminus of the protein,Conor Larkin Chapter 1 24
as the kinase domain alone displays higher intrinsic kinase activity than the full
length protein in vitro. It is of note however that C-terminal truncations that
remove the entire regulatory domain inactivate biological functions implicating
the C-terminus in having both positive and negative inputs into Chk1 regulation
(Ng et al, 2004). Further evidence to support a ‘de-repression mechanism’
comes from the recent observation that when Chk1 is immunoprecipitated from
unstimulated cells the kinase activity of the purified Chk1 can be increased upon
washing with a stringent buffer (Walker et al, 2009). Activation of Chk1
therefore appears to occur through a mechanism that relieves repression of the
kinase domain, be that intrinsic repression by the C-terminus or by other
interacting proteins.
De-repression of Chk1 catalytic activity is achieved at least in part through the
phosphorylation by ATR of multiple SQ sites in the SQ cluster domain between
the kinase domain and the regulatory domain (Capasso et al, 2002; Zhao &
Piwnica-Worms, 2001). The upstream signalling that leads to the
phosphorylation of Chk1 by ATR has now been mostly delineated as discussed
previously, and indeed it is in this step that Claspin functions. (See section 1.3
for the discussion on Claspin function) How exactly this phosphorylation leads to
the activation of Chk1 however remains elusive. Phosphorylation of Ser345
appears to be especially critical. When this site is mutated to a non-
phosphorylatable residue Chk1 kinase activity no longer increases upon
stimulation. In addition this mutant protein is devoid of biological function.
Phosphorylation of Ser345 however is not obligatory for Chk1 kinase activity.
Walker et al. show that a Chk1 S345A mutant protein can exhibit substantial
kinase activity under denaturing conditions. These conditions therefore mimic
the phosphorylation induced activation of wild type Chk1 – either by inducing the
same conformational change as phosphorylation or by removing an inhibitory
protein that normally dissociates upon phosphorylation (Walker et al, 2009)
Amino acid point mutations in the Chk1 C-terminus can also generate a
constitutively active kinase. Such mutations presumably disrupt the repressive
effect of the C-terminus on the kinase domain. The activating mutations
identified so far appear to cluster to two highly conserved domains highlighted
in Figure 1.2. Mutation of the T residue in the TRFF motif of xChk1 to A, leads
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Figure 1.2 Model of Chk1 Activation
A) Schematic representation of Chk1 depicting the N-terminal Kinase domain and the C-terminal
regulatory domain. Residue numbers refer to the amino acid residues in human Chk1. Important
motifs in the regulatory domain are indicated. B) Chk1 is activated by upstream signalling which
leads to its phosphorylation by ATR. This phosphorylation leads to an increase in its kinase activity.
The localisation of Chk1 or other proteins are required for its biological activity.Conor Larkin Chapter 1 26
(ΔKRMTRFF) leads to a constitutively active kinase (Wang & Dunphy, 2000).  The 
same is also true in spChk1 where mutation of the first R in the pombe
equivalent of the KRMTRFF leads to a superactive kinase (Kosoy & O'Connell,
2008). This kinase is functional in yeast and leads to an irreversible arrest in the
G2 phase of the cell cycle. When the entire KRMTRFF motif was deleted this led
to a non-functional protein. The intrinsic kinase activity of this protein was not
determined therefore it is not possible to say whether this mutant has a higher
kinase activity like xChk1. Furthermore, in vertebrate Chk1 mutation of the FF
residues to AA also results in a kinase with much higher basal kinase activity but
this mutant was not functional in checkpoint assays (Scorah et al, 2008). This
indicates that simply increasing the kinase activity of Chk1 alone is not sufficient
for biological function. Indeed it was shown that the TRAA mutant form does
not localise correctly following DNA damage. Therefore in addition to regulating
the kinase activity of the protein the KRMTRFF motif also regulates its sub-
cellular localisation. Whether mutation of just the first R in this motif in
vertebrate cells would lead to a correctly localised kinase with high kinase
activity, as in pombe, is not known.
Mutations of residues in the GD domain of Chk1, also influence the function of
Chk1. Mutations have been identified that both lead to an inactive kinase and a
hyperactive kinase. Deletion of the GD residues in the GD domain in both
spChk1 and scChk1 result in a non-functional kinase. In the case of scChk1 it is
thought that this loss of function could be due to lack of binding to scRad9, a
protein that has been shown to be required for its activation (Chen et al, 2009).
However mutations in the second half of the GD domain lead to an active kinase
but this did not always correlate with an increase in its biological activity. In
scChk1 and hChk1 mutation of the Leucine residue in the GD domain to Arginine
results in increased intrinsic kinase activity of Chk1. Interestingly in yeast this
mutation no longer interacts with scRad9 but is constitutively phosphorylated on
the yeast residues equivalent to S317 and S345. As with other mutations that
lead to an increased kinase activity it appears that this mutation also results in a
biologically inactive protein (Pereira et al, 2009). In spChk1 mutation of the
central glutamic acid residue in the GD domain to alanine results in a non-
functional protein but mutation to an aspartic acid residue leads to an increaseConor Larkin Chapter 1 27
in the biological activity of the kinase, although interestingly this is not through
an increase in kinase activity (Kosoy & O'Connell, 2008).
The overall model of Chk1 activation at the present time is one where the C-
terminus of Chk1 binds to and inhibits the kinase domain. Mutations in the C-
terminus described so far fall into three categories – some mutations lead to an
increase in kinase activity but the protein is non-functional for its biological
activity (ΔTRFF, TRAA, L->R in the GD domain etc); a point mutation has been 
identified that both leads to an increase in kinase activity and a corresponding
increase in biological activity (spChk1 R382A) and mutations have been
described that lead to a non-functional kinase (ΔGD).  A distinction can be made 
therefore between mutations that simply lead to an increase in kinase activity or
mutations that lead to an increase in the biological functional of Chk1. It is
clear that simply over coming the repression exerted on the kinase domain
either by naturally phosphorylation or artificially through mutation is not
sufficient and adds an extra layer of regulation to control the activity of the
kinase.
1.3. The function of Claspin in the DNA Damage
Response
1.3.1. Claspin – Structure and Function
Claspin was originally identified as a novel protein that interacted with Chk1
upon activation of DNA damage signalling using xenopus egg extracts (Kumagai &
Dunphy, 2000). This novel protein is large, very acidic and contains no
previously defined motifs found in proteins involved in the DNA damage response
such as FHA or BRCT domains. However it does contain S/TQ sites which are
known to be preferentially targeted by the ATM/ATR kinases discussed
previously.
Claspin is phosphorylated in an ATM/ATR dependent manner following
checkpoint activation and this modification is necessary for the Claspin-Chk1
interaction (Kumagai & Dunphy, 2003). The phosphorylation leads to a reduction
in the electrophoretic mobility of both full-length Claspin and the isolated C-
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either dephosphorylating Claspin (so it no longer binds to Chk1) or removing
Claspin from Xenopus egg extracts leads to a failure of Chk1 phosphorylation
during replication stress (Kumagai & Dunphy, 2000). The phosphorylation that
regulates the Claspin-Chk1 interaction mainly occurs on the C-terminus of
Claspin (Kumagai & Dunphy, 2003). Closer examination of the C-terminus of
Claspin led to the identification of a domain that contains two tandem repeats
which are essential for Claspin-Chk1 binding. This domain was termed the Chk1
activation domain (CKAD).
The consensus sequence of the tandem repeats is ExxxLC(S/T)GxF. The CKAD
also contains SQ sites down-stream of the SG sites. As the binding of Chk1 to
Claspin was mediated by phosphorylation the significance of each of these sites
was tested. Binding studies showed that only mutation of the S in the SG motif
to A in the isolated CKAD (but not mutation of the SQ sites) resulted in reduced
binding when the residues were mutated singly or resulted in a complete lack of
binding when the two SG sites were mutated to AG (Kumagai & Dunphy, 2003).
In addition introduction of these mutations into full length Claspin resulted in an
inhibition of the Chk1-Claspin interaction and a loss of Chk1 activation during
replication stress (Kumagai & Dunphy,2003). These observations were subsequently
shown to hold true for Human Claspin (Clarke & Clarke, 2005). In addition, the role of
phosphorylation of a third repeat present in human and mouse Claspin was
shown to be minimal, as mutation of the SG site in this motif led to no defect in
Chk1 activation and only very slightly impaired binding of Chk1-Claspin (Clarke &
Clarke, 2005). It is interesting to note that in both Xenopus and Human Claspin
only the slowest migrating form of Claspin (hyperphosphorylated) interacts with
Chk1 (Clarke & Clarke, 2005). Mutation of the 2AG sites in the Chk1 binding
motif singly or in combination do not significantly alter the mobility shift
induced by checkpoint signalling indicating that other residues are also
phosphorylated (Kumagai & Dunphy, 2003).
Having identified the residues on Claspin necessary for interacting with Chk1,
studies then went on to identify what region of Chk1 was required for
interaction with Claspin. Binding assays using fragments of Chk1 identified that
it was the kinase domain of Chk1 that binds to Claspin. A putative phosphate
binding site on Chk1 was identified as the region that contacted the
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inhibits the Chk1-Claspin interaction and no longer allows the upstream
phosphorylation of Chk1 and activation (Jeong et al, 2003). In addition it
appears that hypophosphorylated Chk1 appears to interact with phosphorylated
Claspin more strongly that hyperphosphorylated Chk1.
Another study using purified recombinant proteins (ATR, TopBP1, Claspin and
Chk1) to recapitulate the ATR mediated phosphorylation of Chk1 shows that
Claspin greatly stimulates the kinase activity of ATR towards Chk1 but not other
ATR substrates (Lindsey-Boltz et al, 2009). This activity was shown to increase
further in the presence of damaged DNA and the reaction was dependent on
protein-protein interactions. The specificity of Claspin for ATR mediated
phosphorylation of Chk1 had been reported previously (Liu et al, 2006; Lupardus
& Cimprich, 2006; Yan et al, 2006). This study also defines a minimal region on
Claspin that can facilitate the phosphorylation of Chk1 by ATR. This domain
contains the previously identified CKAD but in addition it also contains a region
adjoining it which shows sequence homology with the yeast Claspin orthologue,
Mrc1 (Lindsey-Boltz et al, 2009).
Given the importance of the phosphorylation induced Claspin-Chk1 interaction,
the next obvious question is which kinase phosphorylates the SG residues. This
issue however remains elusive and somewhat controversial. Claspin
phosphorylation of the 2 SG residues in Xenopus extracts in dependent on ATR,
but ATR is not thought to be the kinase that directly phosphorylates the residues
(Kumagai & Dunphy, 2003). SG does not conform to the motif preferentially
targeted by ATR and phosphorylation of these sites by ATR could not be detected
(Kumagai & Dunphy, 2003). This has also been confirmed by inhibiting ATR with
caffeine or siRNA in human cells and using phospho-specific antibodies to
monitor Claspin phosphorylation at T916 (Bennett & Clarke, 2006; Chini & Chen,
2006). It has been suggested that Chk1 itself may actually phosphorylate Claspin
at this residue (Chini & Chen, 2006) but this has been subsequently disputed
using a Chk1-/- DT40 cell line (Bennett et al, 2008). It is clear however that
Chk1 does affect the phosphorylation of Claspin. Early studies of the Chk1-
Claspin interaction used a phospho-peptide to block the interaction of Claspin
and Chk1. This blocking peptide prevented the interaction of Claspin and Chk1,
reduced Chk1 phosphorylation but also led to a reduction in Claspin
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or the Chk1-Claspin complex is required for further Claspin phosphorylation
(Clarke & Clarke, 2005). A similar observation was made using Chk1-/- DT40
cells where a defect in Claspin phosphorylation (as judged by a mobility shift)
was observed in the absence of Chk1 (Bennett et al, 2008).
A recent study has also raised a question mark as to the function of the
phosphorylation of the SG sites on Claspin (Lindsey-Boltz et al, 2009). Using a
defined system that only contained ATR, TopBP1, a minimal Claspin fragment
and kd-Chk1 they show that only the WT but not 3AG mutant of Claspin
stimulates phosphorylation of Chk1 by ATR. However they could detect no
phosphorylation of the SG residues in this system suggesting that the
phosphorylation of these residues is not essential in vitro and confirming that
phosphorylation of these residues is unlikely to be mediated by ATR. However it
has been shown previously that Chk1 and 3AG-Claspin can interact in vitro but
not in vivo. This indicates that other proteins present within the cell may
regulate this interaction, potentially increasing the importance of
phosphorylation of the SG sites in vivo (Chini & Chen, 2006). Interestingly
however even in the absence of phosphorylation of the SG in the reconstituted in
vitro system, mutation to 3AG inhibited the phosphorylation of Chk1. This
suggests that the mutation itself and not just the lack of phosphorylation may
affect Claspin function.
From the above data it is possible to propose a model of how Claspin facilitates
the activation of Chk1. Upon ATR activation, through the activity of an unknown
kinase regulated by ATR, Claspin is phosphorylated on conserved SG residues in
the CKAD. This phosphorylation results in the recruitment of inactive Chk1,
which binds to Claspin via a putative phosphate binding site in the kinase domain
of Chk1. The Claspin-Chk1 complex is a more efficient substrate for ATR than
Chk1 alone. Claspin also appears to stimulate the autophosphorylation of Chk1
(Kumagai et al, 2004). Chk1 is released from Claspin upon activation leaving the
phosphorylated Claspin molecule free to activate more Chk1 molecules and
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Figure 1.3 Claspin mediated phosphorylation of Chk1
A) Claspin is phosphorylated in an ATR dependent manner on conserved Chk1 binding motifs by
an unknown kinase during replication stress. This generates a binding site for Chk1. B) The
Claspin-Chk1 complex facilitates phosphorylation of Chk1 by ATR. This leads to Chk1 activation
and the active Chk1 molecule dissociates from Claspin. This allows the ‘active’ Claspin to recruit
more inactive Chk1 and facilitate further Chk1 phosphorylation and activation. The cycle of
activation then continues.Conor Larkin Chapter 1 32
1.3.2. Claspin and the DNA replication checkpoint
The first indication that Claspin plays a role in DNA replication came from the
observation that Claspin binds to replicating chromatin in Xenopus egg extracts
(Lee et al, 2003). Claspin binding to chromatin was shown to be dependent on
the Cdc45 mediated unwinding of DNA suggesting that Claspin binding to
chromatin is an early event in DNA replication. Claspin interacts with Cdc45 and
also with the RPA, the RFC complex and MCM proteins (Lee et al, 2005). Binding
of Claspin to chromatin is mediated through the N-terminus and a patch of basic
amino acids has been shown to be required for this (Lee et al, 2005). In addition
to binding to chromatin Claspin also binds directly to DNA (Sar et al, 2004).
Claspin has a higher affinity for branched DNA structures that would be present
at a replication fork. Therefore Claspin recruitment to chromatin might not only
involve interaction with proteins on the chromatin but also with the DNA itself.
In addition Claspin appears to have a ring shaped structure, a feature shared by
other proteins involved in replication such as the MCM helicase and PCNA (Sar et
al, 2004).
This binding of Claspin to chromatin is enhanced upon checkpoint activation
suggesting that Claspin is either actively loaded onto chromatin during
replication stress or modified Claspin has a higher affinity for chromatin than
unmodified (Lee et al, 2003). Unlike the recruitment of Rad17 and ATR, Claspin
recruitment does not require RPA and Claspin itself is not required for the
recruitment of other checkpoint proteins during replication stress. Interestingly
however Claspin does appear to interact with Rad17, another checkpoint protein
and it has been suggested that Rad17 is required for Claspin accumulation on
chromatin in response to replication stress (Lee et al, 2005; Wang et al, 2006).
The fact that Claspin plays an important role in Chk1 activation and the fact that
it binds to replicating chromatin suggests that it the ideal candidate to activate
checkpoint signalling during replication stress. Indeed Claspin is phosphorylated
following replication stress and is required for the S-M checkpoint and
replication slowing following DNA damage during S phase (Chini & Chen, 2003;
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The S phase kinase Cdc7 has also been shown to regulate Claspin during the
replication checkpoint (Kim et al, 2008). Cdc7 binds to and phosphorylates
Claspin. Loss of Cdc7 leads to both a reduction in total levels of Claspin and a
reduction in the phosphorylation and chromatin association of Claspin. This in
turn leads to an impaired Chk1 activation during replication stress (Kim et al,
2008). How the phosphorylation of Claspin by Cdc7 mediates these effects is not
known.
Overall there is ample evidence in the literature that Claspin plays an important
role in the replication checkpoint through its ability to facilitate efficient
activation of Chk1.
1.3.3. Claspin Plays a role in DNA replication
It was noted in early experiments using Xenopus egg extracts that chromatin
replicated more slowly in the absence of Claspin (Lee et al, 2003). This suggests
that in the absence of replication stress Claspin is required to promote normal
replication. This notion was confirmed by DNA fibre analysis, examining
replication progression directly in the absence of Claspin (Petermann et al,
2008). In the absence of Claspin, replication forks progressed more slowly, a
phenomenon that had also been previously observed for Chk1 (Petermann et al,
2006). This may suggest that Claspin works by facilitating Chk1 mediated
replication fork progression. However when both Claspin and Chk1 are
simultaneously depleted from cells there is a greater decrease in replication fork
progression than when the proteins are depleted singly. This suggests that
Claspin and Chk1 have distinct roles in promoting normal replication. Similar
findings were also reported elsewhere (Scorah & McGowan, 2009). This study
revealed that in the absence of either Claspin or Chk1 replicating cells displayed
a higher number of stalled forks and a higher number of fired origins. Indeed
the inter-origin distance was decreased in the absence of Claspin as seen
previously for Chk1. Under conditions of replication stress Chk1 inhibits origin
firing by suppressing the activity Cdk2 however Claspin does not appear to be
essential for Chk1 activation in this context. Claspin depletion did not lead to
an increase in origin firing, indicating that it is not required to suppress origin
firing under conditions of replication stress. Therefore Chk1 and not Claspin
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Claspin regulates origin firing and fork stalling during normal replication however
is not known (Scorah & McGowan, 2009).
Consistent with a role in facilitating normal replication and in agreement with
what is seen for ATR, Claspin knock-down also leads to increased fragile site
instability. Fragile sites are regions in the genome that are particularly sensitive
replication stress and, due to the difficulty in replicating through such lesions,
often lead to chromosomal abnormalities (Casper et al, 2002; Focarelli et al,
2009). In addition Claspin is also required to facilitate PCNA ubiquitination
during replication stress, which facilitates the activity of by-pass polymerases in
order to replicate damaged DNA. It does so by regulating the recruitment of the
Rad18 ubiquitin ligase to chromatin (Yang et al, 2008). This function of Claspin
appears to be independent of ATR but may involve collaboration with another
protein, Timeless (Yang et al, 2008).
Timeless forms a complex with its binding partner Tipin. Interestingly Tipin
depletion leads to S phase slowing, an impaired DNA replication checkpoint and
reduced Chk1 activation during replication stress (Unsal-Kacmaz et al, 2007;
Yoshizawa-Sugata & Masai, 2007). Indeed knock-down of Tipin or depletion from
Xenopus egg extracts led to an inhibition of the accumulation of Claspin during
replication stress and loading onto chromatin (Errico et al, 2007; Yoshizawa-
Sugata & Masai, 2007). Taken together this suggests that a
Claspin/Tipin/Timeless interaction may be important for the regulation of DNA
replication.
1.3.4. Claspin – the molecular switch that turns on
and off the G2-M checkpoint?
Claspin expression levels are regulated during the cell cycle (Bennett & Clarke,
2006). Claspin levels fluctuate with cell cycle progression and are highest in
S/G2 phases of the cell cycle and lowest in G1 cells. Claspin has been shown to
be an E2F target gene (Iwanaga et al, 2006) but the fluctuation of Claspin
throughout the cell cycle is thought to be mediated primarily through
proteasomal degradation. The regulation of Claspin at the protein level is
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been discovered. In addition Claspin stability following genotoxic stress and
during a normal cell cycle appear to be regulated in a different manner.
Following genotoxic or replication stress Claspin is stabilised. This appears to be
mediated at least in part through the action of a ubiquitin protease USP28
(Zhang et al, 2006). USP28 is phosphorylated by ATM following DNA damage
suggesting that this may lead to its activation, but USP28 also stabilises Claspin
in the absence of DNA damage (Zhang et al, 2006). In addition another ubiquitin
specific protease, USP7, has also been implicated in stabilising Claspin, again
under both stressed and non-stressed conditions (Faustrup et al, 2009). Thus the
stabilisation of Claspin following genotoxic stress involves multiple factors.
Indeed it has been shown that Chk1 itself regulates Claspin levels and this may
be an important part of the mechanism by which Claspin is stabilised (Chini et
al, 2006).
Claspin levels are regulated by ubiquitination and it appears that both the
APC
Cdh1 and the SCF
β-TrCP ubiquitin ligases can control the degradation of Claspin.
β-TrCP binds to its substrates via a conserved phospho-DSGXXS motif and, once 
bound, targets its substrates for degradation via the proteasome. Claspin
contains this motif in its N-terminus and if the pS residues are mutated to A this
prevents interaction with β-TrCP and leads to the stabilisation of the Claspin 
(Peschiaroli et al, 2006). Indeed it appears that this degradation of Claspin is
what regulates checkpoint recovery following genotoxic stress (Mailand et al,
2006). Expression of a mutant, non-degradable form of Claspin induces a more
sustained G2-M arrest following genotoxic stress than does WT Claspin. The
stabilised Claspin correlates with sustained Chk1 phosphorylation and prolonged
G2-M arrest (Mailand et al, 2006).
Plk1 has been identified as a kinase that can regulate phosphorylation of the
phospho-degron required for SCF
β-TrCP mediated destruction of Claspin (Mamely
et al, 2006). Plk1 phosphorylates the N-terminus of Claspin and this
phosphorylation is reduced upon mutation of the S residues in the degron to A
(Mailand et al, 2006). Depletion of Plk1 appears to phenocopy the expression of
the non-degradable form of Claspin, with Claspin levels remaining high in mitotic
cells and recovery from G2 arrest impaired in the absence of Plk1 (Mamely et al,
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recovery involving Claspin. Xenopus Plx1 binds to and phosphorylates Claspin,
which leads to Claspin dissociation from chromatin and a defect in checkpoint
adaptation (Yoo et al, 2004). ATR was identified in this study as the kinase that
regulated Plx1 binding to Claspin via its Polo box domain (PBD). The residues on
human Claspin that facilitate PBD binding of Plk1 have not been identified. It
has been shown however that Plk1 and Claspin interact via the PBD of Plk1 and
the C-terminus of Claspin (Mamely et al, 2006). How this then leads to Plk1
phosphorylating the N-terminus of Claspin is not clear.
In addition to being degraded upon entry into mitosis following escape from G2
arrest, Claspin levels are kept low in the G1 phase of the cell cycle through the
activity of the APC
Cdh1 ubiquitin ligase. Claspin interacts with Cdh1 via its N-
terminus through a LLK motif which is not a canonical Cdh1 degron sequence
(Gao et al, 2009). Expression of a version of Claspin lacking this LLK motif
resulted in higher levels of Claspin expression during G1 phase and unscheduled
Chk1 activation in G1 phase. Building on the previous observation that the SCF
β-
TrCP mediated degradation of Claspin leads to checkpoint recovery it has been
proposed that ubiquitination of Claspin and Plk1 by APC
Cdh1 is the molecular
mechanism that controls the activation of the G2 arrest (Bassermann et al,
2008). To activate a G2-M arrest the APC
Cdh1 is reactivated, which leads to the
ubiquitination of both Plk1 and Claspin. Plk1 destruction by the APC
Cdh1 leads to
an inhibition of the SCF
β-TrCP mediated destruction of Claspin but Claspin levels
remain high even though Claspin is also a substrate of APC
Cdh1. It appears that
USP28 counteracts the APC
Cdh1 mediated degradation of Claspin following DNA
damage to keep Claspin levels high and maintain the checkpoint. (See Figure
1.4) Why USP28 displays such specificity for Claspin over Plk1 in order to lead to
its stabilisation is not clear. In addition this model does not explain how the
APC
Cdh1 is then switched off to facilitate recovery, allowing Plk1 levels to
increase and Claspin levels to decrease through the activity of the SCF
β-TrCP.
Overall it is clear that both the degradation and stabilisation of Claspin play an
important, yet complicated, role in the activation, maintenance and recovery
from the G2-M arrest.Conor Larkin Chapter 1 37
Figure 1.4 Claspin Stabilisation and Degradation following genotoxic stress
In unstressed conditions Plk1 phosphorylates Claspin facilitating ubiquitination and degradation by
the SCF
β-TrCP complex. Upon genotoxic stress APC
Cdh1 is activated which leads to the destruction
of Plk1 and inhibition of the SCF
β-TrCP mediated degradation of Claspin. APC
Cdh1 also targets
Claspin for degradation but this is counteracted by the activity of USP28. Stabilised Claspin in
conjunction with checkpoint signalling then activates the cell cycle checkpoint.Conor Larkin Chapter 1 38
1.3.5. Claspin and Cancer
Many mediator proteins involved in DNA damage signalling are either mutated in
cancers or inherited mutations in these genes predisposes to cancer. e.g. Brca1,
Nbs1, ATM etc. Therefore a potential role for Claspin mutations in cancer has
been investigated. A screen for germline Claspin mutations in 125 Finnish
cancer breast families revealed 7 mutations in the CLSPN gene but none of which
appeared to correlate with cancer susceptibility (Erkko et al, 2008). Only three
exon mutations resulted in an amino acid change (G6D, ΔQ1195 and S1280L) and 
of these only one had not been previously reported (ΔQ1195).  None of these 
mutations are located in any region of Claspin that has been shown to be critical
for function (Erkko et al, 2008).
Another study sequenced the CLSPN gene in families with either a history of
breast cancer or a multi-cancer phenotype and from cancer cell lines (Zhang et
al, 2009). Eight mutations not present in the population controls were
described. I236V and A1146S were found to be germline mutations from families
with a history of cancer. Six mutations were found in cancer cell lines. Analysis
of the functional consequence of these mutations revealed that only one of the
mutations, I783S, resulted in impaired Claspin function.
Claspin has also been evaluated as a proliferation marker in cancer tissue
(Tsimaratou et al, 2007). Claspin has been shown to be over expressed in cancer
cell lines compared with normal cells and in human tumours compared with
normal tissue both at the mRNA and protein level (Lin et al, 2004; Tsimaratou et
al, 2007; Verlinden et al, 2007). Claspin expression, as judged by
immunocytochemistry, correlates strongly with that of Ki67, a marker of
proliferation currently in use. The labelling index of Claspin was found to be
lower than Ki67 but this is probably due to the tight S phase specific expression
of Claspin.
Claspin also appears to be a target of the E7 oncoprotein of the HPV-16 virus,
infection with which can lead to squamous cell carcinomas. In addition to being
defective for a whole host of cell cycle checkpoint mechanisms including p53
inhibition activations of hTERT etc cells infected with HPV-16 also fail to
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overcome the G2-M arrest the E7 protein promotes the destruction of Claspin
through deregulation of the normal process that regulates Claspin turnover
(Spardy et al, 2009). In contrast with the inhibition of the DNA damage response
by the oncoprotein E7 the SV40 large T antigen stimulates the DNA damage
response. The LT antigen binds to Claspin and this potentially leads to the
stabilisation of the protein (Hein et al, 2009). In this case Claspin may be
playing a protective role, preventing DNA damage during replication but the
functional significance of Claspin stabilisation by the SV40 LT antigen remains
unclear.
Further study will be necessary to determine whether Claspin is inactivated by
mutation during tumorigenesis. Evidence currently shows that Claspin is over
expressed in cancer cells but whether this alone is enough to deregulate the cell
cycle is not known, but unlikely. However over expressed Claspin is probably
promoting progression through S phase and thus contributing to cancer
progression. This may explain the low number of mutations associated with this
gene.
1.4. Mrc1 – the functional Claspin orthologue in
yeast?
DNA damage signalling components have been widely studied in two model yeast
organisms; budding yeast (Saccharomyces cerevisiae) and fission yeast
(Schizosaccharomyces pombe) (Hartwell, 1967; Nurse et al, 1976). Soon after
the identification of Claspin in Xenopus a novel protein was reported in both
budding and fission yeast termed Mediator of the Replication Checkpoint (Mrc1)
(Alcasabas et al, 2001; Tanaka & Russell, 2001). scRad53/scChk1 and spChk1 are
activated following DNA damage in budding and fission yeast respectively. Two
adaptor proteins facilitating the activation of these kinases, scRad9 and spCrb2,
are necessary for activation in response to DNA damage but not in response to
replication stress (Gilbert et al, 2001; Saka et al, 1997; Schwartz et al, 2002).
Therefore there was a missing link as to whether these kinases (scRad53 and
spCds1) required additional factors to facilitate their activation following
replication stress. To address this, genetic screens were carried out. In budding
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chronic replication stress (Alcasabas et al, 2001). In fission yeast the screen was
devised to identify mutant strains that were sensitive to hydroxyurea (HU),
which induced replication stress, but which could be rescued by over-expression
of spCds1, indicating that the protein identified would play a role in the
activation of this kinase (Tanaka & Russell, 2001). scMrc1/spMrc1 was
identified.
spMrc1 is required specifically for spCds1 activation following replication stress
but not for spChk1 activation following DNA damage.  spCds1ΔspMrc1Δ double 
mutant cells show the same sensitivity to HU as either single mutant. However
both  spCds1ΔspChk1Δ  and  spMrc1ΔspChk1Δ  double  mutants  show  greater 
sensitivity to HU than the single mutants alone (Tanaka & Russell, 2001). This
indicates that spMrc1 acts in the same pathway as spCds1 and that spChk1
function is not impaired in the absence of spMrc1. Consistent with this is the
observation that spMrc1 cells are unable to activate the S-M checkpoint which is
dependent on spCds1 activation but remain competent for the G2-M checkpoint
which depends of the activity of spChk1 (Tanaka & Russell, 2001).
spMrc1 is regulated by Rad3/Tel1 (ATR/ATM) following replication stress. An
spMrc1 electrophoretic mobility shift consistent with phosphorylation by
Rad3/Tel1 kinases (but not by spCds1) is observed following replication stress.
Rad3 and Tel1 generally target S/TQ sites for phosphorylation and it followed
that mutation of the S/TQ sites present in spMrc1 led to a substantial reduction
in phosphorylation of spMrc1 but also greatly sensitised the cells to killing by HU
(Zhao et al, 2003). There was also a substantial impairment of the spCds1
mediated S-M checkpoint. This checkpoint mediated phosphorylation of spMrc1
and not just its mere presence is therefore essential for its role in mediating the
activation of spCds1.
Consistent with spMrc1 playing an adaptor role in the activation of spCds1, the
two proteins have been shown to interact (Tanaka & Russell, 2001). Indeed it
appears that it may be the interaction of spMrc1 and spCds1 that is regulated by
checkpoint signalling. Two residues in spMrc1 were identified as being
important for the cells resistance to HU – S604 and T645 (Zhao et al, 2003).
S604 is phosphorylated by Rad3/Tel1 following HU treatment but its role in
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spMrc1 chromatin association. Phosphorylation of this site is not essential for
the S-M checkpoint and is not required for spCds1 interaction. Interestingly the
other site (T645) lies within the region of spMrc1 that has been shown previously
to be required for interaction with spCds1 via the FHA domain of spCds1 (Tanaka
&  Russell,  2001).    Loss  of  the  C-terminus  of  spMrc1  (Δ610-1019)  prevents 
interaction with Cds1, whereas loss of residues 1-162 has no effect.
Phosphorylation of the T645 site is required for the interaction of spMrc1 and
spCds1 and for the activation of the spCds1 dependent S-M checkpoint (Zhao et
al, 2003). These observations were further extended by Xu et al, who have also
identified another site, T653, as being just as critical as T645 in the response to
replication stress (Xu et al, 2006). Mutation of just these 2 sites, termed
tandem TQ repeats, completely abolished spCds1 phosphorylation following HU
treatment (Xu et al, 2006). Once phosphorylated by Rad3 the TQ repeats form
consensus FHA phospho-threonine binding sites which then interact with the FHA
domain of spCds1. This appears to be the first, so-called ‘priming’, step in
spCds1 activation. It appears that the spCds1-spMrc1 interaction facilitates the
phosphorylation of spCds1 by spRad3 on T11. Phosphorylation of this residue
promotes intra-molecular binding between the pT11 residue of one spCds1
molecule to the FHA domain of the other. Auto-phosphorylation then occurs
leading to full activation of the kinase (Tanaka & Russell, 2004; Xu & Kelly,
2009).
spMrc1 also interacts with chromatin (Zhao et al, 2003) and has been shown to
directly interact with DNA (Zhao & Russell, 2004). A region between amino acids
160 – 317 in the N-terminus of the protein is required for the direct interaction
with DNA. spMrc1 appears to prefer to interact with branched DNA structures
over linear dsDNA. It was also possible to identify two key residues that mediate
the interaction with DNA, K235 and K236. Mutation of these sites in the N-
terminus of the protein rendered the protein fragment no longer able to bind
DNA. Significantly it was also shown that this DNA binding activity is required
for the checkpoint function of spMrc1.
It was noted that in the absence of spMrc1, modest spChk1 activation is observed
(Tanaka & Russell, 2001). As spChk1 is only activated following DNA damage this
suggests that spMrc1 prevents replication induced DNA damage during an
otherwise unperturbed cell cycle. Indeed further studies show that spMrc1 hasConor Larkin Chapter 1 42
functions in DNA replication that are independent of its role in the activation of
spCds1.    The  sensitivity  to  HU  in  the  spCds1Δ  mutant  can  be  suppressed  by 
mutations in either spOrc1 or spCdc45, proteins required for replication
initiation and elongation respectively. This suggests that simply reducing the
rate  of  replication  in  spCds1Δ  cells  increases  viability  (Nitani  et  al,  2006).  
However the same study, now examining the spMrc1Δ mutant cells, showed that 
when replication was perturbed by mutating spOrc1 the cells were more
sensitive to replication stress, not less. Reducing the number of viable origins
would mean that the origins that did fire would have to be viable for longer in
order to complete replication. spMrc1 therefore plays a role in maintaining
viable forks in order to promote viability. However mutating spCdc45 or spMCM
components in the spMrc1Δ cells, as with spCds1Δ cells, leads to an increase in 
viability following HU treatment suggesting that mutations which slow the
elongation phase of DNA replication promote viability in the absence of spMrc1.
This same mutation in spCdc45 promoted recovery from a replication arrest
induced by HU in the spMrc1Δ background (Nitani et al, 2006). 
Most of the observations that are valid for spMrc1 are also valid for scMrc1.
scMrc1 is not required for the DNA damage checkpoints but is required for the
S-M checkpoint, the intra-S checkpoint, and to delay late origin firing in the
presence of replication block. All of these functions serve to maintain viability
of cells subjected to prolonged replication stress (Alcasabas et al, 2001).
Subsequent analysis has shown that scMrc1 is required to facilitate activation of
scRad53 following replication stress.  As seen with spMrc1Δ cells, scMrc1Δ cells 
also accumulate sufficient DNA damage during S phase to lead to the activation
of scRad9. This indicates that scMrc1 prevents the accumulation of replication
associated DNA damage. In contrast with spMrc1, which did not require spCds1
for its phosphorylation, scMrc1 phosphorylation is compromised in the absence of
scRad53 indicating a role for scRad53 in the phosphorylation of scMrc1, possibly
via some sort of an amplification loop (Alcasabas et al, 2001). Further in vitro
characterisation of the role of scMrc1 in the activation of scRad53 shows that
scMrc1 is required to stimulate the kinase activity of scMec1 (the upstream
kinase that phosphorylates scRad53) toward scRad53. It does so, not by
stimulating the catalytic activity of scMec1, but instead by promoting enzyme-Conor Larkin Chapter 1 43
substrate association (Chen & Zhou, 2009). scMrc1 is also required to maintain
scMec1 levels at stalled replication forks (Naylor et al, 2009).
Aside from its function under conditions of DNA synthesis inhibition scMrc1 also
appears to play important roles in a normal S phase. scMrc1 cells progress more
slowly through S phase even in the absence of stress (Szyjka et al, 2005). This
appears to be due to a general overall slowing of replication fork progression
due to the generation of structures in the DNA that must be resolved by
helicases. The function of scMrc1 in normal replication however seems to be
separate from its checkpoint role (Osborn & Elledge, 2003). Unlike in the
complete absence of scMrc1, where damaged DNA accumulates, no such damage
is observed in a checkpoint defective scMrc1 protein (scMrc1-AQ). Further
studies show that scMrc1 specifically localises with the replication fork during S
phase. scMrc1 associates with chromatin following origin firing and then
dissociates from chromatin once S phase is complete (Osborn & Elledge, 2003).
These data strongly indicate that scMrc1 plays a role in a normal S phase.
Further analysis has revealed that scTof1 and scCsm3 are partially required for
the recruitment of scMrc1 to the replication fork, even though it appears that
they also play roles in S phase that are independent of scMrc1 recruitment
(Bando et al, 2009; Hodgson et al, 2007). Finally, evidence has recently been
provided that scMrc1 also interacts with scPol2, the catalytic subunit of DNA
polymerase  ε,  required  for  leading  strand  DNA  synthesis.    Two  independent 
contact sites have been established; the C-terminus of scMrc1 interacts with the
C-terminus of scPol2 and the N-terminus of scMrc1 interacts with the N-terminus
of scPol2. The interaction between the C-termini of scMrc1 and scPol2 appears
to occur constitutively at replication forks but the N-terminal interaction is
subject to checkpoint regulation. Indeed it has also been shown that scMrc1 is
required to maintain scPol2 at a stalled replication fork (Lou et al, 2008).
scMrc1 has also been shown to interact with the MCM helicase and it has been
suggested that scMrc1 plays a role in coupling the replication fork with the
helicase (Katou et al, 2003; Szyjka et al, 2005). Taken together this places
scMrc1 at an ideal location to couple the unwinding of the DNA with the
synthesis of the two daughter strands. It also makes scMrc1 an ideal candidate
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replication. It would be interesting to test whether this coupling function is
conserved in vertebrate Claspin.
It can be seen from the description of the yeast Mrc1 homologues that many
common features are conserved with vertebrate Claspin. They are both large
acidic phospho-proteins. In common with yeast Mrc1, Claspin binds chromatin
and DNA, it is required for the S-M checkpoint following replication stress and
although Claspin activates Chk1 (not Chk2 the vertebrate spCds1/scRad53
orthologue) the mechanism of activation seems quite similar to what is currently
known about Chk1 activation by Claspin. It is interesting to note that spMrc1
activates spCds1
Chk2 whereas Claspin activates Chk1. This data however fits in
well with the observation that vertebrate Chk1 has taken over most of the roles
played by spCds1
Chk2 in the replication checkpoints (Canman, 2001; Chen &
Sanchez, 2004). It has also been observed that spMrc1 is cell cycle regulated
peaking in S phase and this is thought to restrict spCds1 activity to S phase
(Tanaka & Russell, 2001). A similar observation has been made with Claspin.
spMrc1 has also been shown to be regulated by the Tel2 and Hsk-1 orthologues of
human Clk-2 and Cdc7 respectively (Shikata et al, 2007; Shimmoto et al, 2009).
Recent work has also shown that human Claspin is regulated in a similar manner
(Collis et al, 2007; Kim et al, 2008). Although spMrc1 and human Claspin only
share roughly 20% similarity at the amino acid level it does indeed appear that
spMrc1 is the functional homologue of vertebrate Claspin.
1.5. The DT40 Model System
The DT40 cell line was first developed in 1985. It is a chicken suspension cell
line, of lymphoid origin, immortalised by transformation with RAV-1, an avian
leukosis virus (ALV). Hyline SC chickens were infected with the RAV-1 virus then
the resulting tumours were re-implanted into syngeneic chickens and the DT40
cell line was derived from one of these transplantable tumours (Baba et al,
1985). The cell line shows elevated expression of c-myc due to the insertion of
viral DNA upstream of the c-myc gene. Further studies have also shown that this
cell line does not express functional p53. p53 is either not detectable (Takao et
al, 1999) or only detectable following genotoxic stress (Tanikawa et al, 2000).
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are kept very low due to the action of a negative regulator of p53, YY1 (Sui et
al, 2004).
The utility of this cell line however really only became clear when it was
demonstrated that transfected DNA integrated by homologous recombination at
very high frequencies (Buerstedde & Takeda, 1991). This high ratio of targeted
to random integration of transfected DNA makes DT40 ideal for reverse genetics
in somatic cells. Gene targeting by homologous recombination had been shown
previously but largely confined to work in mouse ES cells. (Doetschman et al,
1987) Therefore having a cell line that can be used to knock-out proteins with
relative ease greatly facilitates the characterisation of proteins at both the
molecular and cellular level. Indeed the benefits of the DT40 cell line have
been exploited by researchers over the past 20 years.
The cell line is genetically stable and nearly euploid, with one extra copy of
chromosome 2 and one extra mini-chromosome (Winding & Berchtold, 2001).
However caution has recently been expressed as to how stable the DT40 genome
actually is, with some slight variations of the ‘normal’ DT40 karyotype observed
depending on the source of the cells (Chang & Delany, 2004). The diploid
chicken karyotype consists of 8 pairs of macro-chromosomes, 2 sex chromosomes
(ZW) and 30 pairs of mini-chromosomes (Brown et al, 2003). DT40 are about
10µm in diameter, with a large nucleus. They grow quickly under optimal
growth conditions, with a doubling time of approximately 8 -10 hours when
grown at 39.5°C. (Winding & Berchtold, 2001) On a practical note the quick
doubling time and the fact that the cells grow in suspension greatly facilitate
the process of gene targeting.
Due to the popularity of the chicken as a resource for biological research and
the commercial value of the poultry industry great effort has been invested into
generating genome resources for the chicken research community. This has
obviously benefited research with the DT40 cell line. Genome linkage maps
(Groenen et al, 2000), chicken BAC libraries (Crooijmans et al, 2000), EST
databases (Abdrakhmanov et al, 2000; Boardman et al, 2002) and complete
sequencing of the Chicken Genome (Hillier et al, 2004) provide valuable tools for
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It is not surprising therefore that the DT40 system has been used to address
questions in areas of research pertaining not only to immunology such as B cell
receptor signalling, immunoglobulin diversification etc but also to the areas of
chromosome biology, cell cycle, DNA damage checkpoints and signalling and DNA
repair (Dhar et al, 2001; Sonoda et al, 2001b; Winding & Berchtold, 2001;
Yamazoe et al, 2004).
The short doubling time and the suspension cell nature of DT40 cells make them
very amenable to cell cycle and DNA damage studies. They are particularly easy
to handle for flow cytometry and enrichment for cells in different phases of the
cell cycle is possible by elutriation (Franklin & Sale, 2006; Gillespie & Henriques,
2006; Gillespie & Walker, 2006). DT40 cells lack a functional G1-S arrest and
instead arrest in G2 phase in response to DNA damage. The cells lack functional
p53 as discussed earlier which permits longer cell survival in the presence of
genotoxic insults and allows p53 independent features of pathways to be
investigated. Numerous DT40 knock-outs have been generated for proteins
involved in the maintenance of genomic stability and this has provided valuable
information as to the function of these proteins. (Table 1-1) In addition to using
reverse genetics to probe the basic functions of proteins it is also possible to
make targeted mutations in proteins allowing identification of critical residues,
which facilitates a more in-depth study of protein function (Arakawa et al, 2006;
Ayoub et al, 2009).
Reagents have recently been made available that facilitate the generation of
compound DT40 knock-outs through the recycling of resistance markers
(Arakawa, 2001). Resistance markers flanked by mutant LoxP sites can be
excised once targeting has been confirmed allowing either the reuse of the same
targeting vector to target the second allele of the gene or the use of a targeting
vector bearing the same resistance marker to target a different gene. In
addition novel strategies are being employed in order to increase the benefits to
using DT40 cells for example promoter-hijack strategies in order to generate
conditional knockouts and the use of a temperature sensitive degron to allow
tight temporal control over the expression of proteins (Samejima et al, 2008; Su
et al, 2008).Conor Larkin Chapter 1 47
DT40 Knock-out Reference
Homologous Recombination/Inter-strand Crosslink Repair
Rad54-/- (Bezzubova et al, 1997)
Rad52-/- (Yamaguchi-Iwai et al, 1998)
Rad51
ON/OFF (Sonoda et al, 1998)
Rad51B/C/D-/- (Takata et al, 2000)
XRCC2/3-/- (Takata et al, 2001)
SNM1A/B(Artemis)/C-/- (Ishiai et al, 2004)
Brca1-/- (Martin et al, 2007)
CtIP-/-/- (Yun & Hiom, 2009)
FANC C-/- (Hirano et al, 2005)
FANC D1 (Brca2)-/- (Ayoub et al, 2009)
FANC D2-/- (Yamamoto et al, 2005)
FANC G-/- (Yamamoto et al, 2003)
FANC J-/- (Bridge et al, 2005)
FANC L-/- (Seki et al, 2007)
Blm-/- (Wang et al, 2000)
WRN-/- (Imamura et al, 2002)
Fbh1-/- (Kohzaki et al, 2007)
Non-homologous End Joining
Ku70-/- (Takata et al, 1998)
DNAPKcs-/-/- (Fukushima et al, 2001)
DNA LigV-/- (Adachi et al, 2001)
Mismatch Repair
MSH6-/- (Kobayashi et al, 2006)
MSH3-/- (Nojima et al, 2005)
Translesional Synthesis
  Polκ-/-  (Okada et al, 2002) 
  Rev3 (Polζ)-/-  (Sonoda et al, 2003) 
POLQ-/- (Yoshimura et al, 2006)
Rad18-/- (Yamashita et al, 2002)
  Polη-/-  (Kawamoto et al, 2005) 
  POLΝ-/-  (Yoshimura et al, 2006) 
Rev1-/- (Simpson & Sale, 2003)
  Polλ-/-  (Tano et al, 2007) 
Nucleotide Excision Repair
XPA-/- (Okada et al, 2002)
XPG-/- (Kikuchi et al, 2005)
XPF-/- (Nojima et al, 2005)
Base Excision Repair
Parp1-/- (Hochegger et al, 2006)
  Polβ-/-  (Tano et al, 2007) 
Fen-1-/- (Kikuchi et al, 2005)
DNA damage Signalling
Nbs1-/- (Tauchi et al, 2002)
Mre11
ON/OFF (Yamaguchi-Iwai et al, 1999)
ATM-/- (Takao et al, 1999)
ATR
ON/OFF N Lowndes, Personal communication
Chk1-/- (Zachos et al, 2003)
Chk2-/- (Rainey et al, 2008)
Rad9-/- (Kobayashi et al, 2004)
Rad17-/- (Kobayashi et al, 2004)
H2AX-/- (Sonoda et al, 2007)
53BP1-/- (Iwabuchi et al, 2006; Nakamura et al, 2006)
Table 1-1 List of DT40 Knock-out cell lines of genes involved in the DNA Damage ResponseConor Larkin Chapter 1 48
Overall this model system has proved to be very important in elucidating the
functions of a wide variety of pathways something which is likely to continue
into the future.
1.6. Hypothesis and Aims
It is clear that there is a lot of biochemical evidence now available regarding
Claspin. However a gap exists between in vitro data and what happens in the
context of a cell. Currently there is no clean system, amenable to genetic
manipulation, in order to study the function of Claspin on a cellular level. The
development of a DT40 knockout (discussed in section 1.5) therefore would be
an ideal tool in bridging this gap.
In addition to the benefits already described, the DT40 system potentially has
particular advantages over other systems for studying Claspin function. This is
the only system identified to date where a genetic deletion of Chk1, the kinase
regulated by Claspin, has been possible (Zachos et al, 2003). Therefore this
system has the greatest chance of also producing a viable Claspin knockout.
However, the DT40 system has also been used to gain important information
regarding the function of essential genes through the generation of conditional
knock-out cell lines.
The system also benefits from the fact that many other mediator proteins
implicated in the activation of Chk1 have already been knocked out (see Table
1-1) which would allow a thorough examination of role of the individual proteins
(or combinations thereof) in the activation of Chk1 in an isogenic background. It
is also intended to examine the role Chk1 itself plays in regulating Claspin since
this issue has been raised in the literature. A basic characterisation of the
chicken homologue of Claspin should also yield interesting results.
The generation of a Claspin-/- cell line will greatly facilitate the
characterisation of the role Claspin plays in the activation of Chk1 and has the
potential to allow the discovery of the precise roles it plays during replication.Chapter 2. Materials and MethodsConor Larkin Chapter 2 50
2.1. Materials
2.1.1. General Reagents
Melford Laboratories Ltd. (Ipswich, UK)
Tris Base Ultrapure, Tris Hydrochloride Ultrapure, Agarose, Magnesium chloride,
Magnesium sulphate.
Fisher Scientific (Loughborough, UK)
Sodium chloride, Sodium hydroxide, Hydrochloric acid, Acetic acid, Sodium
acetate, Disodium hydrogen phosphate, Sodium dihydrogen phosphate, Sodium
pyrophosphate, Maltose, Glucose, Sucrose, Manganese (II) chloride, Potassium
hydroxide, Potassium chloride, EDTA, Glycerol, Sodium Dodecyl Sulphate,
Ethanol, Methanol, n-Butanol, Dimethyl sulphoxide, Chloroform, Sodium Citrate,
Potassium dihydrogen phosphate, Ammonium Persulphate, Potassium Acetate.
Buffer Composition
20 × SSC 3M Sodium Chloride, 0.3M Sodium citrate pH
7.0
50 × Denhardts Reagent 1% BSA, 1% Ficoll 400, 1% Polyvinylpyrrolidone
1 × PBS-A 160mM Sodium Chloride, 3mM Potassium
chloride, 8mM Disodium hydrogen phosphate,
1mM Potassium dihydrogen phosphate
1 × PE 160mM Sodium Chloride, 3mM Potassium
chloride, 8mM Disodium hydrogen phosphate,
1mM Potassium dihydrogen phosphate, 1mM
EDTA
50 × TAE 2M Tris Acetate, 50mM EDTA
1 × Semi Dry Blotting Buffer 48mM Tris-Cl pH 9.2, 39mM Glycine, 1.3mM
SDS - 20% Methanol added just prior to use
10 × Tris Buffered Saline Tween 200mM Tris-Cl pH 7.6, 1.37 M Sodium
Chloride, 1% Tween 20
1 × SDS-PAGE Running Buffer 250mM Tris-HCl, 1.92M Glycine, 0.01% SDS
1 × TE 10mM Tris-HCl pH 8.0, 1mM EDTA
LB Broth (and Agar) 10g of NaCl, 10g of tryptone, 5g of yeast
extract per 1000mls of water, then
autoclaved. For 1000mls of LB-agar 20g of
Agar was added prior to autoclaving.
(Ampicillin to a final concentration of
100μg/ml or kanamycin to a final 
concentration of 50μg/ml was added as 
required)
NZY Broth (and Agar) 5g of NaCl, 2g of MgSO4·7H2O,5g of yeast
extract, 10g of NZ amine (casein hydrolysate)
per 1000mls of water then autoclaved. For
1000mls of NZY-agar 20g of agar was added
prior to autoclaving. Top Agar was NZY Broth
containing 0.7% agar then autoclaved.
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2.1.2. Molecular Biology – Analysis of DNA and RNA
2.1.2.1. Recombinant DNA Technology
Cambio (Cambridge, UK)
Klenow Polymerase.
New England Biolabs UK (Hitchin, Hertfordshire, UK)
Mung Bean Nuclease, KpnI Phosphorylated Linkers, T4 DNA Ligase (400U/μl), 
Restriction Enzymes (PciI).
Promega (Southampton, UK)
Shrimp alkaline phosphatase.
GE Healthcare Life Sciences (Little Chalfont, UK)
Nanovue Spectrophotometer.
Roche Diagnostics Ltd. (Burgess Hill, UK)
Restriction Enzymes (KpnI, XbaI, SalI, SfuI, SpeI, NheI, ScaI, BclI, NcoI, MluI,
BglII, XhoI), Rapid DNA Ligation Kit.
Invitrogen (Paisley, UK)
Restriction Enzymes (HindIII, EcoRI, BamHI, NotI, SmaI, SacI, PstI), Chemically
Competent DH5α E. coli, SOC Media, TOPO® TA Cloning Kit for Sequencing, 
ZeroBlunt® TOPO® Cloning kit for Sequencing.
Eppendorf (Histon, Cambridge, UK)
Biophotometer (Spectrophotometer), Refrigerated Microcentrifuge 5415 R,
Microcentrifuge 5415 D.
2.1.2.2. DNA Purification and Clean Up
Qiagen Ltd. (Crawley UK)
Qiaquick Gel Extraction Kit, Qiaquick Nucleotide Removal Kit, Qiaquick PCR
Purification Kit, QiaexII Gel Extraction Kit, Qiafilter Maxi Prep Kit, Qiaprep Mini
Prep Kit.
Fermentas (York, UK)
20mg/ml Glycogen.
2.1.2.3. PCR
Invitrogen (Paisley, UK)
Platinum Taq Polymerase, Pfx Polymerase, Superscript II RT-PCR kit.
Agilent Technologies UK Ltd (Stockport, UK)
Quick Change II Site Directed Mutagenesis Kit (Stratagene).Conor Larkin Chapter 2 52
Applied Biosystems (Warrington, Cheshire, UK)
GeneAmp PCR Core Kit, GeneAmp RNA PCR Core Kit.
VHBio (Gateshead, UK)
10mM dNTP Mix, Oligonucleotide Supplier.
New England Biolabs (Hitchin, Hertfordshire, UK)
Phusion DNA Polymerase.
Takara Bio Europe/Clontech (Saint-Germain-en-Laye, France)
SMART RACE cDNA Amplification Kit.
Biorad (Hemel Hempstead, UK)
PTC-200 Thermal Cycler.
RT-PCR
1F  5′-AATGTTGGTCGACAGGACGGTGACTCTTCTGTGC-3′ 
2F  5′-AATGTTGGTCGACTGCCAGTGAAACAGAAGAACAGC-3′ 
3F  5′-AATGTTGGTCGACGAAGAGAAACAAGTTGAAGACGGT-3′ 
4F  5′-AATGTTGGTCGACAGATGGACTTGTTTCAGAGGG-3′ 
5F  5′-AATGTTGGTCGACAGAAGAGCTGAACGCTGTGC-3′ 
6F  5′-AATGTTGGTCGACCCTTACGGGGTTTCTTTGG-3′ 
1R  5′-CTGCTTCTAGATCATTGCCAGAGCAGATTCG-3′ 
2R  5′-CTGCTTCTAGACTCTGTTGAAGGTGGTTTGGG-3′ 
3R  5′-CTGCTTCTAGACAAATTTTCCAGAGCAAAG-3′ 
4R  5′-CTGCTTCTAGACACTGTTCTCGTTCAAATCTCTC-3′ 
5R  5′-CTGCTTCTAGAATGGGAAAAGCAACGAAGC-3′ 
6R  5′-CTGCTTCTAGAATTGTGAAGGTTGGGAGTGG-3′ 
7R  5′-CTGCTTCTAGAAAGTTGCAGTTGGAGTCGGG-3′ 
10R  5′-AGACAGCAGGAGCAGGGAGAACAACG-3′ 
B  5′-CTCGAGTGCGGCCGCTCATCCTCAGAAAACCGTTC-3′ 
RACE
5′-RACE 1  5′-TCCACCTGCTGGCCCTCTGAGCTTGG-3′ 
5′–RACE 3  5′-CGCTGTCCAGCAGACCCTGTCGAATCCG-3′ 
3′–RACE 1  5′-AGAGAAGGACAGCGACATAGAAGACCC-3′ 
3′–RACE 5  5′-GCCCAGGGTTGACAGCACAGAGC-3′ 
3′–RACE 7  5′-ATCTCTTGCCAAACGGCCCAGGGTTGAC-3′ 
Site Directed Mutagenesis
cClaspin M1Δ For  5′-GCGTCCGGCCCGGGCCGCGGCGGCTCCCG-3′ 
cClaspin M1Δ Rev  5′-CGGGAGCCGCCGCGGCCCGGGCCGGACGC-3′ 
cClaspin S1236P For  5′-CTATTGCCCAGGAATCCATTTGAAACATTCAGACCTGCC-3′ 
cClaspin S1236P Rev  5′-GGCAGGTCTGAATGTTTCAAATGGATTCCTGGGCAATAG-3′
PCR – primers for targeting vector arms
G13F  5′- GGTCGACCAGACCCGTCATACCTATACGTGAGC -3′ 
G10R  5′- CATCGATTGGGCAGTGACCTTCTCTTTTTCC -3′ Conor Larkin Chapter 2 53
G9F  5′- CAGATGTGGGAGAGGAAAAGGAGG -3′ 
G9R  5′- CTATGTCTGCTGATCTGCTTTCCG -3′ 
3F  5′-AATGTTGGTCGACGAAGAGAAACAAGTTGAAGACGGT-3′ 
4R  5′-CTGCTTCTAGACACTGTTCTCGTTCAAATCTCTC-3′ 
Table 2-2 Primer Sequences used in PCR, RT-PCR, RACE and Site Directed Mutagenesis
Restriction enzyme sites added to primers are coloured. SalI in blue; XbaI in green; NotI in red,
ClaI in orange.
2.1.2.4. Agarose Gel Electrophoresis/Southern Blot
Sigma (Poole, Dorset)
Ethidium Bromide, Orange G, Xylene Cyanole, Bromophenol Blue, Whatman 3MM
Chromatography Paper, Methylene Blue.
Cambridge Bioscience Ltd (Cambridge, UK)
GelRed DNA Stain.
Fermentas (York, UK)
O'GeneRuler™ 100 bp DNA Ladder, O'GeneRuler™ 1 kb DNA Ladder, O'GeneRuler™
1 kb Plus DNA Ladder
Biorad (Hemel Hempstead, UK)
Biospin 30 columns, Mini Sub-cell GT Cell and Sub-cell GT Cell Submerged
Horizontal Gel Systems.
Melford Laboratories Ltd. (Ipswich, UK)
Agarose (Molecular Biology grade).
GE Healthcare Life Sciences (Little Chalfont, UK)
Hybond-XL (30cm × 3m roll), EPS601 Power Supply, Rediprime II DNA labelling
Kit. Redivue α-32P-dCTP (3000Ci/mmol, 10mCi/ml), Autoradiography Cassettes 
with intensifying screens.
Perkin Elmer (Beaconsfield, UK)
EasyTide α-
32P-dCTP (3000Ci/mmol, 10mCi/ml).
Thermo Fisher Scientific (Cramlington, UK)
Hybaid Shake’n’stack hybridisation oven and bottles. Hybridisation mesh.
UVitec (Cambridge, UK)
UVitec Crosslinker (CL-E580).
Agilent Technologies UK Ltd (Stockport, UK)
Stratalinker 1800 (Stratagene).Conor Larkin Chapter 2 54
2.1.2.5. DNA/RNA Purification
Gen-Probe Life Sciences Ltd (Manchester, UK)
Nucleon BACC2 DNA Extraction Kit.
Qiagen Ltd. (Crawley UK)
RNeasy Mini Kit.
Amsbio (Abindgon, UK)
RNABee.
2.1.2.6. cDNA Library Screen
GE Healthcare Life Sciences (Little Chalfont, UK)
Hybond-N (22.5cm×22.5cm sheets), Rediprime II DNA labelling Kit. Redivue α-
32P-dCTP (3000Ci/mmol, 10mCi/ml), Autoradiography Cassettes with
intensifying screens.
Agilent Technologies UK Ltd (Stockport, UK)
Stratalinker 1800 (Stratagene), Uni-ZAP XR Pre-made Chicken Fibroblast cDNA
library.
Sigma (Poole, Dorset)
Polyvinylpyrrolidone, Salmon Sperm DNA, PolyA RNA, Corning Square Bioassay
Dishes, Whatman 3MM Chromatography paper.
Biorad (Hemel Hempstead, UK)
Biospin 30 columns.
Melford Laboratories Ltd. (Ipswich, UK)
X-gal, IPTG.
2.1.2.7. Plasmids and Probes
2.1.2.7.1. pCR4-cClaspin
Two cCLSPN mRNA fragments were amplified by RT-PCR using Pfx polymerase.
The following PCR primer pairs were used to amplify a 5′ fragment (7F-2R) and a 
3′  fragment  (2F-10R)  that  overlapped  in  a  region  containing  a  unique  SfuI 
restriction site:  7F-2R: 7F – 5′-GCTCGAAGGTTTCTTACGCGGCAGC-3′ and 2R - 5′-
CTGCTTCTAGACTCTGTTGAAGGTGGTTTGGG-3′  and  2F-10R:  2F  -  5′-AATGTTGG 
TCGACTGCCAGTGAAACAGAAGAACAGC-3′  and  10R  5′-AGACAGCAGGAGCAG 
GGAGAACAACG-3′.  The individual PCR fragments were cloned into pCR4-TOPO.  
Clones were screened ensure that the clones selected contained the cDNA
fragments in the same orientation.  The SpeI/SfuI 5′ fragment from pCR4-7F-2R 
was ligated into SpeI/SfuI digested pCR4-2F-10R (the 3′ fragment).  The resulting Conor Larkin Chapter 2 55
plasmid contained the full length Claspin cDNA inserted in the same orientation
as the T7 promoter. The cDNA sequence was verified by sequencing.
2.1.2.7.2. pET28(a)+ - Claspin fragment
The cClaspin fragment was amplified by PCR using the following primers:
Forward (EcoRI) 5’·ccg gaa ttc gaa gag aaa caa gtt gaa gac ggt 3’, Reverse (NotI)
5’·ctc gag tgc ggc cgc cac aaa ttt tcc aga gca aag 3’. The resulting PCR product
was digested with EcoRI/NotI and ligated with pET28(a)+ precut with EcoRI and
NotI. This vector allows the expression of the cClaspin fragment containing an
N-terminal His6 – T7 tag separated by a thrombin cleavage site and a C-terminal
His6 tag under the control of the T7 RNA polymerase.
2.1.2.7.3. pEGFP-N1-cClaspin
The pCR4-cClaspin vector was digested with SmaI and ScaI. This releases the
cClaspin cDNA but removes the last 4 amino acids and the stop codon. This
fragment was then ligated into SmaI digested pEGFP-N1 (Clontech) in order to
fuse the cClaspin cDNA in-frame with the GFP cDNA. Plasmids were screened to
ensure the cDNA had inserted in the correct orientation. The entire cDNA
sequence was verified by sequencing.
2.1.2.7.4. pCR4-SF.cClaspin
pCR4-SF.cClaspin was generated using InFusion Cloning (Clontech). The primers
were designed such that they overlapped the region surrounding SmaI digested
pCR4-cClaspin by 15 bases. The SF tag was amplified using Pfx polymerase using
the  following  primers:  5′-CCGCCGCCATGGCCCCTCCGCTAGCTCCTTTCTCG-3′  and 
5′-  GACTGCGTCCGGCCCCCAAGCTTGGTACCGAGC  -3′.    The  template  was 
pcDNA3.1-N SF TAP (Dr. J. Gloeckner, Helmholtz Zentrum München). The
resulting PCR product was recombined with SmaI digested pCR4-cClaspin using
InFusion Cloning from Clontech according to manufacturer’s instructions to
generate pCR4-SF.cClaspin. The entire cDNA sequence was verified by
sequencing.
2.1.2.7.5. pTRE-Tight:SF.cClaspin
pTRE-Tight (Clontech) was digested with NheI and ligated to the SpeI SF.cClaspin
cassette from pCR4-SF.cClaspin. The orientation of the inserted cDNA was
confirmed and the entire cDNA sequence was verified by sequencing.Conor Larkin Chapter 2 56
2.1.2.7.6. pTRE-Tight:cClaspin.EGFP
pTRE-Tight (Clontech) was digested with XbaI and SalI and ligated to the
XbaI/SalI cClaspin.EGFP cassette from pEGFP-N1-cClaspin. The entire cDNA
sequence was verified by sequencing.
2.1.2.7.7. pLox-Neo-GFP and pLox-Bsr-GFP
The Multi Cloning site was removed from pEGFP-C2 (Clontech) by digestion with
BamHI/BglII and re-ligating the resulting vector. The resulting plasmid was
digested with MluI/PciI to liberate the GFP expression cassette. This fragment
was blunt ended with Klenow and then ligated with KpnI linkers. The resulting
fragment was then digested with KpnI and ligated into KpnI digested pLox-Neo
and pLox-Bsr (gift from JM Buerstedde) to yield pLox-Neo-GFP and pLox-Bsr-GFP.
2.1.2.7.8. pTET-Off Advanced Puro
pTET-Off advanced was digested with XhoI to remove the Neomycin resistance
cassette. The resulting plasmid was either self ligated to generate pTet-Off
Advanced – Neo (no selectable marker) or ligated with an XhoI Puro resistance
cassette from pLox-Puro.
2.1.2.7.9. pHIS
pHIS was generated by ligating a HindIII/BamHI fragment from the Histidinol
resistance cassette (JM Buerstedde) into the HindIII/BamHI sites of pPUR
(Clontech). This removes the puromycin resistance cassette from pPUR and
replaces it with the Histidinol resistance gene, allowing its expression from the
SV40 promoter.
2.1.2.7.10. pSuperior/Frt-Hygro
pSuperior.neo (Oligoengine) was digested with EcoRI/XmaI and blunt ended using
Klenow. This plasmid backbone was then ligated a blunt PvuII cassette from
pcDNA5/FRT/TO to generate the desired plasmid. This vector was then digested
with BglII and XhoI and ligated with the appropriate annealed shRNA oligos.Conor Larkin Chapter 2 57
Primers Description
A G13F:
5′-GGTCGACCAGACCCGTCATACCTATACGTGAGC-3′ 
G7R:
5′-GATCGATGAATAGAAGTGATGCGTGCTATGG-3′ 
Gel Purified PCR
product (1648bp)
B G10F:
5′-CTTTGACTCAGGTTGTAATCTTAGG-3′ 
5R
5′-CTGCTTCTAGAATGGGAAAAGCAACGAAGC-3′ 
PCR product
digested with PstI
then gel purified
(988bp)
C G14F:
5′-GCTACAGCTATCTTGACAAGTGTG-3′ 
G13R
5′-AAGCAGAGCCCTGCGGCTC-3′ 
Gel Purified PCR
product (584bp)
D G15F:
5′-GAAGAGGGCAGTGATGGCTCG-3′ 
G14R
5′-GGAGCAGCGGAGGAGGGTTG-3′ 
Gel Purified PCR
Product (460bp)
E 3F:
5′-AATGTTGGTCGACGAAGAGAAACAAGTTGAAGACGGT-3′ 
5R
5′-CTGCTTCTAGACACTGTTCTCGTTCAAATCTCTC-3′ 
PCR product
digested with SacI
then gel purified
(2007bp)
Table 2-3 Southern Blotting Probes
2.1.3. Molecular Biology - Analysis of Protein
Sigma (Poole, Dorset)
Tween 20 , Benzamidine, Aprotinin, Leupeptin, Okadaic acid, EGTA, Sodium
orthovanate, Sodium fluoride, β-glycerophosphate, Dithiothreitol, Triton-X-100, 
Brij-35, PMSF, Sodium Pyrophosphate, Protease Inhibitor Cocktail I, Phosphatase
Inhibitor cocktail I, Phosphatase Inhibitor cocktail II, Protein A-Sepharose Beads,
Anti-flag M2 Affinity gel, Flag Peptide, Ponceau S solution, TEMED, BSA, ATP.
Invitrogen (Paisley, UK)
1M HEPES solution, Novex Precast gels, Simply Blue Safe Stain.
Stratech Scientific LTD (Suffolk, UK)
StrepTactin Sepharose (#2-1201-010), D-Desthiobiotin (10X Buffer E).
Merck Biosciences (Nottingham, UK)
NP-40.
Thermo Fisher Scientific (Cramlington, UK)
Bradford Assay Reagent, BCA assay reagent.
Fermentas (York, UK)
High Range, Spectra™ Multicolor Broad Range Protein Ladder, PAGE Ruler
Unstained Protein Ladder.Conor Larkin Chapter 2 58
GE Healthcare Life Sciences (Little Chalfont, UK)
Full Range Rainbow Molecular Weight Markers, Amersham ECL™ Western Blotting
Detection Reagents, Redivue L-S35 Methionine 1000Ci/mmol 10mCi/ml, Amplify
Fluorographic Reagent.
Perkin Elmer (Beaconsfield, UK)
EasyTide -
32P-ATP (3000Ci/mmol, 10mCi/ml).
Millipore (Watford, UK)
Chk1 (Recombinant human active, N-terminally GST tagged, expressed in Sf21
cells).
Biorad (Hemel Hempstead, UK)
Gel Dryer (Model 583) attached to a Gel Master Gel Dryer Vacuum System
(Welch), Empty Micro Biospin chromatography columns.
React Scientific (Troon, UK)
Supported Nitrocellulose Membrane (30cm × 3 m) 0.45μm pore size. 
Severn Biotech (Kidderminster, UK)
30% acrylamide solution (37.5:1), 40% acrylamide solution (125:1).
New England Biolabs UK (Hitchin, Hertfordshire, UK)
Goat Anti-rabbit IgG (H&L) HRP secondary antibody, Horse Anti-mouse IgG (H&L)
HRP secondary antibody, Lambda Protein Phosphatase, 3 × red Loading Buffer
Pack.
Promega (Southampton, UK)
Donkey Anti-Goat HRP secondary antibody, Quick Coupled T7 TNT Kit.
Genetic Research Instrumentation (Braintree, Essex, UK)
AE-6450 Dual Mini Vertical P.A.G.E. Apparatus.
Thistle Scientific Ltd. (Uddingston, Glasgow, UK)
Western Blot Transfer Apparatus - Biometra Fastblot B34 w/o cooling.
Eppendorf (Histon, Cambridge, UK)
Biophotometer (Spectrophotometer), Refrigerated Microcentrifuge 5415 R,
Microcentrifuge 5415 D.
2.1.4. Cell Biology
2.1.4.1. Tissue Culture
BD Biosciences
T25, T75 and T175 Tissue Culture Flasks (Straight Neck, Standard TC Treated),
96 well, 24 well, 12 well and 6 well Tissue Culture Plates (Flat Bottomed,Conor Larkin Chapter 2 59
Standard TC Treated), 35mm, 60mm and 100mm Tissue Culture Dishes (Standard
TC Treated.
Thermo Fisher Scientific (Cramlington, UK)
1.5ml Nunc Cryovials.
Thermo Fisher Dharmacon (via Abgene Ltd., Epsom, Surry, UK)
The negative control siRNA used was siGENOME NON TARGETING Control #2 (#D-
001210-02-20). Both shClaspin.1 and shCdk2.1 were provided as pre-annealed
2’-deprotected desalted oligos. The siEDD pool was a Smart Pool designed by
Dharmacon against the chicken EDD mRNA sequence (XM_424053). The
lyophilised oligos were resuspended in the supplied resuspension buffer then
aliquotted and stored at -80°C.
siRNA Sequence
shClaspin.1
(cClaspin)
Sense Sequence
A.A.G.A.A.G.A.A.A.G.G.A.G.A.G.G.G.A.G.U.U
Antisense Sequence
C.U.C.C.C.U.C.U.C.C.U.U.U.C.U.U.C.U.U.U.U
shCdk2.1
(cCdk2)
Sense Sequence
C.U.G.C.A.C.U.A.C.G.A.U.C.C.C.A.A.C.A.U.U
Antisense Sequence
U.G.U.U.G.G.G.A.U.C.G.U.A.G.U.G.C.A.G.U.U
siEDD Pool A Target Sequences:
G.A.C.A.A.T.A.C.C.T.G.A.T.G.A.A.T.C.T
C.G.A.G.C.A.G.G.A.T.C.A.T.C.A.A.G.T.A
C.G.A.A.A.G.T.T.C.C.G.G.A.C.T.G.T.T.T
G.A.T.G.G.A.G.C.C.T.C.A.T.T.T.G.A.T.A
Table 2-4 siRNA Duplex Sequences
Invitrogen (Paisley, UK)
DMEM (high glucose, with pyruvate, no glutamine), RPMI 1640, 200mM
Glutamine, Tryptose Phosphate Broth, 2.5% Trypisin, MEM Vitamins, Geneticin
(G418), OptiMEM, Lipofectamine 2000, Tetracycline, Zeocin.
Sigma (Poole, Dorset)
DMEM minus Cysteine and Methionine, Penicillin G, Streptomycin, Amphotericin,
Puromycin, Histidinol, β-mercaptoethanol, EBSS, Doxycycline, Chicken Serum, 
Aphidicolin, Hydroxyurea, Caffeine, Doxorubicin, Etoposide, Cycloheximide,
Anisomycin, Emetine, Thapsigargin, Tunicamycin, Dithiothreitol, 30% Hydrogen
Peroxide, MG132, Leupeptin, Bromo-deoxyuridine, Nocodazole.
Oligoengine (Seattle, US)
Suitable target sequences for shRNA were designed against the isolated cCLSPN
mRNA isoform 1 or chicken CDK2 mRNA (EF182713) using the Oligoengine 2.0
software (sequence underlined in Table 2-5). The target sequences were then
made into the appropriate oligo sequence to allow the expression of the oligo as
a hairpin. The oligos were synthesised to produce BglII and XhoI overhangs once
annealed.Conor Larkin Chapter 2 60
shRNA Oligo Sequence
shCdk2 S  5′-GATCCCCCTGCACTACGATCCCAACATTCAAGAGATGTTGGGAT
CGTAGTGCAGTTTTTC-3′ 
shCdk2 AS  5′-TCGAGAAAAACTGCACTACGATCCCAACATCTCTTGAATGTTGGG 
ATCGTAGTGCAGGGG-3′ 
shClaspin S  5′-GATCCCCAAGAAGAAAGGAGAGGGAGTTCAAGAGACTCCCTCTC
CTTTCTTCTTTTTTTC-3′ 
shClaspin AS  5′-TCGAGAAAAAAAGAAGAAAGGAGAGGGAGTCTCTTGAACTCCCTC 
TCCTTTCTTCTTGGG-3′ 
Table 2-5 shRNA oligo sequences
Autogen Bioclear (Calne, UK)
Blasticidin (Invivogen), Foetal Bovine Serum, Tetracycline Free Foetal Bovine
Serum, Dialysed Foetal Bovine Serum.
Roche Diagnostics Ltd. (Burgess Hill, UK)
Hygromycin B.
Axon Medchem Ltd. (Groningen, Netherlands)
BIRB-796.
Merck Biosciences (Nottingham, UK)
Rapamycin, SB202190, SB600125, JNK Inhibitor VIII, Wortmannin, Bafilomycin A1.
Dr. David M. Sabatini, Whitehead Institute for Biomedical Research
Torin1.
Lonza (Slough, UK)
Amaxa® Nucelofection Kit T and L, Nucleofector II.
Biorad (Hemel Hempstead, UK)
Gene Pulser II, 0.4cm electroporation cuvettes.
Promega (Southampton, UK)
Dual Luciferase Assay Kit, Glomax Luminometer.
2.1.4.2. Flow Cytometry
Stratech Scientific LTD (Suffolk, UK)
Anti-mouse FITC (#515-095-072), Anti-rabbit FITC (#111-096-047).
Dako Ltd (Ely, Cambridgeshire, UK)
Mouse Anti-BrdU Antibody - clone Bu20a (#M0744).
Sigma (Poole, Dorset)
Propidium Iodide.Conor Larkin Chapter 2 61
Qiagen Ltd. (Crawley UK)
100mg/ml RNase A.
Millipore (Watford, UK)
Rabbit Anti-pS10 Histone H3 Antibody (#06-507).
SantaCruz Biotechnology (via Insight Biotechnology, Wembley, UK)
Rabbit Anti-pS10 Histone H3 Antibody (#sc-8656-R).
BD Biosciences
FACS Calibur Flow Cytometer, BD FACSFlow, BD FACS Rinse, BD FACS Clean, 5ml
Polystyrene Round Bottom Tubes, 15ml Polystyrene Conical Tubes.
2.1.4.3. Metaphase Spreads/FISH
Sigma (Poole, Dorset)
Demecolchine, Dextran sulphate, Igepal CA 630, Formamide (#F9037).
Dr. Darren Griffin, Farmachrom, University of Kent.
Biotin labelled Ch23 specific BAC (LEI0090), (Digoxygenin labelled Ch23 specific
BAC (LEI0102) not used in this study).
Qbiogene (Cambridge, UK)
FixoGum Rubber Cement.
Qiagen Ltd. (Crawley UK)
100mg/ml RNase A.
GE Healthcare Life Sciences (Little Chalfont, UK)
Cy3 labelled Streptavidin.
Vector Labs (Peterborough, UK)
Vectasheild mounting medium containing 1.5μg/ml DAPI. Conor Larkin Chapter 2 62
2.2. Methods
2.2.1. MOLECULAR BIOLOGY – ANALYSIS OF DNA
and RNA
2.2.1.1. Recombinant DNA Technology
2.2.1.1.1. Restriction Digests
Typically 5-10μg of DNA was incubated with 20U of restriction enzyme in the 
appropriate  buffer  with  a  final  volume  of  30μl,  at  the  recommended 
temperature for 2 hours. If the digest was allowed to proceed overnight then
the amount of restriction enzyme was reduced to avoid star activity. If a double
digest was to be preformed then the most appropriate buffer was chosen for
digestion. If no suitable buffer could be found then the digest would be carried
out sequentially adjusting the salt condition for the second enzyme and then
digesting with the second enzyme. To prevent re-ligation of the vector the DNA
was dephosphorylated. To dephosphorylate the vector DNA 2U of Shrimp
Alkaline Phosphatase was included when setting up the digest. Before further
processing for blunting or digestion with other enzymes the restriction enzymes
were heat inactivated (if possible) at 70°C for 10 minutes.
2.2.1.1.2. End Blunting
Where necessary, in order to create compatible ends for cloning, sticky ends
were converted into blunt ends. Depending on the type of overhang different
enzymes  were  chosen.    Klenow  Polymerase  was  used  to  fill  in  5′  overhangs.  
Mung bean nuclease was used to remove 3′ and 5′ overhangs. 
2.2.1.1.2.1. Klenow Fill in
1-5μg of purified DNA (or heat-inactivated restriction digests supplemented with 
Mg and 40μM dNTP’s) was diluted in reaction buffer supplemented with 40μM 
dNTP’s. 1U of enzyme per μg of DNA was added. The reaction was incubated at 
25°C for 15 minutes. To terminate the reaction EDTA was added to a final
concentration of 10mM and the reaction was heated to 70°C for 10 minutes.
2.2.1.1.2.2. Mung Bean Nuclease Digestion
1-5μg  of  purified  DNA  (or  heat  inactivated  restriction  digest  –  mung  bean 
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Nulcease digestion buffer.  2U of nuclease per μg of DNA was added and the 
reaction incubated at 30°C for 30-60 minutes. The DNA was purified by agarose
gel electrophoresis or spin column purification.
2.2.1.1.3. Linker Ligations
Pre-annealed phosphorylated linkers were ligated to blunt ended DNA in order to
create sticky ends. A 100 fold molar excess of linkers to DNA ends was added to
the blunt ended DNA. The ligation was carried out in 1 × Ligation buffer
containing 400U of T4 DNA ligase overnight at room temperature. The reaction
was then heat inactivated and without purification the ligated linkers were
digested to completion with the appropriate restriction enzyme in order to
generate sticky ends.
2.2.1.1.4. Annealing Oligos
2μg of sense and anti-sense oligos were placed in a 1.5ml screw cap micro tube.  
This was brought up to a final volume of 50μl with annealing buffer (100mM 
NaCl, 50mM HEPES). The oligos were then boiled for 5 minutes and then
immediately placed in a beaker containing ≈ 300mls of boiling water.  This was 
then allowed to cool to room temperature slowly. The annealed oligos were
stored at -20°C until use.
2.2.1.1.5. Vector-Insert Ligations
Prior to ligation the DNA was purified, either by gel purification or by clean up
columns (Qiaquick spin columns), and quantified using the Nanovue
Spectrophotometer. (GE Healthcare). Ligations were carried out using the Rapid
DNA Ligation Kit following manufacturer’s recommendations. A typical ligation
contained approximately 50ng of vector and 2 – 5 fold molar excess of insert
diluted in 1 × ligation buffer containing ATP. 5U of T4 DNA ligase was then
added. Ligations were incubated at room temperature for up to an hour and
then either frozen or transformed into chemically competent bacteria.
2.2.1.1.6. Cloning of PCR products
PCR products (see below) were cloned using the TOPO Cloning kits from
Invitrogen. Standard Taq polymerase (Platinum Taq/AmpliTaq) adds a non-
template A overhang to PCR products. Therefore the TOPO-TA cloning kit can
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Polymerase/Pfx Polymerase) with proofreading ability and exonuclease activity
remove this overhang and generate blunt ended PCR products. Therefore the
TOPO-Blunt cloning kits are used for these products. Alternatively blunt PCR
products are purified and A overhangs can be added.
The TOPO ligation reaction consisted of 1μl of TOPO vector, 4μl of purified PCR 
product and 1μl of the salt solution.  For short PCR products this was incubated 
at room temperature for 10-20 minutes but for long PCR products it was
incubated for 60-90 minutes. The reaction was used immediately for
transformation into DH5α E. coli.
2.2.1.1.7. Adding A overhangs to PCR products
The PCR product was purified using the PCR purification kit. 1 × PCR Buffer
supplemented with 200μM dATP was added.  1U of Taq polymerase was added 
and the reaction is incubated at 72°C for 30 minutes. To prevent loss of the
added A’s the reaction is used immediately for TA cloning.
2.2.1.1.8. Transformations
Typically 1/10
th – 1/5
th (2-5μl) of a ligation reaction or 10-100ng of super-coiled 
plasmid was added to 50μl of chemically competent DH5α E coli cells in a 14ml
round bottom tube. These were incubated on ice for 30 minutes and then heat
shocked at 42°C for 45 seconds. The bacteria were then re-incubated on ice for
2 minutes and 250μl of SOC media was added.  The bacteria were allowed to 
recover at 37°C with shaking before being spread onto the appropriate selective
plates.    To  ensure  single  colonies  were  obtained  both  50μl  and  250μl  of  the 
transformation mix was plated out.
2.2.1.1.9. DNA Clean up
Prior to ligation the DNA was ‘cleaned up’ using one of the following Qiagen kits
following manufacturer’s instructions. In brief the appropriate solubilisation
buffer containing a high salt concentration was added to the digest or gel. Once
dissolved (the gel was heated to 50°C in order to solubilise it) the mixture was
applied to a silica based spin column which binds DNA in the presence of high
salt concentration. The column was washed with Ethanol and the DNA eluted in
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QiaexII Gel extraction kit – for purification of large fragments of DNA from
agarose gels.
Qiaquick Gel Extraction Kit – for routine purification of DNA from agarose gels.
Qiaquick PCR purification kit – for routine clean up of restriction digests, PCR
products etc.
Qiaquick Nucleotide Removal Kit – for the clean up of restriction enzyme digests.
2.2.1.1.10. Ethanol Precipitation
A crude DNA purification can be carried out by precipitating DNA from solution
using Ethanol. To the volume of the DNA in solution (restriction digest etc) was
estimated. To this was added 3M Sodium Acetate pH5.2 (volume equal to 1/10
th
the volume of DNA) followed by ice cold 100% Ethanol (volume equal to twice
the volume of DNA + sodium acetate). The solution was mixed and incubated on
ice for 30 minutes. The tube was then spun at 16,100 x g for 30 minutes at 4°C.
The pelleted DNA was washed once with 70% Ethanol to remove the excess salt,
allowed to air dry for a couple of minutes and then resuspended in an
appropriate butter e.g. 10mM Tris-HCl pH 8.0 or TE buffer. To precipitate DNA
from a dilute solution 40-50μg of glycogen was added to the solution prior to the 
addition of ethanol to aid in the precipitation of the DNA.
2.2.1.1.11. Plasmid Preps
Plasmid preps were carried out using the Qiaprep Maxi/Mini prep kits from
Qiagen. Miniprep DNA was used for routine cloning and DNA sequencing. Maxi
prep DNA was used for transfecting cells. From an overnight culture (3mls for a
miniprep, and 100mls for a maxi prep) the bacteria were pelleted. The pellet
was then resuspended in a buffer containing RNaseA and lysed by the addition of
a SDS/NaOH solution. The SDS and proteins were precipitated by the addition of
potassium acetate. The precipitate was removed (by centrifugation for the
minipreps or by filtration for the maxipreps) and the cleared lysate containing
the plasmid was bound to a column (silica based spin-column for minipreps and
an ion-exchange column for maxipreps). The columns were washed and the DNA
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isopropanol followed by a high speed centrifugation step. The resulting pellet
was re-dissolved in an appropriate volume of 10mM TrisHCl pH 8.0.
2.2.1.2. Nucleic Acid Quantitation
The concentration and quality of nucleic acids (DNA/RNA/oligos) was estimated
by UV spectroscopy, by either using the Nanovue spectrophotometer or the
Biophotometer with UV transparent cuvettes, Uvettes. The A260 reading was
used in order to determine the concentration of nucleic acid using the following
conversion factors. An A260 reading of 1 was equivalent to 50μg/ml for DNA, 
40μg/ml for RNA and 30μg/ml for DNA oligos.  An A260/A280 ratio of greater than
1.8 was classified as a ‘clean’ DNA solution. For greater accuracy A260 readings
were only taken between 0.1 and 1, the DNA was diluted as appropriate.
2.2.1.3. DNA sequencing
DNA sequencing was carried out by the Molecular Technology Service at the
Beatson Institute. DNA sequencing is carried out using the BigDye® Terminator
v3.1 Cycle Sequencing Kit from Applied Biosystems, routinely using
approximately 500ng of plasmid DNA as template and 20ng of sequencing primer.
The resulting sequencing reactions are analysed using an Applied Biosystems
3130xl (16 capillary) sequencer. The data was analysed using Contig Express.
High quality sequence data obtained in triplicate was used to determine new
sequence.
2.2.1.4. Polymerase Chain Reaction
2.2.1.4.1. PCR
Standard PCR was carried out using either Platinum Taq or AmpliTaq PCR kits.
The PCR reactions were assembled in thin walled domed capped PCR tubes and
typically consisted of 1-10ng of plasmid DNA or 50-100ng of genomic DNA, 1 ×
PCR Buffer, 200μM each dNTP, 0.2μM forward and reverse primers and 1-2.5U of 
polymerase in a final volume of 50μl.  A typical PCR cycle consisted of initial 
denaturation at 94°C for 1 minute, followed by 25-35 cycled of 94°C for 30 sec,
annealing at 45-65°C for 30 sec followed by 72°C for 1min per kb. A final
extension of 10 minutes at 72°C was carried out and the PCR product was then
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High fidelity PCR was carried in order to amplify DNA for sequence analysis, for
cloning and for amplifying genomic DNA. The procedure is the same as above
except that a high fidelity polymerase is used according to manufacturer’s
instructions. Unless stated elsewhere the primer sequences used are given in
Table 2-1.
2.2.1.4.2. RT-PCR
Routine RT-PCR was carried out using the GeneAmp RT-PCR Core kit. For cDNA
cloning the Superscript II RT-PCR kit coupled with a Pfx Polymerase amplification
step was used following the manufacturers instructions.  Typically 2μg of total 
RNA was reverse transcribed into cDNA by MuLV reverse transcriptase using both
random hexamers and Oligo dT’s as primers. 1/10
th of the cDNA generated was
used as the template in the corresponding PCR’s. Primer Sequences used are
given in Table 2-2.
2.2.1.4.3. RACE
Rapid Amplification of cDNA Ends was carried out using the SMART RACE kit from
Clontech following manufacturer’s instructions.  3′ RACE cDNA is generated using 
a Universal Primer Sequence attached to dT(30)VN to prime synthesis.  3′ RACE 
PCR’s are carried out using forward primers designed towards the 3′ end of the 
gene of interest and the reverse primer from the universal primer sequence
attached to the dT(30)VN sequence.  5′ RACE cDNA is generated by priming cDNA 
synthesis using a dT(25)VN primer and including a universal primer sequence
ending in a dG(3) sequence. Once the BD PowerScript™ Reverse Transcriptase
reaches the end of the transcript it adds a non-template specific dC(3). This then
anneals to the dG(3) containing primer and this primer serves as a template to
add the universal primer sequence to the ends of all transcripts transcribed.
The 5′ RACE PCR’s are carried out using a reverse primer designed towards the 5′ 
end of the gene of interest and the forward primer from the universal primer
sequence added to the 5′ ends of all transcripts.  The RACE primer sequences 
used are given in Table 2-2.
2.2.1.4.4. Site directed mutagenesis
Site Directed Mutagenesis was carried out using the QuickChange II Kit from
Stratagene according to manufacturer’s instructions. Briefly the mutagenesis
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reverse mutagenesis primers, 1× PCR buffer, 1 × dNTP’s and 2.5U of PfuUltra HF
DNA polymerase in a final volume of 50μl.  The PCR reaction was cycled as per 
manufacturer’s instructions. Following the cycle 10U of DpnI restriction enzyme
was added and incubated at 37°C for 1 hour to digest the parental DNA. The
remaining DNA was then transformed into XL1-Blue Supercompetent E. coli cells.
Plasmid was isolated from the colonies that grew and the DNA was sequenced in
order to identify a plasmid containing the desired mutation. The primer
sequences used for mutagenesis are given in Table 2-2.
2.2.1.5. Agarose Gel electrophoresis
Agarose gel electrophoresis was used for the routine analysis of DNA from
restriction digests and PCR’s etc or as the first step in Southern blotting. 0.8% -
2% agarose gels in 1×TAE buffer was boiled in the microwave, allowed to cool
and poured into the casting tray. Prior to pouring Ethidium Bromide (final conc.
1μg/ml)  or  GelRed  (10,000×)  was  added  to  visualise  the  DNA.    (GelRed  is  a 
sensitive, non-toxic, non-mutagenic dye with a similar excitation and emission
spectrum of EtBr) The DNA was mixed with 6×loading dye (10 mM Tris-HCl pH
7.6, 0.15% orange G, 0.03% Xylene Cyanol FF, 60% glycerol, 60 mM EDTA) and
loaded into the gel along with DNA ladder for size estimation (O’GeneRuler
100bp, O’GeneRuler 1kb and O’GeneRuler 1kb Plus, Fermentas). The gel was
typically run at between 8-10V/cm and the DNA visualised using a
transilluminator or the Syngene Genius Bio imaging system with GeneSnap
Software.
2.2.1.6. Southern Blotting
20μg of purified DNA was first digested with the appropriate restriction enzyme 
(200-300U) in a final volume of 300μl overnight at 37°C.  The digested DNA was 
concentrated by EtOH precipitation and re-dissolved in 30μl of TE buffer.  The 
DNA was loaded onto a 0.8% agarose gel (15cm × 15cm × 0.7cm) and run at 1.2-
1.5V/cm overnight. The gel was examined using the transilluminator in order to
confirm that it had run for long enough. In order to facilitate the transfer of
high molecular weight DNA from the gel a small amount of depurination was
induced by incubating the gel with 0.25M HCl for 30 minutes. This introduces
nicks into the DNA breaks the DNA into smaller pieces when denatured by alkali.
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1 hour with gentle agitation. Finally the gel was neutralised in neutralisation
buffer (1M TrisHCl pH 8.0, 1.5M NaCl) for 1 hour with gentle agitation at room
temperature. In order to transfer the DNA from the gel to the nylon membrane
2 sheets of 3MM paper were wrapped around a glass plate 16cm × 16 cm. The
glass support was placed on rubber bungs in a Pyrex dish. The dish was filled
with 20×SSC and the 3MM paper was allowed to dip into the buffer. The top left
hand corner of the gel was cut off for orientation and the gel was inverted and
placed on the wet 3MM paper. Air bubbles were removed. 4 wide strips of
strong plastic were then placed under the edges of the gel to prevent buffer
from bypassing the gel and entering the paper towels directly. The nylon
membrane was placed on top and the air bubbles were removed. 2 sheets of
3MM paper the same size as the gel were placed on top and were allowed to wet
through, followed by stacks of paper towels placed on top. Another glass plate
was placed on top of this and was weighted using some lead pots. This set up
allows for the buffer in the Pyrex dish to travel through the gel and membrane
into the paper towels, carrying the DNA with it. The DNA will be bound by the
membrane. The transfer was allowed to take place overnight. Once transferred
the DNA was UV cross linked to the membrane at 120mJ/cm
2 using the
Stratalinker 1800 (Stratagene) or the UVitec crosslinker (UVitec). The
membrane was then stored dry until use. In order to ensure successful transfer
of the DNA from the gel onto the membrane, following transfer the membrane
was incubated with a Methylene blue stain (0.04% Methylene blue in 0.5M NaOAc
pH 5.2) for 20-30 minutes. The membrane was then washed gently with water.
DNA stains blue on the white background. To remove the methylene blue stain
the membrane was then washed in 1% SDS/1 × SSC for 20 minutes at room
temperature.
2.2.1.7. Probe Labelling and hybridisation
DNA probes (usually 500bp-1500bp in length) were labelled using random priming
with the Rediprime II Kit. 25-50ng of probe DNA (generated by PCR
amplification of the target DNA and gel purified) was dissolved in 45μl of TE 
buffer, boiled for 5 minutes then cooled rapidly on ice to generate single
stranded DNA. This was added to the labelling tube which contained lyophilised
reaction  buffer,  dNTP’s  and  Klenow  Polymerase.    To  this  5μl  of  α-32P-dCTP 
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minutes. This generally yielded a probe of specific activity of greater than 1 ×
10
9 cpm/μg DNA.  The probe was boiled and cooled rapidly before adding to the 
hybridisation buffer.
Hybridisation was carried out in hybridisation bottled on a rotisserie in
hybridisation oven set to 65°C. The membrane was prehybridised in Church
Buffer (0.25M Na2HPO4 Buffer pH 7.2, 7% SDS, 1mM EDTA) for 1-2 hours at 65°C.
Fresh pre-warmed Church buffer was then added followed by the denatured
labelled probe. The membrane was hybridised overnight at 65°C. After
hybridisation the membrane was washed twice with wash buffer I (20mM
Na2HPO4 Buffer pH 7.2, 5% SDS, 1mM EDTA) and twice with wash buffer II (20mM
Na2HPO4 Buffer pH 7.2, 1% SDS, 1mM EDTA) then exposed to X-ray film in an
autoradiography cassette at -70°C for 1-2 days. The film was then developed in
a Kodak X-Omat 3000RA automatic film processor.
In order to strip the membrane prior to re-hybridisation the membrane was first
incubated with 50mls of 0.4M NaOH for 30 minutes at 42°C then with 50mls 0.2M
Tris-Cl pH7.5, 0.1% SDS, 0.1 × SSC and incubate for 30 minutes at 42°C. This was
followed either directly with pre-hybridisation or a 10 minute wash in Wash
Buffer II to remove the stripping buffer. Throughout the hybridisation process
and exposure to film it is important not to allow the membrane to dry out as to
do so make it more difficult to remove the probe.
2.2.1.8. Genomic DNA purification
Genomic DNA was purified using the Nucleon BACC2 DNA purification Kit. Briefly
approximately 1-2 ×10
7 DT40 cells were harvested and washed once in ice cold
PBS and transferred to a 1.5ml microtube. The cells were then resuspended in
1ml of Nuclear lysis buffer (Reagent A) (10mM TrisHCl pH 8.0, 320mM Sucrose,
5mM MgCl2 and 1% Triton-X-100) and incubated on ice for 5 minutes. The nuclei
were pelleted at 1,300×g for 5 minutes and the supernatant was discarded. The
pellet was then resuspended 2ml of Reagent B, an SDS containing buffer and
transferred to a polypropylene 15ml screw capped tube. The tube was rotated
on an end over end rotary wheel for 2-4 hours at room temperature to allow the
pellet to completely solubilise. 750μg of RNase A was then added to the samples 
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deproteinised by adding 0.5mls of 5M Sodium perchlorate and 2mls of
Chloroform and mixing well following each addition. Without remixing the
phases, 300μl of Nucleon resin was added to the upper phase.  The nucleon resin 
reacts covalently with protein via the protein amino groups thus attaching the
remaining protein to the resin facilitating the separation of the proteins from
the DNA. To separate the phases the tube was spun at 1300×g for 3 minutes.
The upper phase (≈2.5mls) was then removed and  added to 5mls of ice cold 
Ethanol to precipitate the DNA. The DNA was pelleted by centrifugation at
1,300×g for 15 minutes. The resulting pellet was washed once with 70% Ethanol
and resuspended in 500μl of 8mM NaOH.  Once dissolved the pH was adjusted by 
adding HEPES to a final concentration of 10mM. The DNA was quantified using
the NanoVue spectrophotometer and stored at 4°C.
2.2.1.9. Total RNA purification
RNA was purified from cells using RNABee, a reagent containing phenol and
guanidine isothiocyanate. Briefly, approximately 5 × 10
6 cells were washed and
resuspended in 1ml of RNA Bee solution. 0.2mls of chloroform was added to this
and shaken vigorously. It was then incubated on ice for 5 minutes before being
centrifuges at 16,100 x g for 10 minutes. The upper phase containing the RNA
(≈500μl) was then added to 500μl of isopropanol to precipitate the RNA.  After 
incubation at room temperature for 10 minutes the RNA was pelleted by
centrifuging at 16,100 x g for 15 minutes at 4°C. The resulting pellet was then
washed twice with 1ml of 70% Ethanol and allowed to air dry. The pellet was
resuspended in RNase free water and quantified using the NanoVue
spectrophotometer and stored at -80°C. If necessary the RNA was further
purified using the RNeasy Mini Kit from Qiagen.
2.2.1.10.cDNA library screening
2.2.1.10.1. Titering the Library
A chicken Uni-ZAP XR cDNA Library was screened for the presence of a cClaspin
cDNA according to manufacturer’s instructions. In order to determine the titre
of the library the host bacteria were first prepared.  A colony of XL1-Blue MRF′ 
from a freshly streaked plate was inoculated into 50mls of LB containing 10mM
MgSO4 and 0.2% maltose. This was grown for 37°C for 4-6 hours and then the
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were then diluted in 10mM MgSO4 to an O.D. of 0.5. To aliquots of the diluted
bacteria was then added a 10 fold serial dilution of the library from 1:10 –
1:10,000. The phage were allowed to attach to the bacteria at 37°C for 15
minutes.  Then 6mls of molten NZY top agar (kept at 48°C), 30μl of 0.5M IPTG 
and 100μl of 250mg/ml X-gal was added to the bacteria.  This was mixed and 
immediately poured onto a dry pre-warmed 150mm NZY agar plate. The top
agar was spread evenly over the top of the plate. Once the top agar had set the
plates were inverted and incubated at 37°C for 6-8 hours to allow plaques to
form. From a plate with a reasonable number of plaque forming unit’s on it the
titre of the library and the background (the number of blue pfu’s) can be
determined.
2.2.1.10.2. Plating the Bacteriophage
Having just determined the titre of the library an appropriate number of plaques
can be plated out for screening. The library screen was preformed on ten 24.5
cm × 24.5 cm square bioassay dishes with 1.5  10
5 pfu/plate – therefore 1.5 ×
10
6 pfu’s were screened.  The XL1 Blue MRF′ bacteria were prepared as above 
and were resuspended in 10mM MgSO4 at an OD of 0.5. The appropriate volume
of phage was added to 18mls of bacteria and the phage were allowed to attach
to the bacteria at 37°C for 15 minutes. Per plate 1.8mls of this phage-bacteria
suspension was added to 20mls of molten NZY top agar (kept at 48°C). This was
mixed and immediately poured onto a dry pre-warmed square NZY agar plate.
The top agar was spread evenly over the top of the plate. Once the top agar
had set the plates were inverted and incubated at 37°C for 6-8 hours to allow
plaques to form. Once the plaques were visible the plates were removed from
the incubator and stored at 4°C until use.
2.2.1.10.3. Performing the Plaque Lifts
To perform the lifts square sheets of Hybond-N were placed onto the plate. The
plaque DNA was allowed to bind to the membrane for 2 minutes. A needle was
used to insert orientation marks. The membrane was then removed carefully
and placed in a tray of denaturation buffer (0.5M NaOH, 1.5M NaCl) for 2
minutes. Next the membrane was transferred to neutralisation buffer (0.5M
Tris-HCl pH 8.0, 1.5M NaCl) for 2 minutes and finally rinsing buffer (0.2M Tris-
HCl, 2×SSC). The membrane was then dried in 3MM paper and the DNA was
crosslinked to the membrane using the Stratalinker 1800 at 120mJcm
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procedure was repeated for the replica membrane (the needle marks were made
in the same place on the replica membrane for orientation) and for the rest of
the plates.
2.2.1.10.4. Screening and Hybridisation
A fragment of cCLSPN mRNA was cloned by Dr. Elizabeth Black by carrying out an
RT-PCR  using  the  following  primers:  forward  5′-ccggaattcgaagagaa
acaagttgaagacggt-3′  and  reverse  5′-ctcgagtgcggccgccacaaattttccagagcaaag-3′.  
The resulting PCR product was cloned into the EcoRI and NotI sites of pET28a(+)
using the restriction sites engineered into the PCR primers. To generate the
probe to screen the library this plasmid was then digested with EcoRI/NotI to
liberate the 814bp fragment used as the probe. The chicken GAPDH probe was
obtained by digesting pSPT19-GAPDH with EcoRI and the liberated fragment was
gel purified.  The probes were labelled with α-32P-dCTP as described previously. 
Hybridisation was carried out in a square Tupperware box in a shaking water
bath set at 68°C - processing 10 membranes at the time. The membranes were
pre-hybridised in hybridisation solution (6×SSC, 5×Denhardts Reagent, 0.5% SDS,
1μg/ml  PolyA  RNA  and  100μg/ml  Salmon  Sperm  DNA)  for  3  hours.    50ng  of 
labelled denatured probe was then added and the probe was allowed to
hybridise overnight. Following two washes with each of the wash buffers (I: 2×
SSC, 0.1% SDS, II: 1×SSC, 0.1% SDS, III: 0.1×SSC, 0.1% SDS) the membranes were
wrapped in Saran wrap and exposed to film at -70°C in autoradiography
cassettes. The films were developed in a Kodak X-Omat 3000RA automatic film
processor.
2.2.2. MOLECULAR BIOLOGY – ANALYSIS OF
PROTEIN
2.2.2.1. Whole Cell Lysates
Cells were treated or not as appropriate, pelleted at 250×g, then washed once
with ice cold PBS. Unless cells were lysed immediately they were snap frozen on
dry ice and stored at -70°C until use. Cell pellets were lysed in whole cell
extract buffer (400mM Potassium Chloride, 20mM HEPES, 5mM EDTA, 10mM
EGTA,  1mM  DTT,  0.4%  Triton-X-100,  10%  Glycerol,  5μg/ml  Leupeptin,  285μM Conor Larkin Chapter 2 74
PMSF,  1mM  Benzamidine,  5μg/ml  Aprotinin,  5mM  Sodium  Fluoride,  50ng/ml 
Okadaic  Acid,  1mM  Sodium  Orthovanadate,  10mM  β-glycerophosphate,  5mM 
Sodium pyrophosphate) then incubated on ice for 20-30 minutes. The samples
were then sonicated briefly to break up the chromatin (Sonics VCX130 Sonicator
2 sec on 2 sec off for 10 seconds on 30% amplitude) and spun at 16,100 x g in a
refrigerated microfuge for 15 minutes to pellet the cellular debris. The cleared
lysate was then transferred to a fresh tube and an aliquot removed for
quantitation. The remainder was snap frozen on dry ice and stored at -70°C until
use.
2.2.2.2. Protein Quantitation
2.2.2.2.1. Bradford Assay
The Bradford Assay relies on the blue colour generated when Comassie Brilliant
Blue reagent binds to protein side chains. A standard curve of BSA was
generated in a 1:10 dilution of the corresponding lysis buffer at the following
concentrations:  2000μg/ml,  1500μg/ml,  1000μg/ml,  750μg/ml,  500μg/ml, 
250μg/ml, 125μg/ml and 63μg/ml and 0mg/ml.  The protein samples of unknown 
concentration were diluted 1:10 in dH2O.  10μl of each standard (in duplicate) 
and  10μl  of  the  diluted  samples  were  placed  in  a  cuvette.  1ml  of  working 
Bradford Assay reagent (50% Bradford Assay reagent: 50% dH2O) was then added
to each cuvette. The absorbance at 595nm of the standards and samples were
then read using a Biophotometer. The concentration of protein in the unknown
samples was determined by comparison with the standard curve.
2.2.2.2.2. BCA Assay
Where substances in the lysis buffer interfered with Bradford Assay reagent (e.g.
SDS) a BCA assay was carried out. This assay works by the reduction of the Cu
2+
ions by the peptide bonds to Cu
+ and the subsequent chelation of these ions by
bichinconic acid to yield a purple colour. A standard curve was generated in the
same way as for the Bradford Assay.  20μl of each standard (in duplicate) and 
20μl of a 1:10 dilution of the protein samples was placed in a 5ml round bottom 
tube.  980μl of dH2O was then added to each tube.  1ml of working BCA assay 
reagent (25:24:1 Reagent A: Reagent B: Reagent C) was then added to each
tube. The tubes were capped and then mixed and then incubated at 65°C for 1
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purple. The samples were read in the Biophotometer at 562nm. The
concentration of protein in the unknown samples was determined by comparison
with the standard curve.
2.2.2.3. SDS-PAGE
SDS-PAGE was carried out in order to separate proteins so they could be
analysed further by Western Blotting or to directly analyse protein by staining
the gel. The mini vertical gel system from Atto was used. To cast the resolving
gel a solution containing 6-15% acrylamide (acrylamide:bisacrylamide 37.5:1),
375mM Tris-HCl pH 8.8 and 0.1% SDS was made. To polymerise the gel
ammonium persulphate and TEMED was added to a final concentration of 0.1%
and 0.08% respectively. The gel mix was placed in the gel casting apparatus and
over-laid with water-saturated butanol. Once set the stacking buffer (5%
acrylamide (acrylamide:bisacrylamide 37.5:1), 125mM Tris-HCl pH6.8, 0.1% SDS,
0.1% ammonium persulphate and 0.1% TEMED) was layered on top and the combs
were inserted to allow the loading of samples. Once set the gel apparatus was
correctly assembled and 1 × Running Buffer was added to the upper and lower
chambers of the tank.
Samples to be analysed were added to an equal volume of 2 × SDS-PAGE loading
buffer (120mM Tris-HCl pH6.8, 20% Glycerol, 5% SDS, Bromophenol blue
supplemented with 100mM DTT before use) and were boiled for 5 minutes to
denature the proteins. The samples were centrifuged briefly to remove debris
and the samples were then loaded into the wells. Molecular weight markers
were also run to estimate the size of the proteins to be analysed. The gels were
then run at 180V at constant voltage until the dye front had just entered the
running buffer.
To examine Chk1 phosphorylation by an electrophoretic mobility shift a 10%
acrylamide gel but used and the acrylamide to bisacrylamide ratio was changed
to 125:1.
To examine Claspin phosphorylation by an electrophoretic mobility shift a 6%
acrylamide gel (37.5:1) was used but the gel was run for 2 hours 15 minutes at
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2.2.2.4. Western Blotting
Western Blotting was carried out using the semi dry blotting technique. Once
the SDS-PAGE was run it was placed on top of 6 sheets of 3MM paper pre-soaked
in dry blot buffer and cut to the size of the gel. On top of this was placed the
nitrocellulose membrane and 6 more sheets of soaked 3MM paper. Air bubbles
were removed by gently rolling with a marker pen. The ‘sandwich’ was placed
on the transfer apparatus such that the gel was closest to the negative
electrode. The proteins were transferred as standard at 20V, 200mA, 8W for 1
hour 20 minutes.
In order to transfer Claspin and other high molecular weight proteins onto the
membrane they were transferred at 12V, 200mA, 8W for 2 hours and 30 minutes.
Ponceau S stain was used to ensure even transfer of the proteins onto the
membrane. Then the membrane was blocked in blocking buffer (5% Marvel (non-
fat dried milk powder) solution in 1 × TBS-T) for 1 hour at room temperature
with gentle agitation. The membrane was then incubated with the appropriate
primary antibody. (See Table 2-6 for the dilution of antibody used and what
blocking buffer was used) The membrane was then washed three times for 10
minutes each with 1 × TBS-T with gentle agitation. The membrane was then
incubated with the secondary antibody coupled to horseradish peroxidase for 1
hour at room temperature. The appropriate secondary antibodies were diluted
1:5000 in blocking buffer. After this incubation the membrane was washed as
before and the bound secondary antibody was detected using Enhanced
Chemiluminescence and X-ray film. The film was developed in a Kodak X-Omat
3000RA automatic film processor.
Antigen (Ab Type) Supplier Dilution and incubation conditions
cClaspin (pR) In house (HF64B) 1:2500-1:5000 in 5% Marvel in TBS-T
overnight at 4°C
Chk1 (mM) SantaCruz (G-4) 1:1000 in 5% Marvel in TBS-T overnight
at 4°C
Actin (mM) Sigma (AC-40) 1:1000 in 5% Marvel in TBS-T overnight
at 4°C
ATR (pG) SantaCruz (N-19) 1:1000 in 5% Marvel in TBS-T overnight
at 4°C
pS345 Chk1 (mR) Cell Signalling
(133D)
1:1000 in 5% BSA in TBS-T overnight at
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Antigen (Ab Type) Supplier Dilution and incubation conditions
Cdk2 (pG) SantaCruz (M2-G) 1:1000 in 5% Marvel in TBS-T overnight
at 4°C
EDD (pG) SantaCruz (N-19) 1:1000 in 5% Marvel in TBS-T overnight
at 4°C
Tubulin (mM) Sigma (DM1A) 1:5000 in 5% Marvel in TBS-T overnight
at 4°C
Strep II (mM) Calbiochem
(#71590-3)
1:1000 in 5% Marvel in TBS-T overnight
at 4°C
GFP (mM) SantaCruz (B2) 1:1000 in 5% Marvel in TBS-T overnight
at 4°C
c-myc (mM) SantaCruz (C-8) 1:1000 in 5% Marvel in TBS-T overnight
at 4°C
pS6 (pR) Cell Signalling
(#2211)
1:1000 in 5% BSA in TBS-T overnight at
4°C
pS6K (mM) Cell Signalling
(1A5)
1:1000 in 5% BSA in TBS-T overnight at
4°C
S6 (mM) Cell Signalling
(54D2)
1:1000 in 5% Marvel in TBS-T overnight
at 4°C
S6K (pR) Cell Signalling
(#9202)
1:1000 in 5% Marvel in TBS-T overnight
at 4°C
pJNK (mR) Cell Signalling
(81E11)
1:1000 in 5% BSA in TBS-T overnight at
4°C
pATF2 (pR) Cell Signalling
(9221)
1:1000 in 5% BSA in TBS-T overnight at
4°C
p p38 (pR) Cell Signalling
(9211)
1:1000 in 5% BSA in TBS-T overnight at
4°C
p cJun (S63) (pR) Millipore (#06-828) 1:1000 in 5% BSA in TBS-T overnight at
4°C
JNK (mR) Cell Signalling
(56G8)
1:1000 in 5% Marvel in TBS-T overnight
at 4°C
ATF2 (mR) Cell Signalling
(20F1)
1:1000 in 5% Marvel in TBS-T overnight
at 4°C
p38 (pR) Cell Signalling
(9212)
1:1000 in 5% Marvel in TBS-T overnight
at 4°C
cJun (pR) SantaCruz (D) 1:1000 in 5% Marvel in TBS-T overnight
at 4°C
peIF2α (mR)  Cell Signalling 
(119A11)
1:1000 in 5% BSA in TBS-T overnight at
4°C
eIF2α (pR)  SantaCruz  
(FL-315)
1:1000 in 5% Marvel in TBS-T overnight
at 4°C
Table 2-6 List of Primary antibodies
mM – mouse monoclonal; mR – rabbit monoclonal; pR – rabbit polyclonal; pG – goat polyclonal
2.2.2.5. Densitometry
Densitometry of Western blots was carried out using the ‘Analyse -> Gels’
function in ImageJ (NIH).Conor Larkin Chapter 2 78
2.2.2.6. In vitro transcription translation
Coupled in vitro transcription-translation reactions were carried out using the T7
Quick Coupled TNT kit from Promega.  A typical reaction consisted of 40μl of 
TNT mix (containing T7 RNA polymerase, nucleotides, amino acids (except
Methionine) salts and RNAsin Ribonuclease inhibitor as well as the reticulocyte
protein translation machinery), 1μg of plasmid DNA (with the cDNA downstream 
of a T7 promoter e.g. pCR4-TOPO, pBluescript or pcDNA3) 20μM Methionine , 
made up to 50μl with nuclease free water.  The reactions were incubated at 
30°C for 60-90 minutes.  In order to in vitro translate cClaspin 2μl of T7 PCR 
Enhancer Solution (25mM Magnesium Acetate, 2.5mM Potassium Chloride) was
added to the mix and the reactions were incubated at 30°C for at least 3 hours.
In order to label the translated proteins with radioactive Methionine 2μl of L-
[35S]-Methionine  (≈1000Ci/mmol,  10mCi/ml)  was  added  instead  of  the  cold 
Methionine. Reaction products were separated by SDS-PAGE. The S35 Signal
was amplified by fluorography using Amplify
TM. The gel was first rinsed in dH2O
and then fixed in freshly prepared fixing solution (50% Methanol/10% Glacial
Acetic Acid). This was incubated at room temperature with gentle shaking for
30 minutes. This fixing solution was replaced with Amplify solution for another
30 minutes. The gel was finally incubated in 10% glycerol for 5 minutes prior to
drying to prevent cracking. The gel was then dried and exposed to X-ray film in
an autoradiography cassette fitted with intensifying screens.
2.2.2.7. Immunoprecipitation
cClaspin was immunoprecipitated form DT40 cells using the HF64B antibody.
Approximately 2 × 10
7 DT40 cells were treated or not as desired and then
harvested, washed once in PBS and lysed in 200μl of NET-N Lysis buffer (20mM 
Tris-HCl pH 7.5, 10% Glycerol, 137mM NaCl, 2mM EDTA, 1% NP-40, 1×Protease
Inhibitor Cocktail, 1×Phosphatase Inhibitor Cocktail I, 1×Phosphatase Inhibitor
Cocktail II) for 20 minutes, sonicated briefly and then spun at 16,100 x g at 4°C
for 15 minutes in order to clarify the lysate. The protein concentration was
determined by Bradford Assay. 1mg of lysate was diluted in a final volume of
lysis buffer and 5μl of pre-immune serum from the rabbit used to generate the 
HF64B  antibody  and  40μl  of  a  50%  slurry  of  washed,  equilibrated  Protein  A-
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remove the proteins that bind non-specifically to either the beads or IgG. The
tubes were incubated at 4°C for 1 hour on an end-over-end rotator. The beads
were then pelleted and the pre-cleared lysate transferred to a new tube. To
this was added 5μl of HF64B antibody incubated at 4°C on a rotary wheel for 1 
hour.  Then 40μl of washed and equilibrated Protein A – Sepharose beads was 
added and incubated overnight at 4°C. The beads were then washed three
times with lysis buffer and once with PBS with lysis buffer and used as required.
For direct analysis of the purified protein the beads were boiled in SDS-PAGE
sample buffer in order to remove the bound proteins.
2.2.2.8. Phosphatase Treatment
Claspin was immunoprecipitated from treated lysates as described (Section
2.2.2.7) and the beads were washed × 3 with lysis buffer not containing
phosphatase inhibitors and × 2 with PBS. The final wash was in 1 × Lambda
Protein Phosphatase buffer.  The beads were then incubated with 20μl of 1 × 
Lambda Protein Phosphatase Buffer containing 1mM MnCl2 and 80U/μl of Lambda 
protein Phosphatase. The reactions were incubated at 30°C for 30 minutes.
10μl of 3 × SDS-PAGE loading buffer was added to terminate the reaction.  The 
protein was then analysed by SDS-PAGE and Western blotting to determine its
phosphorylation status.
2.2.2.9. TAP Purification and Proteomics
2 × 10
8 DT40 cells stably expressing Strep II – FLAG tagged cClaspin were treated
as required. The cells were then pelleted and washed twice with PBS. The cell
pellet was then lysed in 1.5mls of lysis buffer (150mM NaCl, 30mM Tris-HCl pH
8.0, 1 × Protease Inhibitor, 1 × Phosphatase Inhibitor I, 1 × Phosphatase Inhibitor
II. 01% SDS, 1% Triton-X-100) and incubated on ice for 30 minutes. The lysate
was then sonicated and then spun at 16,100 x g at 4°C for 15 minutes to clarify
the lysate.  The cleared lysate was then filtered through a 0.22μm filter. 
Streptactin Purification:  To the cleared lysate was added 200μl of a 50% slurry 
of pre-washed and equilibrated Streptactin Beads and rotated at 4°C over night.
The beads were pelleted at 1700×g for 1 minute. The pellet was transferred to
an  empty  micro  biospin  column  and  washed  three  times  with  500μl  of  wash 
buffer (150mM NaCl, 30mM Tris-HCl pH8.0, 0.1% Triton-X-100, 1 × ProteaseConor Larkin Chapter 2 80
inhibitor/Phosphatase inhibitor I and II).  To elute the bound proteins 500μl of 1 
× Desthiobiotin Elution buffer (100mM Tris pH 8.0, 150mM NaCl, 1mM EDTA,
2.5mM Desthiobiotin, 1 × Protease inhibitor/Phosphatase inhibitor I and II) was
added to the column. The column was then sealed and was mixed on the rotary
mixer for 20 minutes at room temperature. The column was placed over a 2ml
collection tube and spun to remove the eluted proteins from the column.
FLAG Agarose Purification: The eluate was placed in a fresh micro biospin
column  and  150μl  of  anti-FLAG  agarose  beads  (50%  slurry  of  pre-washed  and 
equilibrated with 1 × desthiobiotin elution buffer) was added. It was then
rotated at 4°C for 2 hours to allow binding of SF-Claspin to the FLAG beads. The
eluate was then discarded and the beads collected and washed three times with
wash buffer and once with 1×TBS. On the last wash the remaining wash buffer
was removed by doing a final spin with no buffer in the column or collection
tube.  The column was resealed and 200μl of FLAG peptide (200μg/ml in TBS) 
was added to elute the proteins off the beads. This was mixed on the rotary
mixer for 20 minutes and then spun to elute the proteins. The sample was then
concentrated by vacuum drying, resuspended in loading buffer and the proteins
were separated on a 10% Novex Gel. The gel was then stained with Simply Blue
Safe Stain to visualise the purified proteins.
Bands of interest were analysed by mass spectrometry by the Beatson Institute
Proteomics Facility. Briefly the gel pieces were excised and digested with
sequencing grade trypsin. The resulting peptides were subject to LC-MS/MS using
an Ultimate 3000 capillary LC system (Dionex) interfaced to a QSTAR XL hybrid
quadrupole time of flight tandem mass spectrometer (Applied Biosystems). The
data generated was compared with the data in the IPI_gallus_v340 database.
Multiple reaction monitoring (MRM) analysis was also employed using the 4000
QTRAP instrument to validate and relatively quantify phosphorylation sites.
2.2.2.10.Kinase Assay
SF-Claspin was translated using the IVT system from Promega as described in
section 2.2.2.6. The tagged claspin was then bound to Streptactin Sepharose
beads as described in section 2.2.2.9 but only using 20μl of beads.  (Purified 
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was washed with 1 × Kinase assay buffer and then used as the substrate for the
kinase assay. The Chk1 kinase was commercially available recombinant active
Chk1 and was diluted to an appropriate concentration in dilution buffer (20mM
HEPES, 1mM EDTA, 0.01% Brij 35, 5% Glycerol, 0.1% 2-mercaptoethanol, 1mg/ml
BSA). Reactions were carried out by assembling the appropriate amounts of
substrate and kinase and bringing the final volume up to 10μl.  10μl of 2 × Kinase 
assay buffer (100mM HEPES, 20mM MgCl2, 1.6mM DTT, 1.6mM EDTA, 20mM β-
glycerophosphate) was then added to each sample.  To start the kinase assay 2μl 
of 1mM ATP was added and the reaction was incubated at 30°C for 1 hour. To
stop the reaction 10μl of 3×SDS Loading buffer was added and the samples were 
boiled for 5 minutes. The proteins were then analysed by SDS-PAGE and western
blotting as described previously.
To monitor the incorporation of phosphate the 1mM ATP solution was
supplemented with a 1:30 dilution of -
32P-ATP (3000Ci/mmol 10mCi/ml) and
processed as above. The samples were separated on a 6% SDS-PAGE and
transferred to nitrocellulose membrane. This membrane was then exposed to X-
ray film in an autoradiography cassette fitted with intensifying screens.
2.2.3. BIOINFORMATICS
2.2.3.1. DNA Sequence analysis
Routine DNA sequence analysis (restriction site mapping, generation of cloning
strategies etc) and figure generation was carried using Vector NTI. DNA
chromatogram analysis and sequencing analysis was carried out in Contig
Express. Comparison between 2 nucleotide sequences was carried out using
Align X. Identification of unknown sequences was carried out using BLAST, NCBI.
Alignment of mRNA to genomic DNA was carried out using Spidey, NCBI.
2.2.3.2. Multiple Sequence Alignment
Multiple Sequence analysis and similarity plots were carried out using Align X
program which is based on the ClustalW method. The residues in the output file
were shaded according to similarity. The following Claspin orthologue
sequences were used in the analysis: Chicken – conceptual translation of isolated
chicken Claspin mRNA; Human - NP_071394.2; Mouse - NP_780763.2, Xenopus -Conor Larkin Chapter 2 82
NP_001082041; Zebrafinch - XP_002195688.1; Cow - XP_585130.4; Chimp -
XP_513311.2; Opossum - XP_001380658;
2.2.3.3. Tertiary Structure Prediction
The tertiary structure of Claspin was predicted using the Phyre Protein Fold
recognition Server. (http://www.sbg.bio.ic.ac.uk/phyre)
2.2.3.4. Isoelectric Point (pI) Plot generation
The entire protein sequence was divided up into 50 amino acid peptides over-
lapping by one amino acid using the Peptide Screening tool on the GeneScript
Website (http://www.genscript.com/peptide_screening_tools.html). The pI of
each of these individual peptides was calculated using the following tool -
http://www.ebioinfogen.com/biotools/protein-isoelectric-point-calculator.htm.
The pI of the peptide was plotted against the residue number (corresponding to
the residue number of the central amino acid of each peptide) using Microsoft
Excel.
2.2.4. CELL BIOLOGY
2.2.4.1. Tissue Culture
2.2.4.1.1. Culturing Suspension Cells (DT40/Cl18)
DT40 cells (ATCC CRl-2111) were cultured in high glucose DMEM containing
pyruvate supplemented with 10% FBS, 1% heat inactivated chicken serum, 2mM
Glutamine,  10μM  β-mercaptoethanol,  50U/ml  penicillin  G  and  50μg/ml 
Stereptomycin. The cells were grown in a humidified incubator at 39°C. Cells
were passaged by simply diluting 1:10-1:20 into fresh media every 2-3 days to
maintain the cells in exponential growth phase. Cl18 DT40 cells (a surface IgM
negative variant DT40 cell line (Buerstedde et al, 1990) obtained from N
Lowndes, NUI Galway) were also grown at 39°C in RPMI1680 supplemented with
10% FBS, 1% heat inactivated chicken serum, 2mM Glutamine and 50U/ml
Penicillin G and 50μg/ml Streptomycin.  These cells were diluted 1:100 every 2 
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2.2.4.1.2. Culturing Adherent Cells (DF-1, CEF, HEK293-Tet
Off)
DF-1 cells (CRL-12203) are immortalised non-transformed chicken embryo
fibroblasts. They were grown at 39°C in high glucose DMEM containing pyruvate
supplemented with 10% FBS and 4mM Glutamine. The cells were passaged at a
ratio of 1:10-1:20 every 3-4 days.
The secondary Chick embryo fibroblasts were derived from frozen stocks of early
passage primary fibroblasts that were previously isolated from 10 day old
chicken embryos. The cells were grown at 39°C in high glucose DMEM containing
pyruvate supplemented with 10% FBS, 10% tryptose phosphate broth, 1% heat
inactivated chicken serum, 2mM Glutamine, 50U/ml Penicillin G and 50μg/ml 
Streptomycin. The cells were passaged at a ratio of 1:10 – 1:20 every 2-3 days.
The HEK293 Tet-Off cells (Clontech) were grown in at 37°C in high glucose DMEM
containing pyruvate supplemented with 10% FBS and 2mM Glutamine. The cells
were passaged at a ratio of 1:10 1:20 every 3-4 days.
2.2.4.1.3. Passaging adherent cells
Once the cells had reached confluence an aliquot of the cells was transferred to
a new flask to allow continued growth of the culture. The media was first
aspirated from the cells and they were then washed three times with 10mls of
pre-warmed PBS. The cells were then washed with 10mls of pre-warmed PE.
1ml of pre-warmed 0.25% trypsin in PE was added to the flask (the volume of
trypsin depends on the size of the flask/dish, 1ml is sufficient for a T75 flask)
and the trypsin solution was distributed evenly over the surface of the
flask/dish. The flask was then returned to the incubator for 2-3 minutes until
the cells had detached form the plate. Once detached, 10mls of fresh pre-
warmed media was added to the cells to inactivate the trypsin. An aliquot of
this cell suspension was then added to a flask containing fresh media. The cells
were then returned to the incubator to allow re-attachment of the cells. (Note:
HEK293 Tet-Off cells are not very adherent and require 2-3 days before the cells
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2.2.4.1.4. Cryogenic Preservation of Cell lines
For long term storage of cells, log phase healthy cells were trypisinsed if
necessary and then resuspended in 90% FBS/10% DMSO and divided into 500μl 
aliquots in 1.5ml cryovials. Initial freezing was carried out in a Mr Frosty
container (containing isopropanol) at -70°C to give a cooling rate of 1°C/minute.
Once a temperature of -70°C was reached the cells were transferred to storage
in liquid nitrogen vapour phase tanks at -180°C. To revive the cells the vials
were retrieved and were quickly warmed up to 37°C by placing in a container of
warm water. Once thawed the cells were added to pre-warmed media. The
following day the cells were passaged or the media was changed depending on
the confluency of the cells.
2.2.4.1.5. Counting Cells
Cells were counted using the automated Casy® Cell Counter and Analyser System
(Innovatis). The appropriate dilution of cells (either directly for suspension cells
or following trypsinisation for adherent cells) was automatically counted by the
machine set to exclude debris from the calculation. This also allows for easy
determination of the viability of the culture. For growth curve analysis
measurements were taken in triplicate.
2.2.4.1.6. Transient Transfection of cells using Lipofectamine
2000
Lipofectamine 2000 was used in order to introduce siRNA or plasmid DNA into
cells following manufactures instructions. Briefly the cells were either set up
the day before transfection to be 90% confluent (for plasmid transfection) or 30-
40% confluent on the day of transfection. The cells were set up in antibiotic
free medium. Separately an appropriate amount of plasmid/siRNA and
Lipofectamine 2000 was diluted in OptiMEM. For plasmid transfections the ratio
of Lipofectamine 2000 to plasmid was typically 2.5μl:1μg and for siRNA it was 
10μl:200pmol.  Following a 5 minute incubation the diluted Lipofectamine 2000 
and plasmid/siRNA was mixed and complexes were allowed to form for 20
minutes. The lipid – plasmid/siRNA complexes were then applied to the cells
and the dish rocked gently to ensure even coverage of the cells with the
complexes. Cells were returned to the incubator and harvested at the
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2.2.4.1.7. Transient Transfection of Cl18 cells with plasmid
DNA using Nucleofection
Cl18 DT40 cells were transiently transfected with plasmid DNA using the Amaxa
nucleofection kit T as per manufacturer’s instructions. Cells were passaged the
day before to ensure that they were in log phase on the day of transfection. Per
nucleofection 1 × 10
6 cells were mixed with 100μl of pre-warmed supplemented 
Solution T and 10μg of plasmid DNA.  This was then mixed gently and transferred 
to an electroporation cuvette and subject to programme B-0023. The cells were
then transferred to a 3-5mls of pre-warmed media and returned to the
incubator.
2.2.4.1.8. Transient Transfection of DT40 cells with siRNA
using Nucleofection
DT40 cells were transfected with siRNA using the Amaxa nucleofection kit L as
per manufacturer’s instructions. Cells were passaged the day before to ensure
that they were in log phase on the day of transfection. Per nucleofection 1 × 10
6
cells  were  mixed  with  100μl  of  pre-warmed  supplemented  Solution  L  and 
100pmol of siRNA. This was then mixed gently and transferred to an
electroporation cuvette and subject to programme B-0023. The cells were then
transferred to a 3-5mls of pre-warmed media and returned to the incubator.
The siRNA sequences are given in Table 2-4.
2.2.4.1.9. Targeted integration of targeting vector – DT40-MCM
Cells
Cells to be transfected were set up the day before at 1 × 10
5 cells/ml. On the
day of the transfection 5 × 10
6 cells were pelleted and resuspended in 500μl of 
supplemented  Solution  T  (Amaxa)  at  room  temperature.    5μg  of  linearised 
targeting vector DNA (purified by EtOH precipitation) was added and the
Cells/DNA/Solution T mixture was divided amongst 5 nucleofection cuvettes.
The cells were then subject to program A-0023. Immediately all the cells were
pooled into 20mls of pre-warmed media. The cells were allowed to recover
overnight at 39°C. The following day the total volume of media was brought up
to 140mls and selective drug (G418 at 2mg/ml or Blasticidin-S at 30μg/ml) was 
added along with Amphotericin B at 2.5μg/ml.  The cells were divided amongst 7 
× 96 well plates using a multi-channel pipette. Colonies were visible after 2-3
weeks. Cells were screened for GFP expression using an Olympus CKX41
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2.2.4.1.10. Targeted integration of targeting vector – Cl18 Cells
Cells to be transfected were set up the day before at 1 × 10
5 cells/ml. On the
day of the transfection 1 × 10
7 cells were pelleted and resuspended in 500μl of 
ice  cold  PBS.    30μg  of  linearised  targeting  vector  DNA  (purified  by  EtOH 
precipitation) was added and the Cells/DNA/PBS mixture was transferred to a
pre-chilled 0.4cm cuvette. The cells were incubated on ice for 10 minutes then
electroporated using a Biorad Gene Pulser II at 550V, 25μF at infinite resistance.  
The time constant is usually in the order or 0.8-1ms. The cells were returned to
ice for a further 10 minutes and then added to 20mls of pre-warmed media. The
cells were allowed to recover overnight at 39°C. The following day the total
volume of media was brought up to 140mls and selective drug (G418 at 2mg/ml
or Blasticidin-S at 30μg/ml) was added along with Amphotericin B at 2.5μg/ml.  
The cells were divided amongst 7 × 96 well plates using a multi-channel pipette.
Colonies were visible after 7-10 days. Cells were screened for GFP expression
using an Olympus CKX41 microscope.
2.2.4.1.11. Generation of stable DT40 cell lines using the Flp-In
T-Rex system
This system from Invitrogen was developed in DT40 cells by Mark Walker. The
cells were engineered to contain at least 2 stably integrated FRT sites in the
genome. This allows Flp recombinase mediated site directed recombination of
plasmid DNA containing FRT sites. In addition the cells also express the Tet
Repressor which represses transcription of transgenes which contain a Tet
operator sequence in their promoter. The transgene of interest is cloned into a
plasmid containing TetO sequences or not depending on whether constitutive or
regulated expression is desired (pcDNA5/FTR or pcDNA5/FRT/TO). This plasmid
contains an FRT site down stream of which is a cDNA encoding for resistance to
Hygromycin but missing the ATG start codon and a promoter. Upon targeted
recombination of the FRT sites the hygromycin resistance gene is placed
downstream of a promoter and regains the ATG start codon resulting in cells that
are resistant to hygromycin allowing for selection of the clones. Random
integration of the plasmid will not convey hygromycin resistance.
The Flp-In T-Rex cells were set up the day before at 1 × 10
5 cells/ml. On the
day of the transfection 5 × 10
6 cells were pelleted and resuspended in 500μl of 
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pcDNA5/FRT  or  pcDNA5/FRT/TO  and  4.5μg  of  a  Flp  recombinase  expression 
plasmid (pOG44) was added and the Cells/DNA/Solution T mixture was divided
amongst 5 nucleofection cuvettes. The cells were then subject to program A-
0023. Immediately all the cells were pooled into 20mls of pre-warmed media.
The cells were allowed to recover overnight at 35°C. The lower temperature
allows the Flp Recombinase (derived from yeast) to work. The following day the
total volume of media was brought up to 140mls and Hygromycin was added to a
final concentration of 1.5mg/ml. The cells were divided amongst 7 × 96 well
plates using a multi-channel pipette. The plates were placed at 35°Cfor a
further 2 days and then transferred to 39°C. Colonies were visible after 2-3
weeks
2.2.4.1.12. Expansion of drug resistant DT40 clones
Following the selection process clones were visible by eye in the 96 well plates.
They could also be seen by a yellowing of the media in wells where clones were
growing. Wells where clones were grown were inspected under the microscope
to ensure no other clones were growing in the same well. Cells from wells with
single clones in them were resuspended and then added to 800μl of fresh media 
in a 24 well plate.  When the cells had reached confluence 500μl of the cells was 
added to 2.5mls of fresh media in a 6 well plate. Following this the cells were
transferred to T25 flasks and larger. An aliquot of the cells from the clones was
frozen down as soon as possibly to prevent in vitro evolution. Clones were
usually maintained under antibiotic selection until they had reached the T25
stage.
2.2.4.1.13. Luciferase Assay
Cells  to  be  assayed  were  transfected  with  7.5μg  of  pTRE-Tight  Luciferase 
(Clontech) and 0.25μg of pTK Renilla (Promega) by nucleofection as described.  
After 24 hours the cells were assayed for the presence of luciferase according to
manufacturer’s instructions. Briefly the cells were washed once in PBS and then
lysed in 1 × Passive Lysis Buffer with gentle agitation on an orbital shaker for 15
minutes.    In  10μl  of  each  sample  was  placed  into  a  96  well  plate  and  the 
luciferase activity (both Firefly and Renilla) was read using a Glomax
Luminometer.  50μl of LAR II reagent and Stop and Glo Reagent was used with an 
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the transfection efficiency (Firefly/Renilla) and the amount of protein between
samples.
2.2.4.1.14. Irradiating Cells
As a method of inducing DNA damage cells were treated with either -IR or UV-C
light. Cells were irradiated with -IR using an Alcyon II Cobalt-60 Teletherapy
Unit. Dose rates varied from 1-2.5Gymin
-1. Cells were irradiated directly in the
media in the culture flask. Control cells were brought to the Co-60 source but
were not exposed to the ionising radiation. Cells were treated with UV-C light
using a Stratalinker 1800 (Agilent Technologies, Stockport, UK) containing 254nm
bulbs set to deliver 5000μJcm
-2 (50Jm
-2). Prior to UV-C exposure the DT40 cells
were first washed with PBS and placed in tissue culture plate suspended in a
small volume of PBS. The cells were returned to full media following
irradiation.
2.2.4.2. Flow Cytometry
2.2.4.2.1. Fixing cells
Cells were treated as required and pelleted at 250×g for 5 minutes in 15ml
polystyrene tubes.  The resulting pellet was then resuspended in 200μl of ice 
cold PBS. While vortexing, 2mls of ice cold 70% Ethanol was added drop wise to
fix the cells. This minimises the formation of clumps and ensures uniform fixing
of the cells. Fixed cells were stored at 4°C overnight or at -20°C for a couple of
hours to several weeks before further analysis.
2.2.4.2.2. DNA Content
Cells were fixed as described and stored at -20°C for at least 30 minutes. The
cells were pelleted and resuspended in 1ml of PBS containing 10μg/ml Propidium 
Iodide and 250μg/ml RNase A.  The cells were stored in the dark for 30 minutes 
before analysis on the flow cytometer.
2.2.4.2.3. S phase
To monitor DNA replication, cells were tested for their ability to incorporate the
thymidine analogue BrdU into their DNA. Cells were treated as required and 15
minutes before harvest 25μM BrdU was added to the culture.  Cells were then 
fixed as above and stored until use. The cells were centrifuged at 250×g and the
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4M HCl was added. The samples were incubated at room temperature for 15
minutes. The HCl treatment denatures the DNA and exposes the BrdU epitopes
that are recognised by the anti-BrdU antibody. The cells were then washed once
with PBS and once with PBT (0.5% BSA, 0.1% Tween 20 in PBS). The resulting
pellet was resuspended in 200μl of PBT containing a 1:40 dilution of the anti-
BrdU antibody and incubated at room temperature for 30 minutes. The cells
were then washed with 1ml of PBT and resuspended in 200μl of PBT containing a 
1:40 dilution of the FITC conjugated anti-mouse antibody. The cells were
incubated for 30 minutes in the dark and then washed with 1ml of PBT. The cell
pellet was then resuspended in 1ml of PBS containing 10μg/ml Propidium Iodide 
and 250μg/ml RNase A.  The cells were stored in the dark for 30 minutes before 
analysis on the flow cytometer. Data was collected on a FACSCalibur flow
cytometer and the data analysed using WinMDI software.
2.2.4.2.4. Mitosis
The number of mitotic cells was estimated by counting the number of cells that
were positive for the mitosis specific marker, pS10 Histone H3, by flow
cytometry. Cells were treated as required, then fixed as above and stored until
use. The cells were centrifuged at 250×g and the ethanol was removed. The
cells were then resuspended in 1ml of PBS containing 0.25% Triton-X-100 and
incubated on ice for 15 minutes. The cells were then pelleted and resuspended
in 100μl of 1% BSA in PBS containing a 1:50 dilution of the anti-pS10 H3 antibody 
followed by a 90 minute incubation at room temperature. The cells were
washed once with 1% BSA in PBS and then resuspended in 100μl of 1% BSA in PBS 
containing a 1:30 dilution of the FITC conjugated anti-rabbit antibody. The cells
were incubated for 30 minutes in the dark and then washed with 1ml of PBS.
The  cell  pellet  was  then  resuspended  in  1ml  of  PBS  containing  10μg/ml 
Propidium Iodide and 250μg/ml RNase A.  The cells were stored in the dark for 
30 minutes before analysis on the flow cytometer. Data was collected on a
FACSCalibur flow cytometer and the data analysed using WinMDI software.
2.2.4.3. Metaphase Spreads
The day before analysis the cells were set up at 2 × 10
5 cells/ml. 2 hours before
harvesting the cells were treated with Demecolcine at 0.1μg/ml to arrest cells in 
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minutes. To swell to cells they were resuspended in 20mls of 75mM KCl for 20
minutes and were then pelleted at 250 × g for 5 minutes. To fix the cells the
resulting pellet was incubated with 20mls of freshly prepared fixative (ice cold
methanol : acetic acid (3:1)). The cells were washed a further 4 times in
fixative each time reducing the volume of fixative to 10mls, 5mls, 2mls and
finally 1ml. The cells could be stored in fixative at -20°C for weeks. Glass
slides were cleaned by incubating in methanol containing a few drops of 1M HCl
for 5 minutes – then wiped dry with lint free tissue. The cells were ‘splatted’
onto glass slides by dropping them from a height for approximately 30cm onto
the slide propped at an angle of approximately 30°. Once the fixative appeared
to be drying out fresh fixative was dropped onto the slide to aid with the
spreading of the chromosomes. The slides were then allowed to dry and age
overnight. A few drops of Vectashield mounting medium containing DAPI was
added and covered with a cover slip and sealed with nail varnish. The slides
were visualised on a Zeiss Axioskop fluoresence microscope with an ×63 oil
objective and analysed using Axiovision Software.
2.2.4.4. FISH
Metaphase spreads were prepared as described above. To prepare the slides for
hybridisation the cytoplasm was first removed by incubation in 70% acetic acid
for 10-20 s. The slides were dehydrated in an ethanol series – 70%, 80% and 100%
for 5 minutes each and then allowed to air dry. They were then incubated at
55°C for 3 hours and passed through the same ethanol series, incubating the
slides for 2 minutes this time.  The slides were air dried and 95μl of RNase mix 
(100μg/ml RNase A in 2×SSC) was added to each slide.  A 22×50mm coverslip was 
placed on top and the slide incubated at 37°C for 1 hour in a humidified
chamber. The slide was then washed in 2×SSC for 5 minutes each. The slides
were dehydrated in the ethanol series for 2 minutes each in 70%, 80% and finally
100% Ethanol and allowed to air dry. The slides were denatured for 90 secs in
70% Formamide in 0.6×SSC preheated to 75°C. The slides were then dehydrated
for 2 minutes each in 70% ice cold Ethanol, 80% Ethanol at room temperature
and 100% ethanol at room temperature and allowed to air dry. To prepare the
probe for hybridisation 1μl of biotin labelled probe (Farmachrom, University of 
Kent) 1μl of herring sperm DNA and 4μl of hybridisation buffer (50% Formamide, 
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incubated at 75°C for 5 minutes and then allowed to re-anneal at 37°C for 45
minutes in a PCR machine. The probe was then applied to the denatured slide
and covered with an 18mm×18mm coverslip, ensuring no air bubbles were
trapped. The cover slip was then sealed with rubber cement and incubated in a
humid chamber for at least 16 hours to facilitate hybridisation. The cover slip
was removed and the slide was washed twice in 50% Formamide, 1×SSC at 37°C
for 10 minutes. The slide was then placed in 2×SSC with 0.1% Igepal CA 630 for 1
minute at room temperature. The slide was then incubated in storage buffer
(4×SSC, 0.05% Igepal CA 630) for 15 minutes and then into block buffer (4×SSC,
0.05%  Igepal  CA  630,  2%  BSA)  for  25  minutes  at  room  temperature.    95μl  of 
detection mix (0.5μl Streptavidin-Cy3 + 100μl 4xSSC, 0.05% Igepal CA 630, 1.5% 
BSA) was placed on each slide and covered with a 22mm×50mm coverslip. It was
then incubated at 37°C in dark humid chamber for 35 mins. The coverslip was
then removed and the slides washed 3 times for 3 minutes each in the dark with
storage buffer with gentle agitation on an orbital shaker. The slide was then
allowed to air dry. The slides were then counterstained with Vectashield
containing DAPI to visualise the chromosomes, covered with a coverslip and
sealed with nail varnish. The slides were visualised on a Zeiss Axioskop
fluoresence microscope with an oil objective (×63) and analysed using Axiovision
Software.Chapter 3. Characterisation of Avian ClaspinConor Larkin Chapter 3 93
3.1. Introduction
The principal aim of this project is to generate a cell line which is genetically
deficient for Claspin expression. To this end the recombinogenic cell line, DT40,
will be used. As the DT40 system is chicken in origin, the chicken Claspin
(cClaspin) homologue must first be cloned and characterised. The description of
this process is contained in this chapter.
3.2. Isolation of avian Claspin cDNA
When this project commenced in 2005 both Xenopus and Human CLSPN genes
had been sequenced
1 (Kumagai & Dunphy, 2000). The first draft of the Chicken
Genome Sequence had also just been released (Hillier et al, 2004). A BLAST
search of the chicken genome sequences with human claspin mRNA sequence
returned an mRNA sequence (XM_425782.1) that was similar to the human
sequence, with the sequences sharing 42% overall identity. However this
chicken CLSPN mRNA was approximately 1.33 times bigger than the human
sequence with only the first
2/3 of the mRNA homologous to human claspin and
the remaining
1/3 of the gene not homologous to any known human genes.
(Figure 3.1-A) The conceptual translation of both the chicken and human genes
showed that the resulting proteins shared 30% identity and 36% similarity at the
amino acid level over the entire length of both proteins. When the non-
homologous region of cClaspin was removed from this calculation, the %
identical residues and % similar residues increased to 45% and 55% respectively.
This strongly indicated that this sequence was the true sequence of the cClaspin
homologue, albeit larger than expected. In order to confirm this predication it
was necessary to isolate this mRNA sequence. The cDNA would also prove useful
in the characterisation of cClaspin.
3.2.1. Uni-ZAP® XR cDNA Library Screen
The first approach taken in order to clone the full length cClaspin cDNA was to
screen a commercially available Uni-ZAP® XR Chicken cDNA library. (Figure 3.1-
B) The library was constructed from oligo dT primed cDNA isolated from
secondary embryonic fibroblasts, cloned uni-directionally into the Uni-ZAP® XR
1 Genbank accession number: Xenopus - AF297867; Human - AF297866Conor Larkin Chapter 3 94
Figure 3.1 Lambda ZAP cDNA library screen
A) Schematic representation of the Human, Chicken and Xenopus mRNA sequences. Numbers
indicate the % identity shared. The unshaded region shows the region of the cCLSPN mRNA not
homologous to human or xenopus CLSPN. The location of the probe used to screen the library is
indicated in yellow. B) Outline of Lambda ZAP cDNA Library screening. Primary screening allows
the identification of few plaques containing the cDNA of interest (black dots) from a large number of
plaques. Following phage purification the phagemid is excised and the cDNA sequenced. C)
Representative films obtained when screening plaque filters with the Claspin or GAPDH probe.Conor Larkin Chapter 3 95
vector. 1.5 × 10
6 pfu’s were screened on duplicate filters using a
32P labelled
fragment of CLSPN mRNA, amplified in order to generate an anti-cClaspin
antibody (Section 3.5). No positive hits, as judged by identical ‘dots’ being
present on both filters, were obtained using this probe. (Figure 3.1-C) A
possible explanation for this is that the average insert size in this library is
1.0kb. The cDNA’s present in the library will therefore be enriched for short
mRNA’s and mRNA’s only containing the 3′ ends.  The probe used may be too far 
5′ in the cDNA to detect the CLSPN mRNA’s present in this library.  Alternatively 
given that there is a high probability that the message detectable by the probe
is present in very small numbers, more plaques may need to be screened in
order to identify a positive one. To confirm the integrity of the DNA on the
filters I reprobed 2 filters with a chicken GAPDH probe. Many positive plaques
were identified ruling out the possibility that there was a problem with the
filters or the hybridisation method. (Figure 3.1-C) Due to these difficulties
encountered with library screening, an alternative strategy was adopted.
3.2.2. RACE and RT-PCR
In order to obtain the sequence of the 5′ and 3′ ends of the CLSPN mRNA, Rapid 
Amplification of cDNA Ends (RACE) was used. This would allow me to obtain
enough sequence information in order to design primers for RT-PCR so that the
entire cDNA could be cloned. As the CLSPN mRNA is quite long I chose to use the
SMART
TM RACE Kit from Clontech (Switching Mechanism at 5′ end of RNA
Transcript).  This kit uses a template switching mechanism in order to attach a 5′ 
specific primer to the end of mRNA transcripts. This relies on the non-specific
terminal transferase activity of reverse transcriptase which adds d(C)3 to the 5′
ends of RNA transcripts. This terminal transferase activity is highest once at the
end of the message so it preferentially allows the amplification of full length
cDNA’s. However, partially degraded or fragmented RNA can also be amplified
using this method.
Firstly I carried out a preliminary RT-PCR characterisation of the predicted
cCLSPN mRNA. Primers were designed along the full length of the predicted
mRNA in both the homologous and non-homologous regions. Primer pairs that
would span the gap between the homologous and non-homologous region of the
predicted mRNA were also used (4F, 5R in Figure 3.2-A). The results of this RT-Conor Larkin Chapter 3 96
PCR are shown in Figure 3.2-B. Only the portions of the gene that were
homologous to the human gene could be amplified. I was unable to amplify
across the gap and unable to amplify any of the predicted gene that shared no
homology with human CLSPN. This led me to believe that the prediction
program  was  incorrect  and  I  designed  3′  RACE  primers  close  to  where  the 
homology ended rather than at the end of the predicted gene sequence as this
appears not to be expressed in cells. The RT-PCR fragments were cloned and
sequenced and the RACE primers were designed based on this sequence.
For the 5´ RACE PCR’s I designed 3 ‘reverse’ primers towards the very start of
the gene. I chose regions of the gene that when translated showed some
homology with human and xenopus Claspin. 2 of these primers gave me distinct
PCR products which were cloned and sequenced. (Figure 3.2-C) The sequencing
data from these cloned products allowed the identification the ATG start codon,
which  was  surrounded  by  a  Kozak  sequence  (Kozak,  1987).    The  5′  UTR  also 
contained an upstream in frame stop codon, indicating that I had identified the
genuine start of the gene. As this method for RACE does not select for the
presence  of  complete  mRNA  transcripts  that  contain  the  5′  7meG  cap  it  is 
possible that I have not cloned the entire 5′ UTR sequence.  However enough 
information was obtained to facilitate the generation of an accurate intron-exon
map and to clone the cDNA.
The 3′ RACE proved more difficult.  Four ‘forward’ primers were selected from 
the end of the sequence data obtained by RT-PCR. However, even though these
primers amplified what appeared to be specific PCR products, when sequenced
they shared no homology with the claspin genomic locus. (Figure 3.2-C) On
closer examination of the Claspin Genomic locus, a region of DNA was identified
that, when translated, gave rise to a peptide sequence that shared very high
homology with the extreme C-terminus of both Human and Xenopus Claspin.
This was immediately followed by a TGA stop codon. (Figure 3.2-D) An in frame
stop codon was located approximately 100bp upstream of this potential Claspin
stop codon so it was postulated that the last exon would be present between
these two stop codons. This potential exon contained approximately 10 suitable
AG splice acceptor sites so primers for RACE were designed at the extreme 3′ 
end of the potential exon so as to minimise the possibility of designing primersConor Larkin Chapter 3 97
Figure 3.2 Isolation of Claspin mRNA Sequence by RT-PCR and RACE
A) Schematic representation of the location of primers designed along the predicted CLSPN mRNA
sequence. B) RT-PCR results using primers illustrated in A. C) RACE products obtained. Each
product obtained using a separate primer. Products boxed in red show CLSPN UTR sequence,
blue shows unrelated sequence. D) (i) Alignment of C-terminal residues from indicated Claspin
homologues. (ii) Highlighted area shows the identification of a homologous region to the C-
terminal peptide in the cClaspin genomic locus.Conor Larkin Chapter 3 98
across an intron-exon boundary. Using these newly designed primers I
successfully amplified the last exon of the CLSPN gene. (Figure 3.2-C) The
upper  band  contained  1165bp’s  of  3′  UTR  sequence.    The  lower  band  also 
contained 3′ UTR sequence but was smaller by 626bp due to a splicing event 
within the UTR sequence. Both UTR’s contains a polyadenylation signal 20bp
upstream from the start of the poly(A) tail. Thus 2 distinct transcripts were
isolated  indicating  a  potential  role  for  the  3′  UTR  in  regulating  cClaspin 
expression.
Having obtained sequence from both ends of the mRNA, this then allowed the
design of primers in order to amplify the entire cDNA. Attempts at cloning the
entire cDNA in one fragment failed.  Therefore 2 fragments were amplified, a 5′ 
fragment and a 3′ fragment that overlapped.  In both cases single specific bands 
were obtained, indicating no alternative splicing taking place in the coding
region of the gene. The overlapping region contained a unique restriction site
(SfuI) which facilitated the ligation of the two fragments together in order to
generate the full length cDNA. Once assembled, the cDNA was subject to 3
rounds of sequencing using primers spanning the entire cDNA. Using only the
high quality sequencing data obtained, the cDNA sequence was assembled. This
data was combined with the data obtained data for the UTR’s to generate the
sequence for entire mRNA. (Figure 3.3-A)
The mRNA sequence was then compared with the genomic DNA sequence
available in the database. Some differences were observed and are summarised
in Table 1.1. Most polymorphisms were silent and resulted in no change to the
amino acid sequence. 3 amino acid changes were observed. At position 24 the
residue encoded for by the genomic DNA sequence is a serine residue whereas in
the mRNA sequence it was a glycine residue. At position 742 an asparagine
residue was converted to an aspartic acid residue. As these changes should not
significantly alter the structure of the protein they were left unchanged. In
addition these residues were not conserved in Claspin from other species.
At position 1235 a proline residue was changed to a serine residue. As proline
residues can contribute significantly to the secondary structure of a protein, and
this residue is present in a highly conserved motif albeit of unknown function,
this mutation was investigated further. At the nucleotide level this mutationConor Larkin Chapter 3 99
Figure 3.3 cCLSPN mRNA structure
A) Schematic representation of both cCLSPN mRNA isoforms isolated. Isoform 2 differs only in a
626bp deletion in the 3’ UTR B) Investigation of P1235S mutation. The Claspin mRNA contains 2
EcoRI sites and the potential EcoRI site that would be generated if the P1235S mutation was
correct circled in red. The indicated PCR products were amplified using Pfx polymerase with the
primers indicated using either cDNA (RNA) or genomic DNA as the template. The products were
then digested with EcoRI and analysed by agarose gel electrophoresis. pBluescript was linearised
with EcoRI to confirm the activity of EcoRI. The predicted sizes of the DNA fragments are as
follows: pBluescript – 2961bp; 1F,1R - 1324bp; 1F,1R + EcoRI – 762bp, 562bp; 4F,10R mRNA –
715bp; 4F,10R mRNA + EcoRI – 395bp, 320bp; 4F,10R Gen. DNA – 2026bp; 4F,10R Gen. DNA +
EcoRI – 1491bp, 335bp.Conor Larkin Chapter 3 100
Table 3-1 Differences between Claspin mRNA sequence isolated and Claspin genomic
Locus sequence
mRNA position refers to base positions in isolated CLSPN mRNA isoform 1. The Claspin mRNA
sequence isolated was compared with the corresponding genomic DNA sequence from the NCBI.
Differences are listed.Conor Larkin Chapter 3 101
resulted from a C->T transition. This introduced an extra EcoRI site into the DNA
sequence allowing me to easily test which DNA sequence was correct. A PCR
was carried out on genomic DNA and on cDNA using primers that spanned this
mutation site using a high fidelity Taq polymerase. The resulting PCR products
were then digested with EcoRI. If the proline residue was correct then the PCR
product should be resistant to digestion by EcoRI. This turned out to be the
case, indicating that the serine residue was introduced during either the reverse
transcriptase step or the PCR amplification step when cloning the gene. For
comparison the EcoRI digests pBluescript plasmid and a PCR product known to
contain an EcoRI site, 1F, 1R. The P1236S mutation was reverted to a proline
using site directed mutagenesis.
3.3. cClaspin Domain Structure
Translating the cDNA sequence isolated, gives the amino acid sequence of
cClaspin. A multiple sequence alignment, comparing cClaspin, hClaspin and
xClaspin shows that the proteins are highly similar sharing 78% overall homology
and 35% identity. (Figure 3.4-A) (See Appendix D for a complete multiple
sequence alignment of Claspin orthologues from various species) Based on this
homology is it possible to map the domains already identified in xClaspin and
hClaspin with the homologous sequences in cClaspin (Lee et al, 2005; Sar et al,
2004). Figure 3.5-A shows this in schematic form. The identity plot in Figure
3.5-B (based on the multiple sequence alignment in Figure 3.4-A) shows the
regions of the protein that are highly conserved. The N-terminus of the protein
contains the region of the protein shown to interact with DNA and chromatin.
This region of the protein is not very highly conserved at the amino acid level.
The C-terminal portion of the protein has been shown to mediate Chk1
activation through phosphorylation of conserved motifs in the Chk1 activation
domain. The consensus sequence for this motif is ExxLC(pS/pT)GxF. Three
repeats of this motif are present in human and chicken with only two present in
xenopus. Once phosphorylated this serves as a binding site for Chk1 which
facilitates its activation by ATR through an unknown mechanism. The kinase
that phosphorylates the S/TG residues remains unknown but is dependent on
ATR. Interestingly a BRCT binding motif (pSxxF) is contained within the Chk1
binding motif (Manke et al, 2003). It has not been shown that this motifConor Larkin Chapter 3 102
Figure 3.4 Claspin Amino Acid sequence Alignment
A) Clustal Alignment of the Human, Xenopus and Chicken Claspin amino acid sequences. The
figure was generated using AlignX.Conor Larkin Chapter 3 103
Figure 3.5 Claspin Domain structure
A) Schematic representation of the cClaspin Domain structure. Domains are based on homology
with those identified in Xenopus and Human Claspin. Numbers indicate the % identity shared within
the domains indicated. Values are derived from the multiple sequence alignment in Appendix D.
B) Similarity plot based on chick/human/frog claspin alignment in Figure 3.4. (Window size = 10)
Amino acid residues broadly mirror the domain structure present in A. C) Iso-electric Point Plot of
chick/frog/human Claspin. (Window size = 50)Conor Larkin Chapter 3 104
actually mediates any interaction between Claspin and any other BRCT
containing family members, but may hint at another layer of complexity in the
way Claspin mediates Chk1 phosphorylation. High sequence conservation is
observed in the Chk1 Activation domain. The rest of the C-terminal portion of
the protein also shares high sequence homology.
It has been noted previously that even though overall Claspin protein is quite
acidic the protein contains patches of basic residues which appear to be
important for the correct functioning of the protein (Lee et al, 2005). An
isoelectric point plot of the protein reveals the 4 basic patches identified in this
study (patches 2-5 in Figure 3.5-C) and also identifies another basic patch at the
N-terminus of the protein. These basic patches are highly conserved suggesting
that they play an important role in the overall structure and function of the
protein.
Tertiary structure predication was attempted using the Phyre Protein Fold
recognition server (Kelley & Sternberg, 2009). However no significant homology
with any known structures was returned. Regions of low complexity and coiled
coil regions were however identified.
3.4. Analysis of in vitro translated cClaspin
I used coupled in vitro-transcription-translation in order to confirm my cloned
cDNA did indeed code for protein. The cDNA had been cloned into the pCR4-
TOPO vector for cloning which contained the T7 promoter. This promoter
facilitates transcription of genes by the T7 RNA polymerase. I used the T7 Quick
Coupled TNT Kit from Promega, which allows the coupled transcription and
translation of proteins in one tube.
35S-methionine was included in the reaction
mix in order to radioactively label any proteins produced. Initial attempts at
translating the protein failed. (Figure 3.6-A(i)) This system is generally less
efficient at translating large proteins. However by optimising the reaction by
increasing the reaction time and adjusting the salt condition allowed the
detection of a band by SDS PAGE which ran at approximately 250kDa. These
conditions also allowed the translation of EDD, an E3 ubiquitin ligase, which has
a calculated molecular weight of 309kDa. It has been reported previously that
although the predicted molecular weight of Claspin is 150-160kDa, on SDS-PAGEConor Larkin Chapter 3 105
Figure 3.6 cClaspin antibody Characterisation
A) (i) Optimisation of in vitro translation of cClaspin. Standard IVT reaction facilitates the
translation of Luciferase and Chk1 (Lanes 2-3) but not of cClaspin, even with increasing template
(Lanes 4-5). Adding increasing amounts of Salt (PCR Enhancer, Promega) (Lanes 6-7) but not
extra Methionine (Lanes 8-9) facilitates the translation of cClaspin. (ii) Optimised cClaspin in vitro
translation reaction. High molecular weight proteins (including EDD, a protein twice the size of
Claspin) are efficiently transcribed under these conditions. (1µg template, 1µl PCR Enhancer and
a 3 hour incubation) B) Western blot characterisation of HF64B antibody using pre-immune serum
(PI) and serum from the final bleed (FB) post immunisation. I = in vitro translated protein, L= DT40
cell lysate. Arrow indicates the cClaspin band. C) Western blot characterisation of HF129B
antibody using pre-immune serum (PI) and serum from the final bleed (FB) post immunisation. L=
DT40 cell lysate. Arrow indicates where the cClaspin band should be.Conor Larkin Chapter 3 106
the protein migrates above 200kDa (Kumagai & Dunphy, 2000). This
phenomenon was also seen with avian Claspin.
3.5. Generation and characterisation of cClaspin
Antibodies
An antibody that detects cClaspin would be a useful reagent in order to study
the function of the protein. All commercial antibodies available are raised
against the human Claspin sequence. The commercially available antibodies (N-
20 and Q-20 goat polyclonal antibodies from Santa Cruz and the BL45, BL73 and
BL91 rabbit polyclonal antibodies from Bethyl Laboratories) were tested for their
ability to recognise cClaspin by Western blot. None of these antibodies could
detect cClaspin. (Data not shown) Therefore it was decided to generate an
antibody specific for cClaspin.
3.5.1. Anti-cClaspin antibody (fusion protein)
A region of cClaspin which shared high homology with human and xenopus
Claspin and for which there was EST sequences available was selected as the
immunogen for the antibody. This polypeptide corresponded to amino acids 675
– 944 which contains a portion of the Chk1 binding domain, with both N- and C-
terminal His6 tags. This fragment was amplified by RT-PCR and cloned into
pET28a(+), which allows the expression in bacteria of a His6 tagged polypeptide.
The cClaspin fragment was expressed in BL21 E.coli cells and purified using
Nickel affinity chromatography. The generation of the expression construct and
purification of the Claspin polypeptide was carried out by Dr. Elizabeth Black.
The purified immunogen was injected into 3 rabbits to elicit an immune
response. (Beatson Antibody Production Facility)
One of the rabbits (HF64B) showed a good response by ELISA so this serum was
tested by Western blot to see if it can detect cClaspin. Using both in vitro
translated cClaspin and DT40 whole cell lysate as samples, both pre-immune
serum and serum from the final bleed post-immunisation were tested. As can be
seen in Figure 3.6-B the antibody detects a band at 250kDa, the same molecular
mass as in vitro-translated cClaspin. This band was not detected with the pre-
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rabbits (HF64A and HF64C) gave no response by ELISA and did not detect any
immune specific bands on a Western blot. (Data not shown)
3.5.2. Anti-cClaspin antibody (peptide antibody)
The antibody generated above worked well in Western blot. However the
antibody also recognised many non-specific proteins also. While it is possible to
affinity purify antibodies generated against larger antigens, it is easier and
usually more successful with antibodies raised against peptides. Such an affinity
purified antibody would be useful in techniques such as flow cytometry or
immunofluorescence where the specificity of the antibody is more crucial. In
addition the region to which the fusion protein antibody was raised spans the
Chk1 binding domain. It is known that this region is modified by phosphorylation
and also mediate protein-protein interactions. Therefore an antibody which
reacts with a site other than this region would prove useful.
The extreme C-termini of proteins are usually flexible and unstructured making
them suitable epitopes for the generation of anti-peptide antibodies (Lane &
Harlow, 1988). Having sequenced the mRNA, the C-terminus of the chicken
Claspin protein was known. The C-terminal 15 amino acids were synthesised.
An N-terminal Cys residue was added to facilitate coupling of the peptide to a
carrier protein. The peptide was coupled to KLH using MBS conjugation
chemistry. The resulting antigen was injected into 3 rabbits and the final serum
was tested for the presence of anti-claspin antibodies.
This immunogen gave a very poor responses by ELISA with only one rabbit
(HF129B) giving a small response. It was tested by Western blot for its ability to
detect cClaspin. (Figure 3.6-C) However this serum failed to cross react with
cClaspin.
3.6. Discussion
An important issue resolved in this Chapter was the isolation of the authentic
cCLSPN mRNA sequence. This has confirmed that the original cCLSPN sequence
from the GenBank database (XM_425782.1) was incorrect. It is important to
remember that this sequence was generated by a prediction program, Gnomon,
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pseudo gene located downstream of the cCLSPN CDS. This sequence has since
been revised (XM_425782.2) and the current sequence is much more homologous
to the sequence identified in this study. Some differences however remain due
to the incorrect prediction of splice sites.
In addition, using the information obtained from mRNA sequence has facilitated
the generation of a cClaspin antibody. This will allow functional
characterisation of the cClaspin homologue and will be a valuable tool in further
exploring the potential functions of Claspin.Chapter 4.Generation of a Claspin +/- cell lineConor Larkin Chapter 4 110
4.1. Introduction
The isolation and sequencing of the chicken Claspin homologue described in the
previous chapter has allowed the generation of an accurate map of the chicken
CLSPN genomic locus. Having a detailed understanding of the genomic structure
of the cCLSPN gene thus allows precise control over how best to design the
targeting and screening strategy in order to knock-out cCLSPN. Using this
information cClaspin+/- cells were generated.
4.2. Characterisation of chicken Claspin Genomic
Locus
The chicken CLSPN gene maps to the long arm of Chromosome 23, one of the
microchromosomes, according to the Genbank entry for its genomic sequence
(NW_001471589). A schematic representation of the cCLSPN locus is shown in
Figure 4.1-A. The gene is located downstream of a cluster of Argonaut genes
(EIF2C1, EIF2C3 and EIF2C4) which are involved in RNAi splicing, and upstream of
PSMB2, a proteasome subunit.  Close to the 3′ end of the gene is a putative 
hypothetical protein which may or may not be expressed, but for which EST
sequences are available. The EIF2C4 gene, the gene closest to the 5’ end of
CLSPN, is positioned in the opposite transcriptional orientation from the CLSPN
gene. This same genomic organisation is conserved between species. The CLSNP
locus on chicken chromosome 23 shows shared synteny with human chromosome
1p34-1p35 and mouse chromosome 4D2.2-4D2.3. The chicken CLSPN genomic
locus is flanked on both sides by runs of NNN’s denoting unknown sequence.
Consequently much of the sequence of the promoter region of CLSPN remains
unknown.
Using the sequence obtained from cloning the chicken claspin cDNA (Section 3.2)
and the genomic DNA sequence from the CLSPN locus from the database, an
accurate intron-exon map of the CLSPN genomic locus was generated using
Spidey, an mRNA to Genomic DNA alignment program from the NCBI. This
program identified all the splice sites as canonical GU-AG splice sites and
organised the CLSPN gene into 25 exons with 24 intervening introns. The entire
gene spans 13.5kbp.Conor Larkin Chapter 4 111
Figure 4.1 cCLSPN Genomic Locus
A) Schematic representation of the cCLSPN genomic locus located on Chromosome 23. Exons are
marked by grey lines. Genes are boxed. Gaps in the sequence are represented by the black
boxes labelled 1 – 11. B) DAPI stained metaphasechromosomes of DT40 and chicken embryo
fibroblasts. Macrochromosomes are labelled. Note 2 copies of chromosome 2 are present in DT40
cells.  Scale bar = 100μm.   Conor Larkin Chapter 4 112
The DT40 cell line is known to contain an extra copy of chromosome 2 and an
extra microchromosome. Compare the normal chicken karyotype of Chicken
Embryo Fibroblasts with the DT40 karyotype in Figure 4.1-B. The identity of this
microchromosome is unknown. (Winding & Berchtold, 2001) An extra copy of
Chromosome 23 would have implications in targeting any gene mapping on that
chromosome, as 3 rounds of targeting would have to be carried out. Due to the
size of the microchromosomes it is impossible to identify them on a standard
karyogram. Therefore in order to determine the copy number of Chromosome
23 in DT40 cells I used FISH with a chromosome 23 specific BAC as the probe.
The number of hybridisation ‘spots’ correlates with chromosome number
(Masabanda et al, 2004). Metaphase spreads prepared from WT DT40 cells, MCM
DT40
1 cells and secondary Chicken Embryo Fibroblasts were hybridised with a
biotin labelled Ch 23 specific BAC. (Figure 4.2-A) After extensive washing and
detection with Cy3 conjugated Streptavidin, two spots were detected in all
metaphase spreads from the 3 cell lines. This confirms that two copies of Ch23
are present. Unless a gene duplication event has taken place at the CLSPN
locus, this strongly indicates that there are two copies of the CLSPN gene
present in the cells.
4.3. Generation of CLSPN gene targeting
constructs.
There are two basic approaches to generating a knock-out DT40 cell line. In the
first approach, termed gene disruption, a drug resistance cassette is inserted
into an exon of the gene of interest. Transcription from the drug resistance
cassette (usually under the control of a strong promoter) disrupts the
transcription of the gene of interest and usually its splicing. Combined this
should dramatically inhibit translation of the protein of interest resulting in a
null allele. However depending on the splicing of the mutant mRNA functional
proteins or fragments of proteins may still be produced. A targeting vector in
for this strategy is usually made by amplifying a large region of the gene by PCR
and simply inserting a drug resistance cassette into the middle of an exon
sequence at an appropriate restriction enzyme site. No DNA is deleted by this
method and all of the coding sequence remains in the genome, albeit disrupted.
1 MerCreMer DT40 cells – see Section 4.4Conor Larkin Chapter 4 113
Figure 4.2 FISH with a Ch 23 specific probe
A) A biotinylated Ch23 specific BAC bound to MCM-DT40, WT-DT40 and CEF metaphase spreads
is detected by Cy3-streptavidin. 2 spots are detected in each case. Chromosomes are detected
with DAPI.  Scale bar = 100μm Conor Larkin Chapter 4 114
In contrast the other method, termed gene deletion, results from the physical
removal of an appropriate region of DNA. The choice of how much to delete
(either the entire gene or only a part of the gene) depends on the size of the
gene. For small genes usually the entire gene is deleted. However for larger
genes either a critical region encoding for a crucial function of the protein or
the promoter region and the start codon are deleted. Removing these regions of
the gene usually result in null alleles. A targeting vector for this strategy is
made by amplifying 2 regions of genomic DNA, termed ‘arms of homology’. The
DNA fragments are designed such that they flank the region of DNA to be
deleted. A drug resistance cassette replaces the intervening sequence. Both
strategies rely on the process of homology directed recombination which directs
the integration of the targeting vector to the appropriate region in the genome.
In order to knock-out cCLSPN this second, gene deletion, approach was taken.
Ideally the entire coding region of cClaspin would be removed. However a
targeting vector designed to remove such a large region would integrate at lower
frequencies than one designed to delete a smaller region (Arakawa &
Buerstedde, 2006). In addition it was not possible to amplify DNA from the
promoter region of cCLSPN. Sequence data from this region is not present in the
database and attempts at cloning this region failed probably due to the
repetitive sequence and high GC content present. (data not shown)
A more conservative approach was therefore taken. A schematic diagram of the
targeting strategy is shown in Figure 4.3-A.  For the 5′ arm of homology I cloned 
a 1.8kb fragment using primers designed just upstream from the 5′ UTR (G13F) 
and in exon 3 (G10R).  This fragment contained the 5′ UTR, exons 1 and 2 and a 
small portion of exon 3 which could potentially encode for the first 105 amino
acids of the protein. To minimise the possible translation of this truncated
polypeptide the ATG start codon, contained within exon 1, was deleted by site
directed mutagenesis. Deletion of this codon also deletes an NcoI site which can
be used for screening at a later stage.  For the 3′ arm of homology primers were 
designed in the 3′ UTR (G9F) and down stream of the CLSPN gene (G9R).  The 
resulting 3.3kb fragment was cloned adjacent to the 5′ arm and in the same 
orientation. Upon targeted integration exons 4-24 (which spans 11.5kbp) would
be deleted only leaving exons 1-3 remaining.Conor Larkin Chapter 4 115
Figure 4.3 cCLSPN Targeting Vector Design
A) Targeting Strategy 1 – deletes amino acids 106 - 1337. B) Targeting Strategy 2 – deletes amino
acids 106 – 675. WT cCLSPN Locus is shown with the exons represented by grey boxes. The
primers used to amplify the arms of homology are indicated. The arms are cloned such that they
flank the Drug resistance cassette (Res.). The mutated start codon is represented by the asterisk.
The GFP cassette outside the arms of homology is shown. C) The 4 different targeting vectors
constructed.Conor Larkin Chapter 4 116
As the above approach is quite ambitious a second more conservative approach
was also taken. (Figure 4.3-B) For this targeting vector a 3.8kb genomic
fragment was generated using primers designed in exons 11 (3F) and 21 (4R),
was cloned adjacent to the same 5′ arm as was used for the first approach.  This 
second approach was taken in order to maximise targeting efficiency by deleting
a smaller region (5.2kb) of DNA. This approach however leaves much more of
the coding region of cCLSPN intact in the genome essentially only deleting amino
acids 106 – 675 (570 amino acids) in the protein. The region deleted is contained
within the DNA binding/replication fork interacting domain. Again, however, as
the initiating Methionine is deleted from the 5′ arm of homology the probability 
that any mutant polypeptide would be produced is low.
In both cases both arms of homology were cloned into a modified pLox-Neo or
pLox-Bsr vector (Arakawa, 2001). These vectors contain within their multi-
cloning sites either the Neomycin phosphotransferase gene (confers resistance to
G418) or the Blastcidin-S-deaminase gene (confers resistance to Blasticidin)
which will be used as positive selection during the targeting process. Unique
restriction sites are present on both the 5′ and 3′ sides of the resistance genes 
which facilitate the insertion of the arms of homology by conventional cloning
strategies.  The expression of both resistance genes is driven by the chicken β-
actin promoter. Both G418 and Blasticidin are inhibitors of protein synthesis.
The pLox-Neo and the pLox-Bsr vectors described above were modified to
contain a GFP expression cassette (from pEGFP-N1, Clontech). The cassette was
ligated with KpnI adaptors and cloned into the KpnI site of the multi-cloning site
of the plasmid. In the final targeting vector this cassette is outside the arms of
homology therefore serving as a negative selection marker in a manner similar to
the Thymidine Kinase/Gancyclovir or diphtheria toxin systems for negative
selection (Mansour et al, 1988; McCarrick et al, 1993). Upon targeted
integration of the targeting vector the GFP cassette will be deleted and the
clones derived from such integrations will be GFP negative. However in clones
where random integration of the targeting vector has taken place the GFP
cassette will remain and the clones will express GFP. The presence or absence
of GFP was used as the initial screening.Conor Larkin Chapter 4 117
To construct the final vector the arms of homology were then inserted into this
vector such that they flanked the drug resistance cassette. The arms of
homology for the 3′ arms (either G9F,G9R or 3F,4R (modified to remove the SalI 
site present in the 3F primer) were amplified by high-fidelity PCR using DT40
genomic DNA as template. The PCR fragments were then cloned by TA cloning
into the pCR4-TOPO TA vector for sequencing. Following sequence verification
the fragments were sub-cloned directionally into the NotI/SpeI sites in the MCS.
The NotI/SpeI sites in the pCR4 vector were used to facilitate this.  The 5′ arm 
was then inserted into SalI/ClaI sites in the MCS using SalI and ClaI sites
engineered into the G13F and G10R primer sequences. This resulted in the final
targeting vectors; pTV1-Claspin deleting the larger region and pTV2-Clasin
deleting the smaller region – both with the BsdR resistance cassettes; the pTV3-
Claspin deleting the larger region and pTV4-Claspin deleting the smaller region –
both with NeoR resistance cassettes. (Figure 4.3-C) A ScaI site located in the
Ampicillin resistance gene was used to linearise this final targeting vector.
In summary the targeted loci should not produce any functional, stable mRNA
due to the deletion of large portions of the coding region. Any transcript
produced is likely to be degraded by nonsense mediated decay. The
transcription of any mutant transcript will be reduced by interference from the
drug  resistance  cassette  which  is  under  the  control  of  the  strong  β-actin 
promoter, which yields high levels of gene transcription. Finally even if a
stable, functional mRNA is produced the deleted start codon will inhibit
translation of protein from this locus.
The drug resistance cassettes I chose are flanked by mutant LoxP sites (Arakawa,
2001). Upon Cre mediated recombination the resistance cassettes are deleted
yielding a single non-functional LoxP site and a cell line that is now sensitive to
the drug of interest. The advantage of this is two fold – firstly by removing the
resistance cassette the cell line now becomes re-sensitised to the drug allowing
the same targeting vector to be used to target the second allele. In addition it
also opens up the possibilities of generating compound mutant cell lines by
allowing more choice in which selection marker is available for use. In practice
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4.4. Characterisation of MCM-DT40 and Cre1-DT40
cells
To take full advantage of this system I wanted to use a cell line that expressed
an inducible Cre recombinase which could easily facilitate the removal of the
drug resistance cassettes. Two such cell lines were available DT40-Cre1
(Arakawa, 2001) and DT40-MCM (Brummer et al, 2003). Both cell lines
constitutively express a CreER fusion protein under the control of the modified
oestrogen receptor (Zhang et al, 1996). The modification makes the receptor
more responsive to the synthetic oestrogen analogue, tamoxifen, than
endogenous oestrogen. Upon tamoxifen addition, the CreER protein is released
from an inhibitory complex with heat shock proteins and translocates to the
nucleus as a fully functional protein which mediates recombination between 2
adjacent LoxP sites. The LoxP sites flanking the drug resistance cassettes are
orientated such that recombination deletes rather than inverts the sequence.
The LoxP sites have also been mutated such that once recombination has taken
place the resulting single LoxP site is no longer functional (Arakawa, 2001).
As one of the main defects expected with my Claspin
-/- cells would be defective
DNA damage signalling I characterised both cell lines for their ability to initiate
both the G2-M DNA damage checkpoint and the S-M mitotic checkpoint. In the
G2-M checkpoint the ability of cells to inhibit entry into mitosis in the presence
of DNA damage is assessed. From Figure 4.4-A it is evident that the DT40-Cre1
cells, even though they display a block in cells entering mitosis it is clear that
the cells do not mainly arrest in G2 like the WT and MCM cells. They are also
more sensitive to killing by -IR than the WT-DT40 cells. From the PI plots it can
be seen that whereas the WT-DT40 and MCM-DT40 cells maintain the G2-M arrest
the DT40-Cre1 cells are distributed through-out the cell cycle or are dying. It is
probable that the Cre1 cells treated with -IR with S/G1 DNA content represent
G2-M cells that are dying. The MCM cells while they do not have as a robust a
checkpoint as WT cells (≈ 20% of the cells enter mitosis compared with 7% for 
WT) they do arrest in G2. The second checkpoint that was assessed was the
ability of cells to halt entry into mitosis in the presence of unreplicated DNA.
(Figure 4.4-B) It has previously been reported that in the absence of Chk1 cells
can enter mitosis in the presence of unreplicated DNA (Zachos et al, 2005).Conor Larkin Chapter 4 119
Figure 4.4 Characterisation of MCM-DT40 and DT40-Cre1 Cells
A) G2-M Checkpoint Assay. Cells were treated for 8 hours with Nocodazole with or without 10Gy
of γ IR.  The number of cells in mitosis (pS10 H3 positive cells) after 8 hours was assessed by flow 
cytometry. Density plots and the DNA histogram are shown. The quantification of the number of
mitotic cells for each cell line and each treatment is shown below the FACS plots. n=3 B) S-M
Checkpoint Assay. Cells were treated for 14 hours with Nocodazole with or without 60uM
Aphidicolin. The number of cells in mitosis (pS10 H3 positive cells) after 14 hours was assessed
by flow cytometry. Density plots and the DNA histogram are shown. The quantification of the
number of mitotic cells for each cell line and each treatment is shown below the FACS plots. n=3Conor Larkin Chapter 4 120
Treating the cells with a high dose of aphidicolin results in the persistence of
unreplicated DNA and inhibits entry into mitosis. Cells with an impaired S-M
checkpoint will display 2N cells which are pS10 H3 positive. From Figure 4.4-B it
can be seen that both MCM-DT40 and DT40-Cre1 cells while they both show an
increased sensitivity to Aphidicolin treatment compared with WT cells, they do
not show any signs of cells entering mitosis in the presence of unreplicated DNA.
However DT40-Cre1 cells appear to be sensitive to prolonged mitotic arrest.
After the 14 hour incubation only approximately 15% of the cells are trapped in
mitosis compared with nearly 60% for WT-DT40 cells. It is clear from the above
results that while the DT40-Cre1 cell line appears to have functional checkpoints
it is hyper-sensitive to DNA damage, replication stress and mitotic arrest. These
and other defects (including defective spindle checkpoint and abnormal
centrosome number) have also been observed else where. (Bree et al, 2007)
The MCM-DT40 cell line while not behaving exactly the same as WT-DT40 cells is
more similar than the DT40Cre1 cells. It was therefore decided to use the MCM-
DT40 cell line as the background for the generation of the Claspin
-/- cell line.
4.5. Generation of Claspin+/- cells in MCM-DT40
Background
An outline of the targeting process is presented in Figure 4.5. Briefly MCM-DT40
cells were transfected linearised pTV1-Claspin targeting vector. After
recovering the cells were plated into 96 well plates under selection of
Blasticidin. After 2 weeks drug resistant clones were screened for the presence
or absence of GFP using fluorescence microscopy. Most clones expressing GFP
were discarded at this stage but some were routinely expanded as controls. GFP
negative clones were expanded and screened by southern blotting.
A summary of the results obtained with the MCM-DT40 cells is shown in Figure
4.6. From the results it is clear that many problems were observed when using
the MCM-DT40 cells.
A big problem observed was the failure of clones to expand. It is usual in and
DT40 knock-out project, even just when making stable cell lines, that a portion
of clones die during the expansion process. However, the number of clones that
failed to expand with the MCM-DT40 cells was far higher than would reasonablyConor Larkin Chapter 4 121
Figure 4.5 Overview of the Claspin Targeting Methodology
This schematic outlines the steps involved in targeting 1 allele of a gene in DT40 cells. Cells
transfected with the targeting vector are cloned by limiting dilution to ensure each clone arises from
1 transfected cell. Only wells with one clone growing are picked. GFP is used as a negative
selection marker.Conor Larkin Chapter 4 122
Figure 4.6 Summary of Screening for Claspin +/- MCM-DT40 Cells
A) Pie charts show the portion of GFP negative clones obtained with each targeting vector. (GFP
positive in green and negative in grey) The fate of the GFP negative clones is indicated. The 77
GFP –ve clones obtained with pTV1-Claspin were incorrectly classified as GFP –ve. When
expanded these clones were in fact expressing GFP. Numbers in the pie charts represent the total
number of clones obtained following transfection of each targeting vector. The number of
transfections per targeting vector is indicated below each pie chart. B) HindIII Southern Blot of
pTV3-Claspin targeted clones. Clones 15 and 16 are GFP positive clones for comparison.Conor Larkin Chapter 4 123
be expected. In conjunction with this there was a possible issue with the
stability of the Blasticidin used in these experiments. With clones taking 2-3
weeks to appear it is possible that some of the clones that grew were actually
not resistant to Blasticidin. During the expansion process Blasticidin is added
back to the growth media to kill off any such cells. This may have contributed
significantly to the high attrition rate of clones observed during expansion.
The first vector that was used in order to target cCLSPN was the pTV1-Claspin
vector. Three separate transfections were set up and 557 clones grew. Of these
only 77 were GFP negative. However during the expansion process it was
evident that most of the clones that been classed as GFP negative were actually
GFP positive. In addition the cells that remained GFP negative died during the
expansion process. No viable GFP negative clones were obtained either using
this strategy or with the pTV2-Claspin vector. For this reason the BsdR versions
of the targeting vectors were abandoned in favour of the NeoR versions. G418 is
much more stable in culture and therefore drug stability issues should not be as
problematic with G418.
The first attempt using the NeoR vectors was made using the pTV3-Claspin
targeting vector. This vector is designed to remove most of the coding region of
the cCLSPN gene. Using this targeting vector 248 clones were screened initially
for GFP expression. 14 of these were GFP negative and therefore possibly
targeted. 8 of these survived expansion and all were negative for GFP by PCR.
(data not shown) Again 50% of these clones died during the expansion process
which may suggest that the Blasticidin is not to blame for the failure of cells to
expand. The viable GFP negative clones were screened by Southern blot for
targeted integration.
A major drawback to knocking out the entire coding region of the cCLSPN gene is
that in order to design the targeting vector virtually the entire known 5′ and 3′ 
flanking regions of DNA were included in the targeting vector. As mentioned
earlier,  at  both  the  5′  and  3′  end  of  the  gene  there  are  regions  of  unknown 
sequence. Attempts at cloning and sequencing these regions proved
unsuccessful. Therefore this made selecting an appropriate location for an
external probe very difficult. A compromise was reached where it was decided
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enzyme combinations in order to confirm targeting. If the predicted bands
appeared using multiple enzymes then this should reliably indicate a targeting
event.
The first enzyme chosen for Southern Blot was HindIII in conjunction with a
probe contained within 5′ arm (Probe A).  This is predicted to detect a WT band 
of approximately 5kb. As is evident from the targeting diagram the ‘external’
HindIII site is outside at region of unknown sequence so it is possible that there
is a HindII site within this region, which would alter the length of the WT band.
However as the HindIII site in the targeted locus is rearranged within the known
sequence it will always be 1kb smaller than the WT allele regardless of its
length. As can be seen from Figure 4.6-B this probe detects a WT band of
approximately 6kb in length. Three of the clones screened showed a pattern
that would be consistent with correct targeting – clones #1, 12 and 14 all showed
‘targeted’  band  running  at  ≈5kb.    It  is  interesting  to  note  however  that  the 
intensity of the ‘targeted’ band is not equal to the WT band which would be the
case if targeted integration had taken place and only two copies of the gene
were present.
Following this potentially successful result it was necessary confirm this with
more enzyme-probe combinations. The next Southern preformed was on ScaI
digested DNA. (Figure 4.7-A) The WT band in this case is recognised by an
internal probe located in the 3′ arm of homology (Probe B).  Upon integration all 
the ScaI sites present within the gene are deleted and the restriction band to
which the probe hybridises is generated by 2 ScaI sites which flank the
remainder of the cCLSPN gene.  Again it is worth noticing that the 5′ ScaI site is 
external to the region of unknown sequence. As expected Probe B hybridises to
the correct WT band. (Figure 4.7-A(i)) Assuming the HindIII result is correct
then it would be reasonable to assume that clones #1, 12 and 14 would show a
targeted band with ScaI as well. However, with ScaI it appeared to be opposite
way around. This time clones # 3, 7, 9, 10 and 11 showed bands which may be
consistent with targeting and clones #1, 12 and 14 showed no extra DNA. Again
the ‘targeted’ bands were not the same intensity as the WT bands and it was
slightly bigger than expected. This however could be explained by the fact that
the length of DNA in the gap region is unknown – therefore the increase in size of
the expected fragment could be simply due to this gap being larger thanConor Larkin Chapter 4 125Conor Larkin Chapter 4 126Conor Larkin Chapter 4 127
Figure 4.7 Southern Blot Screening of pTV3-Claspin Transfected MCM-DT40 clones
A) ScaI Southern Blot with pTV3-Claspin targeted clones. (i) Southern using Probe B (ii) Southern
using Probe C (iii) Southern using Probe A B) NdeI Southern Blot with pTV3-Claspin targeted
clones. Probe A should detect a 4kb band in WT clones and a 6.8kb band in targeted clones. A WT
band of 5.5kb is detected with extra bands at 6kb detected in some lanes including the GFP +ive
controls C) BclI Southern Blot with pTV3-Claspin targeted clones. Probe D is an external probe
but failed due to non-specific binding. No WT band at 3.9kb could be detected.Conor Larkin Chapter 4 128
expected. It was curious why there was such a disparity between the ScaI result
and the HindIII result.  In order to try and resolve the situation a 5′ External 
probe was generated and hybridised to the membrane (Probe C). This gave a
single  band  in  all  cases  of  ≈7kb  which  would  be  entirely  consistent  with 
predicted gap size. (Figure 4.7-A(ii)) The absence of any other bands with this
probe would indicate that none of the clones are targeted. However it is
possible  that  this  band  was  generated  by  the  5′  external  ScaI  site  and  an 
unknown ScaI site within the gap region. To clarify this, the membrane was
probed for a third time with Probe A. This returned the exact same pattern as
that obtained with Probe C indicating that they are infact detecting the same
restriction fragment. (Figure 4.7-A(iii)) The only other, but unlikely, possibility
for this to occur would be that an unknown ScaI site lies directly in the middle of
the two known ScaI sites – where upon ScaI cleavage two fragments of equal
length are produced. Therefore hybridisation with my probes would actually
generate the observed pattern.
The uncertainty with the HindIII and ScaI results led me to try and find another
screening method to identify targeted integration. However Southerns with NdeI
and BclI digested DNA did not shed any more light on the situation. (Figure 4.7-
B and 1.7-C) The major flaw with this approach was the lack of a reliable
external probe with which to genotype the clones. Also the very low frequency
of GFP negative clones growing was worrying. Therefore it was decided to
abandon this targeting strategy in favour of the second targeting strategy, where
the targeting vector should, in theory, integrate with better frequencies and for
which a reliable Southern blot screening strategy exists.
Using the pTV4-Claspin targeting vector, designed to knockout the smaller region
of the cCLSPN gene, in total 835 clones were screened from 3 separate
nucleofections. Of these 55 were GFP negative, but of these only 14 survived
the expansion process and remained GFP negative by PCR. These clones were
screened by southern blot but none showed the presence of the targeted band.
(Figure 4.8)
Again the percentage of GFP negative cells was very low with this targeting
vector. In theory the targeting efficiency with the cells should be approximately
50%. Assuming that all the GFP negative cells are not going to be targeted itConor Larkin Chapter 4 129
Figure 4.8 Screening pTV4-Claspin transfected MCM-DT40 Clones
A) Map of WT and targeted locus indicating the location of the probes and the BamHI restriction
sites. (i) BamHI digested DNA from pTV4-Claspin transfected MCM-DT40 cells probed with the
External Probe (Probe B) (ii) The same membrane stripped and re-probed with the Internal Probe
(Probe E) GFP positive clones are indicated in green.Conor Larkin Chapter 4 130
would therefore be reasonable to assume that an even greater number of clones
should be GFP negative. These results therefore might call into question the
capacity of these cells for homologous recombination.
To test the capacity of the MCM DT40 cells for their ability to undergo targeted
recombination of targeting vectors at a high frequency I obtained the Ovalbumin
targeting construct (PuroR version) which integrates into the ovalbumin locus at
high  frequencies  (≈80%)  into  the  DT40  genome  (Buerstedde  &  Takeda,  1991).  
Upon transfection of this construct into MCM DT40 cells and selection of clones,
18 clones were screened for the presence of a correctly targeted Ovalbumin
locus. Of the 18 screened none of the clones had integrated the targeting
vector in the correct location (0/18 = 0% targeting efficiency). This confirms the
suspicion that this cell line has lost its capacity for homologous recombination
and explains much of the difficulties observed in trying to obtain a knock-out
cell line. Upon realising this it was decided to revert to the ‘gold standard’ high
efficiency DT40 cell line variant, Cl18.
The main reason for choosing the MCM-DT40 cell line was to use the inducible
Cre to delete the resistance cassette. This can also be achieved in Cl18-DT40
cells by transient transfection of Cre recombinase and screening for clones
where recombination has taken place.
4.6. Generation of Claspin+/- cell in Cl18 DT40
Background
Due to the difficulties encountered with using the MCM-DT40 cell line I obtained
a fresh aliquot of Cl18 DT40 cells from the Lowndes group (NUI Galway, Ireland)
who were using the cells with success to generate knock-out DT40 cell lines. In
order to confirm that these cells did indeed show high levels of targeted
recombination the control targeting experiment was repeated with these cells.
Of 20 clones picked 6 were targeted indicating that these cells did have the
capacity for targeted recombination. This targeting efficiency of 30% was still
lower than that originally observed so it was also reasoned that the method of
transfecting our cells (Amaxa Nucleofection) may also be impacting on the
targeting efficiency. It was decided to revert to using the GenePulser (BioRad)
in order to transfect the cells with DNA. This allows the delivery of a definedConor Larkin Chapter 4 131
pulse to the cells as opposed to a complex pattern of electrical pulses delivered
by Amaxa system (Lonza).
Three consecutive rounds of electroporation were set up and 254 clones were
obtained in total. Of these 116 were GFP negative which were then screened by
Southern blot for targeted integration. (Figure 4.9-A) 37 of these clones
showed the 9kb targeted band giving an overall targeting efficiency of 32% of
those screened. Overall, for all the clones, it gave a targeting efficiency of 15%.
The membranes were then reprobed with the internal probe to ensure that the
targeting vector had not also integrated into an ectopic site in the genome. It is
worth noting that the intensity of the remaining WT allele and the targeted
allele are the same, indicating that there are indeed only two copies of the
cCLSPN gene present in Cl18 cells. (Figure 4.9-B)
The clones confirmed to be targeted were counter screened by PCR for the
presence of the GFP cassette. 8 of the targeted clones were positive for the
GFP cassette.  This can arise due to correct integration of the 3′ arm (which is 
assayed for by the Southern Blot) but non-homologous integration of the 5′ arm 
nearby. These clones were discarded for further study.
An important feature of this strategy relies on the deletion of the initiating ATG
start codon in order to minimise the possibility of translating a mutant cClaspin
polypeptide. In order to assay for the loss of the ATG codon the region
surrounding the codon was amplified and digested with NcoI. (Figure 4.10)
Using the Targeting vector DNA as a template the resulting PCR product is
resistant to digestion by NcoI. However using DNA isolated from WT Cl18 cells
yielded an unexpected result.  As expected bands at ≈1200bp and ≈400bp were 
obtained.    However  bands  at  ≈700bp  and  ≈550bp  were  also  obtained.    This 
suggests that there is an extra NcoI site in one allele of cClaspin – termed allele
2. Mapping these sites around the NcoI site at the ATG position shows that there
must also be another NcoI site upstream of the known site. Theses sites would
map to intronic sequence. A schematic representation of the predicted
locations of the NcoI sites is shown in Figure 4.10-A. The location of these sites
does not affect the screening strategy as it is designed to simply assay for an
allele that is completely resistant to digestion. Clone #2.1 is shown to be non-Conor Larkin Chapter 4 132
Figure 4.9 Screening of pTV4-Claspin transfected Cl18 clones
A) Summary of screening results. Pie chart shows the portion of GFP negative clones obtained.
Numbers in the pie charts represent the total number of clones obtained following transfection of
the targeting vector. The number of transfections is indicated below the pie chart. B) Southern Blot
Screening – Location of internal and external probe with respect to the relevant BamHI sites
(indicated by a B) is shown. (i) Representative blots obtained when using the External Probe,
Probe B. Asterisks indicate the targeted clones. (ii) Representative blots obtained when using the
Internal Probe, Probe E. No other DNA hybridises with the internal probe indicating that only one
copy of the targeting vector has integrated.Conor Larkin Chapter 4 133
Figure 4.10 Screening for the loss of the ATG start codon
A) Schematic representation of the G13F,G7R PCR Product. Position of NcoI sites and predicted
fragment sizes are indicated. B) Digested PCR Products. -ive = No template DNA, TV = Targeting
vector used as template, 2.1 and 2.5 = DNA from Non-targeted clone, 2.3, 2.4 and 2.6 = DNA from
targeted clones. Products from digestion of Allele 1 are shown in Blue. Products from digestion of
Allele 2 are shown in Red. A non-specific band (*) is amplified by the primers in the PCR.Conor Larkin Chapter 4 134
targeted by Southern blot. It should contain both WT alleles and the allele from
the targeting vector. However only the 2 WT alleles are seen. (Figure 4.10-B)
Presumably as the targeting vector in this clone integrated randomly, the DNA in
the  5′  arm  is  disrupted  such  that  no  PCR  product  is  generated  from  the 
integrated DNA. Clone #2.5 which is shown to be targeted by Southern blot but
is also GFP positive by PCR retains both WT cCLSPN alleles and the allele from
the 5′ arm of the targeting vector.  Clones #2.3 and #2.4 although shown to be 
targeted by Southern blot and GFP negative by PCR have not recombined in such
a way as to delete the endogenous start codon. However Clones #2.6 which
have been confirmed as targeted by Southern blot and GFP negative by PCR has
deleted the ATG start codon. WT allele 2 has been replaced by the targeting
vector sequence and only allele 1 remains. This clone was selected for further
analysis and for the generation of the complete Claspin
-/- cell line. Of all the
targeted clones (targeted by Southern blot and GFP negative by PCR) only 5 had
completely integrated the entire targeting vector. All of these had targeted WT
allele 2.  In the others presumably the cross-over event took place too far 3′ 
relative to the ATG site to allow for its deletion.
4.7. Characterisation of Claspin+/- cells
A basic characterisation of the Claspin
+/- clone was carried out. Firstly the
Southern Blot was repeated in order to confirm the results from the screening.
Figure 4.11-A shows that the diagnostic targeted band of 9.3kb is detected when
using the external probe. Importantly this is also the only band detected by the
internal probe showing that the targeting vector has only integrated once into
the genome. The intensity of the bands is also roughly equal and half that of the
signal obtained on the +/+ cells indicating that there are indeed only two copies
of cCLSPN present in the DT40 genome.
But how does the loss of one copy of the cCLSPN gene impact on expression at
the protein level? To address this issue +/+ and +/- cells were harvested in
triplicate for Western Blot analysis using the HF64B antibody described in section
3.5.1. A representative blot is shown in Figure 4.11-B(i) with the quantitation of
triplicate blots shown in Figure 4.11-B(ii). From the quantitation it is clear that
only half the amount of full length cClaspin is expressed in +/- cells compared
with the +/+ cells – strongly suggesting that this targeting strategy does indeedConor Larkin Chapter 4 135
Figure 4.11 Characterisation of cClaspin+/- Cells
A) Clone #2.6 was subjected to Southern blot using internal (In) and External (Ex) Probes in order
to confirm targeting. See Figure 4.9-B for targeting diagram. B)(i) Representative Western Blot
using HF64B antibody showing cClaspin Levels in +/+ and +/- cells. An equal quantity of lysate as
determined by Bradford Assay was loaded for +/+ and +/- cells. (ii) Quantification of cClaspin
levels in +/+ and +/- cells. n=3. C) Growth curve with +/+ and +/- cells. Cells were seeded at 1 ×
10
4 cells/ml and then counted using a Casy counter at the indicated times. This experiment was
repeated in triplicate.The doubling time for +/+ = 9.62hrs and 9.46 hrs for +/- cells. n=3.Conor Larkin Chapter 4 136
disrupt the expression of full length cClaspin. It is worth noting however that
this reduction in protein expression has no impact on the growth of the cells.
From Figure 4.11-C it can be seen that the +/- cells grow at the exactly the
same rate as the +/+ cells, both doubling roughly every 9 hours.
While the a reduction in cClaspin levels does not impact on the growth of the
cells under unstressed conditions I next wanted to test whether these cells
would show any defects in response DNA damage. Following DNA damage DT40
cells progress through S phase and arrest in G2 in order to repair the DNA
damage before entering mitosis. This arrest is usually maximal around 8 hours.
A BrdU pulse experiment over an 8 hour time-course shows which cells are
actively replicating their DNA at a given point. From Figure 4.12-A it can be
seen that there is no difference between the +/+ and the +/- cells in their
ability to progress through S phase in the presence of damaged DNA in order to
arrest in G2 phase and repair the damaged DNA. Examining cClaspin expression
and the activation of Chk1 by western blot throughout this time course shows
that the +/- cells behave similarly to the +/+ cells. There is no defect in Chk1
phosphorylation as the pS345 Chk1 signal is as high and maybe even slightly
higher in the +/- cells. (Figure 4.12-B) Chk1 phosphorylation at S345 is rapidly
induced but soon decreases only to rise again at the later time points. cClaspin
is stabilised following DNA damage in the +/+ cells but this stabilisation does not
occur in the +/- cells probably due to the lower amount of cClaspin present in
these cells. How significant this stabilisation of cClaspin is, is not apparent
given that the +/- cells can activate and maintain a block in their cell cycle just
as efficiently as the +/+ cells. There is no apparent reduction in the levels of
phospho-Chk1 indicating that the level of cClaspin remaining in the +/- cells is
sufficient to mediate the activation of Chk1 and hence the G2-M checkpoint.
Given this data it is not surprising therefore that directly assaying the ability of
the cells to activate the G2-M checkpoint, by the nocodazole trap method, shows
that the +/- cells are completely competent for this checkpoint. (Figure 4.12-C)
One of the most striking phenotypes of the Chk1
-/- DT40 cells is their ability to
enter into mitosis in the presence of incompletely replicated DNA (Zachos et al,
2005). If the level of cClaspin in the +/- cells was too low to mediate the
activation of Chk1, a defective S-M checkpoint might also be observed in the +/-
cells. Chk1
-/- DT40 cells begin to enter the premature mitosis between 9 and 16Conor Larkin Chapter 4 137
Figure 4.12 Characterisation of DNA damage response in Claspin+/- Cells
A) BrdU time-course following 10Gy γ-IR.  (i) BrdU plots (ii)  Corresponding PI profiles B) Western 
Blot analysis of cells treated with 10Gy γ-IR.  Time-points are the same as for flow cytometry.  
Arrow indicates a fragment of Chk1 that is generated from caspase mediated cleavage. This
indicates that some degree of apoptosis is taking place in the culture at this time. C) G2-M
Checkpoint Assay. Cells treated for 8 hours with 1μg/ml Noc with or without 10Gy γ-IR . Conor Larkin Chapter 4 138
Figure 4.13 Characterisation of the Claspin+/- Cells following Replication Stress
A)  +/+ and +/- cells were treated for 16 hours in the presence of 1μg/ml Nocodazole and the 
indicated concentration of Aphidicolin (μM) The cells were then harvested and analysed for the 
presence of mitotic cells (pS10 H3 positive) by flow cytometry. B) Cells were treated with 15μM 
aphidicolin. Cells were harvested at the indicated time and blotted for the indicated proteins. Arrow
indicates a fragment of Chk1 that is generated from caspase mediated cleavage. This indicates
that some degree of apoptosis is taking place in the culture at this time.Conor Larkin Chapter 4 139
hours post inhibition of DNA replication (Oehler, 2008). Therefore a similar
assay was preformed with the +/+ and +/- cells. However the Cl18 DT40
background appears to be much more sensitive to replication stress than the WT
DT40 background used to generate the Chk1
-/- cells. (Figure 4.13-A) I was
unable to identify a concentration of aphidicolin (a DNA polymerase inhibitor)
that was sufficient to inhibit DNA replication but not so toxic that it would kill
the cells.  A concentration of 0.6μM Aphidicolin was not toxic to the cells but not 
sufficient to block DNA replication.  Even a concentration of 2μM Aphidicolin was 
sufficient to induce significant cell death. Therefore it was not possible to assay
the +/- cell for their ability to mediate the S-M checkpoint. Further optimisation
of this assay, such as analysing the cells at an earlier timepoint e.g. 9 hours or
using a less toxic but equally effective DNA replication inhibitor e.g. thymidine,
will have to be carried out.
In addition to the flow cytometry data, the cells were also analysed for Chk1
activation by western blot. (Figure 4.13-B) Following replication stress Chk1
kinase activity is much more strongly induced than following γ-IR (Walker et al, 
2009). This is also seen here – with both Chk1 S345 phosphorylation and the
level of Chk1 autophosphorylation (autophosphorylated Chk1 migrates slower on
SDS-PAGE) being much stronger than compared with γ-IR.  There is no defect in 
Chk1 phosphorylation in the +/- cells. Claspin is also phosphorylated following
replication stress leading to an alteration in its electrophoretic mobility by SDS-
PAGE. Even though the total levels of cClaspin are lower in the +/- cells it
appears that, to compensate, comparatively more of the cClaspin in the +/- cells
becomes phosphorylated than in the +/+ cells. This level of phosphorylation is
sufficient to maintain the high levels of S345 Chk1 phosphorylation.
In summary the +/- cells even though they express approximately half of the
amount of cClaspin compared with +/+ cells show no obvious defect in
unperturbed DNA replication, in Chk1 activation following replication stress or in
the activation of the G2-M DNA damage checkpoint.Conor Larkin Chapter 4 140
4.8. Discussion
This chapter described the successful generation of a cClaspin
+/- cell line.
However it is evident that some parts of the overall strategy employed to
generate the cell line did not work as planned.
The first of these was the design of the targeting vectors themselves. As the
option for deleting the entire cCLSPN locus was not available (due to the large
size of the locus and the lack of some crucial sequence data) the next best
option was to delete a crucial part of the gene. As Claspin is not a kinase and
the function of each domain is not fully understood choosing the region to delete
proved difficult. Therefore it was decided to try and delete as much of the gene
as possible using the first targeting strategy describes. However this strategy
was flawed by the fact that a robust screening strategy was not thought of at
the time. Even though attempts were made to genotype the clones transfected
with this construct, no satisfactory screening method was found. This strategy
was therefore abandoned. However the second strategy employed was more
robust and even though it was designed to knock out a smaller region it
generates a null allele as can be seen from the reduction in cClaspin levels in
the cClaspin
+/- cells.
The second major obstacle that was encountered arose from the use of the MCM-
DT40 cells. These cells were chosen in order to make full use of the floxed
resistance cassettes that had recently become available (Arakawa, 2001). A cell
line expressing inducible Cre recombinase easily facilitates the recycling of the
drug resistance cassettes allowing compound mutations to be made and speeding
up the generation of knock-out cell lines due to the necessity to only generate
one targeting vector. There was no reason to suspect that there would be a
problem with these MCM DT40 cells. They had been successfully used in order to
make knock-out DT40 cell lines previously.(Brummer et al, 2003; Brummer et al,
2002) However the fact that there was a problem with the cells should have
been picked up earlier. Even using the GFP expression as a rough estimate as to
the targeting efficiency, the GFP negative cells were never more than ≈10% of 
the cells that grew. It should have been clear that the cells had impaired
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conclusion that these cells had lost capacity for homologous recombination. The
reason for this is unknown.
The method of transfection used in order to generate knock-out cells also
appears to be very important. The first transfection of the targeting vector into
Cl18 cells was done using nucleofection. (Data not shown) Even though these
cells display high ratios of targeted integration none of the 15 GFP negative
clones screened were positive for correct targeting. This might also explain the
reduced targeting efficiency observed when using the ovalbumin construct. A
targeting efficiency of only 30% was observed compared with the reported
efficiency of 70-80%. It appears that Nucleofection is not suitable for the
generation of knock-out DT40 cell lines.
A novel method for negatively selecting clones was used in this strategy. The
GFP cassette outside the arms of homology served to rule out some clones that
were not targeted. This strategy appeared to work well with none of the clones
screened that expressed GFP by visual inspection showing positive targeting. As
would be expected however not all of the GFP negative clones were targeted. It
is also interesting to note that some of the clones that didn’t express GFP
actually still contained the GFP expression cassette. Therefore combining a
visual inspection with a PCR for the GFP cassette proved more useful.
Although problems were encountered during the generation of the cClaspin
+/-
cells once the targeting vector and screening strategy were optimised and the
correct cells used, obtaining the hemizygous cells was very straight forward.
With these cells, in which one allele of cCLSPN was deleted, it was now possible
to continue with the strategy and attempt to make the complete knockout.Chapter 5.Generation of Claspin-/- Cell LineConor Larkin Chapter 5 143
5.1. Introduction
Having confirmed the genetic deletion of the one cCLSPN allele in Cl18 DT40
cells the next step is to generate the complete knock-out by repeating the
process. This is accomplished by targeting the remaining allele of cCLSPN in the
hemizygous cells.
5.2. Targeting the second cCLSPN allele
Generating the complete knock-out cell line requires that the second allele of
cCLSPN must also be disrupted. As the NeoR cassette in the targeting vector is
flanked by MLoxP sites it is possible to remove the cassette by transient Cre
transfection and then reuse the same targeting vector. However in order to
speed up the knock-out process it was decided to switch to using the Blasticidin
version of this same targeting vector. Problems already experienced with
Blasticidin should not be encountered with the Cl18 cell line (section 4.5) as
clones from this cell line appear within 7 days following plating as opposed to 2-
3 weeks for the MCM-DT40 cells.
Hemizygous cells were transfected with the linearised targeting vector and
selected in the presence of both Blasticidin and G418. It is possible that the
targeting vector could integrate into the already targeted allele. In this case
the cells will no longer be resistant to G418. Selecting cells in both G418 and
Blasticidin will ensure that any cells which target the NeoR allele will not grow.
The results from the first transfection showed that there was a dramatic
reduction in the total number of clones that were growing. For this transfection
only 7 clones grew. Indeed the average number of clones that grew under
double selection, after repeating a further four times, was only 12. (Figure 5.1-
A(i))  This was a dramatic reduction from an average of ≈80 clones obtained per 
transfection when targeting the first allele (See Figure 4.9).
In order to try and clarify this situation more cells were transfected with the
linearised targeting vector but this time the cells were selected in parallel in
either Blasticidin alone or with both Blasticidin and G418. On this occasion in
the presence of Blasticidin alone 109 colonies grew (Figure 5.1-A(ii)) but again
under selection with both drugs only 20 colonies grew. A possible explanationConor Larkin Chapter 5 144
Figure 5.1 Summary of Results and Screening from Targeting the Second cCLSPN Allele
A)(i) Pie chart shows the proportion of GFP negative and positive cells obtained when transfecting
cClaspin+/- cells with the pTV2-Claspin targeting vector following selection in both Blasticidin and
G418. The numbers are the sum total of all transfections. The number of transfections is shown
below the pie chart. (ii) Pie chart shows the proportion of GFP negative and positive cells obtained
when transfecting cClaspin+/- cells with the pTV2-Claspin targeting vector following selection in
Blasticidin alone. The numbers shown represent data from only one transfection. B) Southern Blot
screening strategy for screening for loss of the second allele. Note that both targeting vectors
generate the same pattern using this screening strategy. Therefore loss of the WT allele confirm
deletion of both alleles. The + and – symbols above the screened clones indicate whether they
express GFP or not.Conor Larkin Chapter 5 145
for this is that the BsdR vector is preferentially targeting the NeoR allele –
resulting in clones that are re-sensitised to G418. In this case it would be
assumed that the vector would integrate faithfully and clones arising from the
BsdR vector targeting the NeoR allele would be GFP negative. Therefore to
account for the ≈80% reduction in viable clones it should follow that ≈80% of the 
clones grown under the selection of Blasticidin alone should be GFP negative.
However this was not the case. In fact 70% of the clones were GFP positive
indicating that they were not correctly targeted. Therefore faithful targeting of
the NeoR allele by the BsdR vector cannot explain the dramatic reduction in the
number of clones that appear. As noted before however it is possible to
integrate the 3′ arm of homology correctly while not recombining correctly at 
the 5′ end. This possibility, as it was not directly tested by screening all the
clones by Southern blot, cannot be ruled out.
Another possible explanation for the lower number of viable clones is that cells
cannot survive in the absence of cClaspin. The targeting efficiency with the
NeoR targeting vector for targeting the first allele was 30% when screening the
GFP negative clones. It is reasonable to assume that the BsdR version of the
targeting vector will target at approximately the same efficiency. Therefore
roughly
1/3 of GFP negative clones derived from targeting the second allele
should be targeted. However this was not the case. In total 29 GFP negative
clones were screened by Southern blot but none of them were targeted. (Figure
5.1-B)
The assumption that
1/3 of GFP negative clones should be targeted would only be
valid if the overall targeting efficiency of the Claspin+/- cells had not decreased.
Although Claspin has not been implicated in the process of homologous
recombination, if it did play a role then the reduction in cClaspin protein in the
Claspin+/- cells may impact on the targeting efficiency. To directly test this
possibility the Claspin+/- cells were transfected with the same Ovalbumin
targeting construct used to test the efficiency of the MCM-DT40 and Cl18 cells.
Southern blot analysis of the clones that grew show that there is no defect in
targeting efficiency in the hemizygous cells. Of 60 clones screened 38 were
targeted giving a targeting efficiency of 60%. Therefore a reduction in targeting
efficiency cannot account for the inability to obtain a Claspin
-/- clone. In fact
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targeting of the remaining allele (resulting in cell death due to lack of Claspin)
combined with targeting of the NeoR allele (resulting in cell death due to
sensitivity to G418) probably accounts for the dramatic reduction in viable
clones. Due to the nature of the Southern blot screening strategy used to screen
the clones both targeted alleles co-migrate at 9.3kb on the Southern blot.
Therefore it is impossible to distinguish between them.
Although the inability to obtain a cClaspin-/- cell line by routine targeting of the
second allele is not direct evidence that completely targeting Claspin in DT40
cells is incompatible with the cells viability, it is enough evidence to change
strategy and generate a conditional knock-out cell line.
5.3. Generation of a conditional cClaspin
expressing cell in the Claspin+/- background
The generation of conditional knock-out cells using the DT40 system is possible
(Hudson et al, 2002). By far the most popular method for achieving this is the
Tet On/Off system based on the Tetracycline regulated gene expression in
bacteria (Hillen et al, 1982; Jorgensen & Reznikoff, 1979). The tetracycline
transactivator (tTA) system provides a convenient method for the controlled
expression of proteins in cells. (Figure 5.2) The regulation is achieved at the
level of gene transcription by the binding of the tTA to the Tet Operator (TetO)
sequences (termed Tet Responsive elements - TRE) placed immediately up-
stream of the gene of interest. Binding of the tTA, and hence indirectly
activation of transcription, is regulated by tetracycline. The tTA itself is
composed of two parts; the Tet repressor and the transactivation domain viral
VP16 protein. The Tet repressor binds the TRE in the absence of its high affinity
ligand, tetracycline. Transcription is regulated by the VP16 transactivation
domain which serves to recruit transcriptional co-transactivators. This system
has been successfully used with the DT40 system for the generation of
conditional null cell lines (Sonoda et al, 2001a; Sonoda et al, 1998; Wakasugi et
al, 2007).
In order to generate the Claspin+/- + cClaspin ON/OFF cell line the first step is
to generate Claspin+/- clones that stably express the tTA. (Figure 5.3) ClaspinConor Larkin Chapter 5 147
Figure 5.2 Overview of Tetracyline controlled transcriptional regulation
In the absence of Dox the tTA binds to the TRE and mediates transcription of the cClaspin mRNA.
Upon addition of Dox to the system it binds to the tTA and induces an conformational change which
renders the tTA incapable of binding to DNA. Consequently gene transcription is shut down.Conor Larkin Chapter 5 148
Figure 5.3 Overview of the generation of Claspin On/Off Cell line
A Claspin +/- cell line is stably transfected with the ‘advanced’ tet-Transcriptional Transactivator.
(The advanced tTA is an improved version of the tTA available from Clontech) Once the
expression and functionality of the tTA is verified, the cell line is the transfected with a tagged
version of Claspin (Strep II-FLAG) under the control of a Tet Responsive Element (TRE) promoter.
A cell line expressing near endogenous levels of Claspin with tight regulation by tet is selected.
The second allele of Claspin is targeted in this cell line to generate an On/Off cell line.Conor Larkin Chapter 5 149
+/- cells were transfected with the tTAAD vector which had been modified to
replace the NeoR cassette with a PuroR cassette. The tTAAD tet transactivator is
an updated version of the original tTA provided by Clontech (Resnitzky et al,
1994). The improved version is optimised for higher levels of expression and
contains three repeats of the minimal VP16 transactivation domain. Clones were
selected in the presence of Puromycin and then tested for tTAAD expression. A
luciferase assay was carried out in order to test for the presence of functional
tTAAD. 9 clones were transfected with the pTRE-Tight Luciferase construct (and
pTK-Renilla Luciferase) and were grown in the presence or absence of
doxycycline for 24 hours. A dual luciferase assay was then preformed in order to
identify clones with high luciferase activity that could be repressed in the
presence of dox. (Figure 5.4-A) Two clones were selected that showed either
high luciferase activity (Clone #4) or very tightly controlled luciferase activity
(Clone #1). To confirm this result these two clones were transfected with pTRE-
d2EGFP which expresses a destabilised form of GFP under the control of a Tet
responsive promoter. As can be seen from Figure 5.4-B both cell lines show both
high GFP expression which is tightly controlled by the addition of dox. Together
this data suggests the cell line contains functional levels of the tTAAD.
Two expression cassettes were generated where either a C-terminally GFP
tagged cClaspin protein (cClaspin.EGFP) or an N-terminally tagged SF (Strep
II/Flag TAP tag) cClaspin protein (SF.cClaspin) were cloned down stream of a
TRE promoter. The tag will distinguish the ectopically expressed protein from
the endogenous protein left in the cell. Expression of the tagged versions of
cClaspin from these plasmids was confirmed by transient expression in a HEK293
Tet-Off cell line (Clontech). (See Figure 5.5) Expression from the TRE-Tight
plasmids was lower than from a plasmid where expression is driven by the CMV
promoter. Having confirmed that the plasmids were functional, they were then
co-transfected with a Histidinol Resistance (HisR) cassette into both of the tTAAD
expressing clones isolated above. Clones were selected in the presence of
Histidinol and then were screened for expression of the transgenes. However
unfortunately, following multiple transfections and rounds of screening for
expression of the transgenes I was unable to identify a clone that expressed
either the SF-cClaspin or cClaspin-EGFP. Due to time constraints, I could not
complete this part of the project.Conor Larkin Chapter 5 150
Figure 5.4 Testing the tTAAD expression in Claspin+/- + tTAAD Clones
A) Luciferase Assay. Claspin+/- cells transfected with the pTet-Off Advanced plasmid were
selected in the presence of puromycin. The resulting clones were then transiently transfected with
pTRE-Tight Luc and pTK-Renilla and were grown in the presence and absence of Dox. A Dual
Luciferase Assay preformed. The data was normalised for both the amount of protein and Renilla
Luciferase Expression.Conor Larkin Chapter 5 151
Figure 5.5 Testing pTRE-Tight SF.cClaspin and pTRE-Tight cClaspin.EGFP vectors
HEK293 Tet-Off cells were transfected with the indicated plasmids and blotted with the indicated
antibodies. The HF64B antibody raised against cClaspin does not detect hClaspin.Conor Larkin Chapter 5 152
5.4. Generation of Claspin
On/Off cell line
Due to the difficulty in obtaining the conditional cClaspin expressing cell line the
Claspin
On/Off cell line could not be generated. In theory once this cell line is
generated, the second allele of cCLSPN can be targeted and a cell line that no
longer expresses cClaspin from the endogenous locus selected. The transgene
that kept the cells alive during the targeting process can then be switched off in
order to reveal the null phenotype.
5.5. Downregulation of cClaspin expression using
siRNA and shRNA
Due to the difficulties described above in generating the cClaspin
-/- cell line an
alternative approach was also attempted. Although the main advantage of the
DT40 system is the generation of a clean genetic cell line deficient for the
protein of interest, this can sometimes be a difficult and lengthy process. shRNA
technology has greatly improved over the past years had been shown to work in
DT40 cells (Yuan et al, 2006) and can prove especially useful in the creation of
conditional knock-down cell lines (Johnson et al, 2009). It was therefore
decided to attempt the generation a conditional cClaspin Knock-down
(cClaspin
KD) cell line using shRNA. Given that the major phenotype we see with
the cClaspin
-/- cells is one of lethality an inducible system would be valuable in
characterising this cell death and might allow the identification of novel
functions of cClaspin by titering cClaspin levels such that its function is impaired
but not to the extent that it induces cell death.
The system developed in order to do this was composed of two parts – a Flp-In –
T-Rex (Invitrogen) DT40 cell line and a modified pSuperior (Oligoengine) shRNA
expression cassette. The Flp-In T-Rex DT40 cell line (made in the Chk1
-/-
background) was developed by Mark Walker. (Figure 5.6-A) It contains a
defined locus into which expression cassettes can be integrated. The process is
highly efficient and is mediated via the Flp recombinase. The cell line also
expressed the Tet repressor to allow for conditional expression of the hairpin.
The pSuperior vector drives expression of the shRNA from a H1 PolIII promoter.
It contains a TetO site between the H1 promoter and the shRNA transcription
start site which represses transcription of the hairpin in the absence ofConor Larkin Chapter 5 153
Figure 5.6 Schematic Overview of the generation of Inducible shRNA expressing cell line
A) The Chk1-/- Flp-In T Rex cell line expresses the Tet repressor and contains an FRT site. Flp
Recombinase (transiently expressed) mediates recombination between the FRT site in the genome
of the cell line and the FRT site in the plasmid. This results in stable incorporation of the plasmid of
interest. B) In the absence of Dox the Tet Repressor binds tightly to the H1 Pol III promoter
inhibiting access to the polymerase. The hairpin is not expressed and there is no effect on mRNA
levels. In the presence of Dox the repressor is displaced allowing expression of the hairpin which
knocks-down mRNA levels.Conor Larkin Chapter 5 154
tetracycline. (Figure 5.6-B) Upon the addition of tetracycline the hairpin is
expressed which targets the cCLSPN mRNA for degradation. This vector was
modified to replace the Puromycin resistance cassette with the FRT-Hygro
cassette from pcDNA5/FRT. It is this FRT site that recombines with the FRT site
stably integrated into the Flp-In cell line. The resulting plasmid, pSuperior/Frt-
Hygro, was used to express shRNA oligos directed against cCLSPN and cCDK2 as a
control. The shRNA oligos were designed using an algorithm developed by
Oligoengine. The most suitable hairpins from this prediction program were
selected and cloned into the expression vector.
Clones of the Chk1-/- Flp-In T-Rex cells having stably integrated the shRNA
expression cassette directed against either cCLSPN or cCDK2 were isolated.
They were then grown in the presence of tetracycline to induce the expression
of the shRNA and left for 72 hours to allow processing of the shRNA and knock-
down of cClaspin or cCdk2. The cells were then analysed by western blot for the
presence or absence of the protein of interest. (Figure 5.7-A) However after
screening multiple clones for both the shcCLSPN and the shcCDK2 no clone was
identified for its ability to knock-down its target protein.
Possible reasons for this are that the shRNA is not actually expressed from the
cassette, there is a defect in the shRNA processing or the siRNA generated does
not mediate effective knock-down it its target mRNA. To test this, the
equivalent siRNA duplexes corresponding to the siRNA duplexes that would be
generated from the shRNA were synthesised and transfected directly into cells.
The method used had previously been shown to achieve knock-down of Chk1 in
DT40 cells (Churikov & Price, 2008). Examining the level of knock-down 72 hours
post transfection revealed that these oligos could not mediate knock-down of
either cClaspin or cCdk2. (Figure 5.7-B) As DT40 cells are difficult to transfect
the experiment was repeated with DF-1 chicken fibroblasts (Himly et al, 1998).
This time the EDD positive control siRNA seems to mediate knock-down of its
target indicating that the siRNAs are being effectively delivered to the cells.
(Figure 5.7-C) However the cCLSPN siRNA did not reduce cClaspin levels, but the
siRNA directed against cCDK2 did appear to show some efficacy. The reason this
oligo does not work as a hairpin is probably due either to low expression of the
hairpin or defective processing to generate functional siRNA.Conor Larkin Chapter 5 155
Figure 5.7 shRNA Knock down of cClaspin
A) Clones stably transfected with either shcCLSPN or shCDK2 were treated with Tetracycline for
72 hours. Clones were then analysed for the expression of cClaspin or cCdk2 by western blot.
Cdk2-/- DT40 cells were obtained from Helfrid Hochegger (Hochegger et al, 2007) B) DT40 cells
were transfected with the indicated siRNA duplexes. 72 hours post-transfection the cells were
harvested and analysed by western blot for the indicated proteins. C) DF-1 fibroblasts cells were
transfected with the indicated siRNA duplexes. 72 hours post-transfection the cells were harvested
and analysed by western blot for the indicated proteins.Conor Larkin Chapter 5 156
The oligos chosen to knock-down cClaspin are not effective. More oligos would
need to be tested for their ability to first work as an siRNA and then they could
be tested for their ability to work in the shRNA expression cassette.
5.6. Discussion
The major unresolved issue from this Chapter is whether knocking out cClaspin
in DT40 cells is actually lethal. The inability to obtain Claspin
-/- cells by simply
targeting the second allele is a strong indication that this is the case, but is not
definitive proof. To resolve this issue it is necessary to generate a conditional
knock-out and characterise the cell death following repression of the rescuing
transgene. This has also however proven unsuccessful. Why a cell line that
conditionally expresses either the SF.cClaspin or cClaspin.EGFP cannot be
obtained is currently unknown. It is not due, however, to the cells not being
able to tolerate high expression of these transgenes. Stable cell lines have been
made with these plasmids previously in DT40 cells but in different genetic
backgrounds. The expression level in these cells is roughly 10 times above
normal level. Therefore cells can tolerate high levels of cClaspin. Efforts to
generate this Claspin+/- cell line conditionally expressing cClaspin will continue.
What options remain for the generation of the conditional cell line? Obviously
the most straightforward option would be to continue with the current strategy
and obtain a cell line in which cClaspin can be switched off by the addition
tetracycline. The major hurdle in this effort is obtaining enough cell lines to
screen in order to identify a cell line that is positive for both tTAAD expression
and that also has integrated enough copies of the TRE-cClaspin transgene. This
process should be relatively straight forward as DT40 cells quite readily
integrate exogenous DNA randomly into their genomes. However it may be
necessary to increase the probability of obtaining the correct cell line by using
enzyme mediated recombination. Systems such as the Jump In™ System from
Invitrogen  which  uses  ΦC31  integrase-mediated  recombination  to  stably 
integrate DNA of choice at defined genomic regions (Groth et al, 2000) or the
Tol2 transposase system which has been shown to work in chicken cells (Sato et
al, 2007).Conor Larkin Chapter 5 157
Targeting the second allele with a different targeting vector might also prove
fruitful. The chicken genome sequence has been updated since the release of
the first draft. In it more DNA sequence flanking the cCLSPN gene has become
available. This allows the generation of external probes that could be used in
order to screen clones targeted by the first strategy using SacI digested genomic
DNA. Up until now this targeting vector had been abandoned due to the
unreliability of screening resulting clones by Southern blot. Targeting the
second allele by a different mechanism to the first reduces the possibility of
targeting of the already targeted allele.
An alternative approach would be to completely redesign the entire knock-out
strategy. Conditional alleles in mice are often generated by flanking exons in
critical regions of genes by LoxP sites. Upon the controlled activation of Cre
recombinase the intervening regions are deleted and a null allele is generated.
Such an approach could also be taken with DT40 cells – but would require
significantly more work.
It may also prove useful to revisit the conditional shRNA knock-down approach.
This approach requires the identification of suitable oligos that effectively
knock-down cClaspin levels. Once identified the hairpin could be in the
cClaspin
+/- background – which already expresses half the amount of cClaspin
compared with the Cl18 cells, in order to reduce the levels of cClaspin. This
would of course require in addition to the shRNA that the cells express the Tet
Repressor to control expression of the hairpin.
More work will be required in order to complete the DT40 cClaspin knock-out
cell line.Chapter 6.Analysis of cClaspin
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6.1. Introduction
Claspin was originally identified as a mediator protein which facilitated the
activation of Chk1 (Kumagai & Dunphy, 2000). It is thought that Claspin
mediates this function through protein-protein interactions, presumably by
bringing ATR into close enough proximity or in the correct orientation to
facilitate Chk1 phosphorylation and activation. It is known that Claspin and
Chk1 interact and this interaction is dependent on phosphorylation of Ser/Thr
residues in the Chk1 Binding Domain of Claspin. The kinase that mediates
phosphorylation of these sites remains unknown. The possibility that this kinase
was actually Chk1 itself had been raised in the literature (Chini & Chen, 2006).
Having generated an antibody that recognises cClaspin (Section 3.5.1) and
having Chk1
-/- DT40 cells available it was decided to try and examine this
further.
6.2. Analysis of cClaspin Phosphorylation
following Replication Stress
A system was developed where the phosphorylation of cClaspin could be
monitored following replication stress. Claspin has been shown previously to
undergo a phosphorylation induced mobility shift in response to checkpoint
activation following replication stress (Chini & Chen, 2003; Clarke & Clarke,
2005; Kim et al, 2008). In order to analyse cClaspin phosphorylation following
replication stress a similar system was set up. DT40 cells were treated with
aphidicolin (directly inhibits DNA polymerase α, δ and ε) or Hydroxyurea (which 
inhibits ribonucleotide reductase thus decreasing available dNTP pools) to
induce replication stress and the resulting lysates were run on different SDS-
PAGE gels in order to maximise the phosphorylation induced mobility shift
observed.  Samples treated with 60μM aphidicolin and run on a 6% SDS-PAGE gel 
until  only  proteins  greater  than  ≈  150kDa  remained  on  the  gel  showed  the 
greatest mobility shift. (Figure 6.1-A) This concentration of aphidicolin also
induced the strongest activation of Chk1 at S345. Agents that best induce this
modification of cClaspin are those that impact on DNA replication such as
aphidicolin and hydroxyurea, in addition to UV-C light which damages DNA
through the introduction of cyclobutane pyrimidine dimers and 6,4-
photoproducts. These treatments also induce the strongest Chk1 activation asConor Larkin Chapter 6 160
Figure 6.1 Claspin Phosphorylation following Replication Stress in WT and Chk1
-/- DT40
cells
A) Cells were treated with the indicated drugs at the indicated concentrations for 90 minutes. The
cells were then harvested and processed for western blotting. Western Blots using the indicated
antibodies are shown. B) DT40 cells were treated with 10Gy γ-IR, 200ng/ml Doxorubicin, 10μM 
Etoposide, 800μg/ml Zeocin, 30μM Aphidicolin, 10mM Hydroxyurea or 50Jm
-2 UV-C. Cells were
harvested 2 hours later and analysed by western blotting for the indicated proteins.Conor Larkin Chapter 6 161
judged by phosphorylation at S345. In contrast treatments which induce
different DNA damage seem to lead to an accumulation of the protein. Such
treatments do not lead to a very strong induction in Chk1 activity. It appears
that there is a direct correlation with the mobility shift observed following
replication stress and the activation of Chk1. (Figure 6.1-B) Pre-treating the WT
cells with caffeine, which is known to inhibit ATM/ATR signalling (Sarkaria et al,
1999), inhibits the cClaspin mobility shift following aphidicolin treatment.
(Figure 6.2-A) This indicates that the cClaspin phosphorylation induced mobility
shift is dependent on the activity of the ATM/ATR kinases. In contrast to the
situation observed in the WT cells no cClaspin mobility shift was observed in
Chk1
-/- cells undergoing replication stress. (Figure 6.1-A) This indicates that
somehow Chk1 is involved in regulating cClaspin phosphorylation following
during replication stress.
To probe this role of Chk1 in the phosphorylation of cClaspin a time course was
carried out to see whether the phosphorylation mobility shift was completely
absent or simply delayed in the Chk1
-/- cells. As can be seen from Figure 6.2-B(i)
cClaspin is rapidly phosphorylated in WT cells following the induction of
replication stress. This phosphorylation remains up the 8 hours, the latest time
point examined in this time-course. In contrast no mobility shift is observed in
the Chk1
-/- cells at any of the time points analysed. To further this observation
the time-course was repeated with Chk1
-/- cells which stably expressed either
WT Chk1 (Chk1 Rev) or Kinase Dead version of Chk1 (KD Chk1) (Walker et al,
2009). Figure 6.2-B(ii) shows that stably re-expressing WT but not the KD
version of Chk1 restores the cClaspin mobility shift. This implicates the Chk1
kinase activity in playing a direct role in mediating the cClaspin mobility shift
induced by replication stress.
There are two possible explanations for this. Chk1 itself may directly
phosphorylate or contribute to the phosphorylation of cClaspin. Alternatively a
downstream function of Chk1 (which relies on its kinase activity) such as
maintaining viable replication forks, is necessary to facilitate the
phosphorylation. Unperturbed replication in Chk1
-/- cells is known to progress
relatively normally (Petermann et al, 2006). However Chk1 is known to be
required to maintain replication forks in a competent state for replicationConor Larkin Chapter 6 162
Figure 6.2 Time course of cClaspin phosphorylation following Replication Stress
A) WT DT40 cells were either pre-treated or not with 5mM Caffeine for 1 hour. Cells were then
treated with 601μM aphidicolin. After 45 minutes the cells were harvested and blotted for the 
indicated proteins. B) (i) WT and Chk1
-/- cells were treated with 60μM Aphidicolin.  Samples were 
taken at the indicated times (hour). Lysates were blotted with the indicated antibodies. (ii) Chk1
Revertant (Chk1 Rev) and Kinase Dead Chk1 (KD Chk1) cells were treated as in A(i).Conor Larkin Chapter 6 163
allowing replication to recommence once the stress has been resolved. One
hypothesis of how Chk1 fulfils this function might be through keeping the
required proteins at the stalled replication fork. cClaspin might be one of these
proteins. Mis-localised cClaspin might not be effectively phosphorylated
following replication stress. If this hypothesis were correct however it would be
expected that cClaspin phosphorylation would be normal until replication fork
collapse takes place. Therefore at early time-points following the addition of
aphidicolin phosphorylated cClaspin would still be expected to be seen in the
absence of Chk1. It is probable therefore that Chk1 plays a more direct role in
promoting the phosphorylation of cClaspin following replication stress.
In order to test this directly an in-vitro kinase assay was carried out to see
whether Chk1 can phosphorylate cClaspin. cClaspin tagged with a tandem
StrepII-FLAG tag was expressed using the in vitro transcription-translation as
described in section 3.4. The SF.cClaspin was then bound to Streptactin Beads
and used as the substrate in a kinase assay using increasing amounts of
recombinant active Chk1. The reaction was first carried out using ‘cold’ ATP
and the samples were analysed by Western blotting. From Figure 6.3-A however
it is clear that in an in vitro kinase assay Chk1 is not able to induce the mobility
shift even using a presumed large molar excess of Chk1. Although Chk1 does not
induce the cClaspin mobility shift it may still phosphorylate the protein. The
kinase assay was therefore repeated in the presence of radioactive ATP in order
to monitor the incorporation of phosphate into cClaspin. From Figure 6.3-B it
can be seen that there is non-specific incorporation of
32P into an unknown
protein that binds non-specifically to the Streptactin Beads and runs with a
similar molecular mass to cClaspin. This incorporation is present in the absence
of recombinant Chk1 indicating that unknown kinases are also present in the
kinase assay. However in addition to this background incorporation there seems
to be incorporation of
32P into cClaspin as well. The incorporation increases with
increasing Chk1 levels but because cClaspin is only phosphorylated by Chk1 when
it is in vast excess it is unlikely that cClaspin is a true substrate. Assuming that
the in vitro situation fully recapitulates what is occurring in cells Chk1 appears
not to be able to efficiently phosphorylate cClaspin.Conor Larkin Chapter 6 164
Figure 6.3 In vitro Chk1-Claspin Kinase Assay
A) In vitro Kinase assay on SF.cClaspin using recombinant active Chk1. IP’ed IVT SF.cClaspin
was incubated with increasing amounts of Chk1 in the presence of ATP. The reactions were
incubated for an hour at 30°C.
1/6 of the reaction was run on a 10% acrylamide gel (Chk1) and the
remainder was run on a 6% acrylamide gel (cClaspin). Western Blot analysis was preformed using
the indicated antibodies. B) IP’ed IVT SF.cClaspin was incubated with increasing amounts of Chk1
in the presence of γ-
32P-ATP. The reactions were incubated for an hour at 30°C. The reactions
were separated on a 6% SDS-PAGE gel then the proteins were transferred to nitrocellulose
membrane and exposed to film. The resulting autoradiograms are shown.Conor Larkin Chapter 6 165
6.3. Analysis of cClaspin Phosphorylation
following Protein Synthesis Inhibition
While comparing the phosphorylation of cClaspin in both WT and Chk1
-/- DT40
cells in response to replication stress it was apparent that cClaspin in the Chk1
-/-
cells was, in addition to not being phosphorylated, more unstable than in WT
cells. It has been reported that Chk1 is required to maintain Claspin stability so
it was therefore decided to examine this further (Chini et al, 2006). A
cycloheximide (CHX) chase experiment was performed in order to analyse the
turnover of cClaspin in WT and Chk1
-/- cells. As can be seen in Figure 6.4-A the
trend is that cClaspin is more stable in the WT cells than in the Chk1
-/- cells
indicating that Chk1 is required to stabilise cClaspin.
In addition it was also noted that cClaspin undergoes a pronounced mobility shift
following treatment with CHX. In contrast with the mobility shift induced by
replication stress, this shift occurs in both the WT and Chk1
-/- cells and the
entire population of cClaspin is modified indicating that cClaspin is being
modified in all cells in all phases of the cell cycle.
In order to determine whether this response is specific to CHX or whether it is a
more general response to protein synthesis inhibition, cells were treated with a
panel of protein synthesis inhibitors. Anisomycin, Emetine, Puromycin and
Blasticidin were chosen. All of these inhibitors inhibit protein synthesis at the
translational elongation phase but they have distinct chemical structures and
inhibit elongation by different mechanisms. As can be seen from Figure 6.4-B
they all induce the mobility shift as efficiently as CHX. In addition a dose
response experiment using a range of CHX concentrations shows that the
modification of cClaspin only occurs when the CHX level is high enough to inhibit
protein synthesis. (Figure 6.4-C) c-myc loss was used as a marker of protein
synthesis inhibition in these cells since c-myc is over-expressed in DT40 cells but
is turned over very rapidly and is quickly lost when protein synthesis is inhibited
(Salghetti et al, 1999). This indicates that it is an effect on protein synthesis,
rather than an indirect action of CHX that is leading to the modification of
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Figure 6.4 cClaspin is modified following treatment with Protein Synthesis Inhibitors
A) CHX chase experiment. WT and Chk1
-/- cells were treated with 50μg/ml CHX.  Samples were 
harvested at the indicated times and analysed for the indicated proteins by western blot. B) WT
DT40 cells were either left untreated or treated with C (50μg/ml CHX), A (10μg/ml Anisomycin), E 
(20μM Emetine), P (10μg/ml Puromycin) and B (30μg/ml Blasticidin) for 90 minutes.  The resulting 
extracts were blotted for cClaspin. C) DT40 cells were treated with the indicated concentrations of
CHX for 1 hour, then blotted for the indicated proteins.Conor Larkin Chapter 6 167
Protein synthesis can also be inhibited by using the cells own surveillance
mechanisms that monitor protein biosynthesis. Initiation of cap-dependent
protein synthesis requires the eIF2A initiation factor which controls the
recruitment of the tRNA-iMet to the 40S ribosome in a GTP dependent manner.
(Figure 6.5-A) eIF2A, now in the GDP bound state, must be converted back to
the GTP bound state in order for the cycle to be repeated and the synthesis of
other proteins initiated. This reaction is catalysed by eIF2B which is usually
present in cells at a much lower level than eIF2. However phosphorylation of
the α subunit of eIF2A results the formation of a tight complex between eIF2A 
and eIF2B. This sequestration of the eIF2B subunit means that it is no longer
capable of re-setting eIF2A and protein synthesis is stops (Brostrom et al, 1997).
Phosphorylation of eIF2A occurs in response to distinct cellular stresses which
include Endoplasmic Reticulum (ER) stress and amino acid deprivation.
Therefore inducing these stresses should also lead to protein synthesis inhibition
but by a different mechanism to direct inhibition by chemicals.
In response to amino acid starvation protein biosynthesis is inhibited on two
levels. Elongation is inhibited by the lack of amino acid precursors but initiation
is also inhibited through the GCN2 mediated phosphorylation of eIF2A. As can be
seen from Figure 6.5-B growing DT40 cells in the absence of amino acids (either
all amino acids or just Glutamine, Methionine and Cysteine) leads to an increase
in the phosphorylation of eIF2A. c-myc levels decrease in the cells grown in the
absence of amino acids indicating that protein synthesis is indeed inhibited. As
was seen when inhibiting protein synthesis using drugs cClaspin is also modified
following protein synthesis inhibition by amino acid starvation.
Inhibition of protein synthesis can also occur in response to ER stress, which
leads to the activation of PERK (PKR-like ER Kinase) which in turn phosphorylates
eIF2A. In this instance protein synthesis is only inhibited through the p-eIF2
pathway. Cells were treated with drugs that cause ER stress. (Figure 6.5-C)
Thapsigargin depletes ER calcium stores thus inhibiting calcium dependent ER
chaperones like calreticulin leading to an immediate accumulation of unfolded
proteins. Tunicamycin inhibits protein N-Glycosylation which is a crucial step in
the folding of newly synthesised proteins. Inhibition of N-glycosylation will lead
to a gradual accumulation of unfolded proteins. DTT causes a redox imbalanceConor Larkin Chapter 6 168
Figure 6.5 Inhibition of Protein Biosynthesis through p-eIF2A also leads to cClaspin
modification
A) Schematic representation of how eIF2A controls translational initiation. Phosphorylation of
eIF2A results in the formation of a complex between eIF2A and eIF2B which inhibits the initiation
cycle. B) Cells were washed in pre-warmed PBS and then returned to full media with or without
CHX or to media lacking all amino acids (EBSS supplemented with 10% dialysed serum and MEM
Vitamins) or to full media lacking only Glutamine, Methionine and Cysteine (Q/M/C) supplemented
with dialysed serum. C) Cells were treated with 50μg/ml CHX, 2μM Thapsigargin, 5μg/ml 
Tunicamycin or 2mM DTT for 1 hour. Western blot analysis using the indicated proteins is shown.Conor Larkin Chapter 6 169
in the ER and thus leads to improperly formed disulphide bonds and unfolded
proteins. Treating cells with these agents leads to an increase in p-eIF2A as
expected. This treatment also leads to the same modification in cClaspin as
seen before. No modification is seen with tunicamycin treatment but this is
probably due to the fact that there is lower p-eIF2 induced with a short
treatment of tunicamycin. CHX leads to a reduction in p-eFI2A levels
presumably through reducing the biosynthetic load on the ER.
It has now been firmly established that cClaspin is modified following protein
synthesis inhibition. The next issue that was addressed was what modification
was occurring to lead to the altered electrophoretic mobility. Many post-
translational modifications have been identified (Kia-Ki & Martinage, 1992).
Some of these lead to an altered electrophoretic mobility by SDS-PAGE. As
phosphorylation of cClaspin has already been shown to alter its electrophoretic
mobility this was a reasonable candidate to investigate first. To test whether
treating cells with protein synthesis inhibitors leads to the phosphorylation of
cClaspin, cClaspin was immuno-precipitated from cells that had been treated
with CHX in order to induce the mobility shift. The partially purified cClaspin
protein was then incubated with λ Protein phosphatase in order to remove any 
potential phosphate groups from the protein. cClaspin was then boiled off the
beads and analysed by western blot. Figure 6.6-A shows that this modified form
of cClaspin can be readily purified from cells treated with CHX and that this
modification can be completely reversed by phosphatase treatment providing
evidence that phosphorylation of cClaspin is responsible for the mobility shift. It
is interesting to note that the completely dephosphorylated form of cClaspin
runs lower than the cClaspin from untreated cells indicating that even in an
unstressed state cClaspin exists in a phosphorylated protein.
Having now confirmed that cClaspin is hyperphosphorylated following protein
synthesis inhibition the next obvious question to address is which kinase is
responsible for the phosphorylation. A candidate approach using selective
kinase inhibitors was first taken in order to try and identify the relevant kinase.
Protein synthesis inhibition using drugs (especially Anisomycin) has been known
for some time to activate signalling pathways, especially those mediated by theConor Larkin Chapter 6 170
Figure 6.6 cClaspin is phosphorylated following Protein Synthesis Inhibition but not by
p38/JNK
cClaspin was immunoprecipitated from cells either untreated or treated with 50μg/ml of CHX for 90 
minutes.  The partially purified protein was then incubated with λ phosphatase.  cClaspin was then 
boiled off the beads and analysed by western blot. B) Cells were pre-treated with the indicated
combinations of inhibitors for 15 minutes prior to treatment with either 50μg/ml CHX or 1mM H2O2.
Cells were harvested 30 minutes later and analysed by western blot for the indicated proteins. (VIII
= JNK Inhibitor - 10μM, II = JNK Inhibitor SB600125 - 10μM, SB = p38 Inhibitor SB202190 - 10μM, 
B = p38 Inhibitor BIRB 796 - 5μM, C = Cycloheximide, H = Hydrogen peroxide) Conor Larkin Chapter 6 171
p38 and JNK family members (Cano et al, 1994; Hazzalin et al, 1996). Cells
pre-treated with inhibitors to these kinases were then challenged for their
ability to mediate cClaspin hyperphosphorylation following protein synthesis
inhibition. To inhibit p38 a combination of SB202190 and BIRB-796 was used.
This has been recommended to inhibit all isoforms of p38 (Bain et al, 2007). To
inhibit JNK two commercially available inhibitors were used. JNK Inhibitor VII
shows Ki values of = 2 nM, 4 nM and 52 nM for JNK1, 2 and 3, respectively and
JNK Inhibitor II (SB600125) shows IC50 values of 40 nM for JNK-1 and JNK-2 and 90
nM for JNK-3. The results from these studies are shown in Figure 6.6-B. Firstly
it is interesting to note that CHX does not induce phosphorylation of JNK or p38
or their down stream targets c-Jun and ATF2. Therefore these pathways are not
always activated in response to protein synthesis inhibition. In addition H2O2,
which activates p38 and JNK, also induces hyperphosphorylation of cClaspin.
H2O2 exerts multiple effects on the cell including DNA damage but it will most
likely also disrupt protein synthesis. Using p-ATF2 as a readout of p38 activity
and p-c-Jun as a readout for JNK activity it can be seen that the combination of
inhibitors used effectively inhibits the target kinases. The combination of JNK
inhibitors leads to a complete loss of c-Jun phosphorylation in response to H2O2
treatment and inhibiting p38 leads to a reduction in ATF2 signalling. However
even though these kinases have been inhibited effectively there is no effect on
cClaspin hyperphosphorylation even when both pathways are inhibited
simultaneously. This strongly indicates that the p38/JNK pathway is not
involved.
The next pathway that was examined was the mTOR pathway. (Figure 6.7-A)
mTOR belongs to the same family of kinases as ATM and ATR, the PI3 Kinase-like
Kinases. mTOR has also been shown to be activated by protein synthesis
inhibition through the loss of a short-lived repressor protein REDD1 (Kimball et
al, 2008). Inhibition of protein synthesis also leads to an increase in intracellular
amino acid levels which presumably also activates mTOR. Using two chemical
inhibitors of mTOR, rapamycin and Torin1, the possible role of mTOR in cClaspin
hyperphosphorylation was examined (Thoreen et al, 2009; Thoreen & Sabatini,
2009). Rapamycin effectively blocks the phosphorylation of the ribosomal
subunit S6 used here as an indirect readout of mTOR activity.Conor Larkin Chapter 6 172
Figure 6.7 Testing mTOR and DNA damage signalling inhibitors for their ability to inhibit
cClaspin hyperphosphorylation
A) Cells were treated with the indicated drugs for 1 hour prior to treatment with 50μg/ml of CHX for 
a further hour. Western blot analysis with the indicated antibodies is shown. B) Cells were treated
with either 5mM Caffeine or 10μM Wortmannin for 1 hour prior to the addition of 50μg/ml CHX.  
Cells were harvested 1 hour later and blotted for the indicated proteins.Conor Larkin Chapter 6 173
However there is no effect on cClaspin hyperphosphorylation. Torin1, an ATP
competitive inhibitor of mTOR itself also effectively blocks both S6 Kinase and
S6 phosphorylation but is unable to inhibit cClaspin hyperphosphorylation either.
This excludes the possibility that both mTOR complexes (mTORC1 and mTORC2)
are involved in the pathway that leads to cClaspin hyperphosphorylation.
Although cClaspin hyperphosphorylation occurs in the absence of Chk1 it is still
possible that DNA damage signalling might be responsible for cClaspin
hyperphosphorylation following protein synthesis inhibition. To test this directly
cells were treated with the ATM/ATR inhibitor caffeine and Wortmannin which
inhibits not only PI3 Kinase but also Plk1 and 3 and DNAPKcs which are involved
in DNA damage signalling (Liu et al, 2007; Sarkaria et al, 1998). (Figure 6.7-B)
However pre-treatment with either drugs could not inhibit the mobility shift.
The phosphorylation status of a protein is regulated by two opposing enzymes;
kinases which phosphorylate proteins and phosphatases which dephosphorylate
proteins. Activation of a kinase or inhibition of a phosphatase will both lead to
an increase in the phosphorylation of a protein. It has been assumed thus far
that the cClaspin hyperphosphorylation observed is due to the action of a kinase
but it is equally plausible that inhibition of protein synthesis may lead to the loss
of a phosphatase that normally keeps cClaspin dephosphorylated. In order to
examine this possibility, protein degradation was blocked prior to inhibition of
protein synthesis. Blocking protein degradation via the proteasome (MG132) or
lysosome (leupeptin and bafilomycin A1) should ensure that the phosphatase or
negative regulator of a kinase would not be degraded. However as can be seen
from Figure 6.8-A inhibiting protein degradation has no impact on cClaspin
phosphorylation following protein synthesis inhibition. This again points to the
fact that protein synthesis inhibition leads to the activation of an, as yet,
unknown signalling pathway that leads to the phosphorylation of cClaspin.
The last issue that was examined was whether inhibition of protein synthesis had
any impact on DNA replication, a process that cClaspin may be involved. It has
been shown in the past that inhibitors of protein synthesis also inhibit DNA
synthesis to some extent (Grollman, 1967; Grollman, 1968). DT40 cells were
treated with CHX, Anisomycin, Emetine, DTT and Thapsigargin and DNA
replication was monitored by the cells ability to incorporate BrdU. As can beConor Larkin Chapter 6 174
Figure 6.8 cClaspin hyperphosphorylation is not due to the loss of a short-lived protein
A) DT40 cells were treated with 10μM MG132, 10μg/ml Leupeptin or 10nM Bafilomycin A1 for 1 
hour to inhibit protein degradation. They were then treated with CHX for a further hour and blotted
for the indicated proteins.Conor Larkin Chapter 6 175
Figure 6.9 Effect of Protein synthesis inhibition of DNA replication
Cells were treated with 20μM Emetine, 10μg/ml Anisomycin, 2μM Thapsigargin, 2mM DTT of 
50μg/ml CHX and samples were harvested at the indicated times (mins). Cells were pulsed with 
25μM BrdU 15 minutes prior to harvest and processing for flow cytometry.  The resulting density 
plots are shown.Conor Larkin Chapter 6 176
seen from Figure 6.9 all inhibitors have an effect on DNA replication. There is
an overall effect on the rate of DNA replication as can be seen by a reduction in
the intensity of BrdU incorporation but there seems to also be a more specific
effect on mid-late S phase cells (see arrows in Figure 6.9). Interestingly Chk1
-/-
cells are particularly sensitive to protein synthesis inhibition as by 2 hours post
treatment with CHX the cells have completely shut down replication. This is in
contrast with DNA damage where Chk1
-/- cells continue to replicate their DNA
following -IR (data not shown). In Chk1
-/- cells however, cClaspin is
phosphorylated to the same extent as it is in WT cells which indicates that this
phosphorylation of cClaspin is not, at least in the context of Chk1 loss, able to
facilitate active DNA replication.
6.4. Discussion
6.4.1. cClaspin Phosphorylation following replication
stress
When examining the phosphorylation of cClaspin in the Chk1
-/- cells it was
observed that there was a defect in cClaspin phosphorylation in the absence of
Chk1. A phosphorylation induced mobility shift could not be detected in the
Chk1
-/- cells. This mobility shift was never induced in the absence of Chk1 and
could only be rescued by the reintroducing WT Chk1 but not KD Chk1 into the
Chk1
-/- cells. It is known that Claspin is phosphorylated in an ATR dependent
manner and Chk1 kinase activity is activated by ATR. Therefore it was
reasonable to hypothesise that Chk1 itself might actually phosphorylate
cClaspin. However when this possibility was tested directly, by doing an in vitro
kinase assay, it was seen that cClaspin was not phosphorylated efficiently under
the assay conditions used. In addition it is worth noting that a panel of kinase
inhibitors has previously been shown inhibit the mobility shift induced by
replication stress (Clarke & Clarke, 2005). Here it was observed that UCN-01,
Staurosporine, Ro318220 and Bim1 could inhibit the phosphorylation induced
mobility shift induced by replication stress. These kinase inhibitors, while they
do show some selectivity towards some kinases over others, are generally
classed as general kinase inhibitors and inhibit a wide variety of kinases (Davies
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extent with UCN-01 being the most potent. However Gö6976 which is also a
potent inhibitor of Chk1 amongst other kinases only partially inhibits the
phosphorylation mobility shift of Claspin.
The sites that are phosphorylated following replication stress that contribute to
the mobility shift are unknown. However it is likely that many phosphorylation
sites are involved. Therefore it is reasonable to assume that a single kinase
might not be solely responsible for mobility shift. Chk1 may act as a priming
kinase which facilitates the phosphorylation of cClaspin once it has been
phosphorylated by Chk1. Alternatively kinases downstream of Chk1 might also
contribute to the mobility shift. Interestingly while the phosphorylation induced
mobility shift is dependent on the presence of catalytically active Chk1,
phosphorylation at S911 which lies within the SG motif in the Chk1 binding
domain, is not compromised in Chk1
-/- cells (Bennett et al, 2008). Previously
Chk1 itself had been implicated in phosphorylating this site (Chini & Chen,
2006). It is clear therefore that both the phosphorylation state of Claspin and
the kinases that mediate this phosphorylation are very complex.
6.4.2. cClaspin phosphorylation following Protein
Synthesis Inhibition
This study has identified a novel phosphorylation pattern of cClaspin following
inhibition of protein synthesis. This phosphorylation is induced by drugs that
directly inhibit the process of translational elongation but also through the
inhibition of the initiation of protein synthesis protein medicated by p-eIF2A.
Experiments carried out have shown that it is the activation of a kinase directly
rather than the loss of a repressor or phosphatase that is responsible for the
phosphorylation. However attempts at identifying this kinase, using a candidate
approach, have failed.
How could the identity of this kinase be elucidated? It is clear from my initial
studies that a more global approach will need to be taken in order to identify
the kinase. One possibility is to carry out in vitro kinase assays using
fractionated cell lysates in order to try and try and identify a fraction that can
induce the cClaspin mobility shift. Once this fraction has been identified the
proteins it contains can be identified by mass spectrometry. Another approachConor Larkin Chapter 6 178
would be the use of a siRNA library that targets the human kinome. By removing
each kinase individually would allow the identification of the kinase responsible.
Finally instead of using very specific kinase inhibitors as I have used here it is
also possible to use very unspecific inhibitors. Once an inhibitor has been
identified, technology is now available to couple the inhibitor to beads to allow
the purification of the kinases inhibited by the compound (Daub, 2005). The
kinases identified could then be tested for their ability to phosphorylate
cClaspin. Identifying the kinase would also probably provide an insight into how
and why protein synthesis inhibition leads to the phosphorylation of cClaspin.
One possibility not discussed thus far is that protein synthesis inhibition leads to
the activation of multiple signalling pathways that contribute to the
phosphorylation of cClaspin. In this instance multiple kinases are likely to be
involved. Therefore simply assaying every kinase for its ability to phosphorylate
cClaspin will never result in the recapitulation of the cClaspin mobility shift.
An alternative approach would be to try and identify the sites on cClaspin that
are phosphorylated in response to protein synthesis inhibition. In this way by
examining the amino acids surrounding the phosphorylated site may give a clue
as to which kinase is responsible. To this end some preliminary experiments
have been carried out in order to try and map phosphosites on cClaspin. A
system had been generated in which cClaspin can be readily purified from cells
following stimulation to facilitate analysis by mass spectrometry. This approach
also allows the identification of binding partners under different conditions.
Unfortunately the data obtained thus far has only been obtained from one
experiment and is too preliminary to report. A list of potential binding partners
has been included in Appendix G for reference purposes. In trying to maximise
the coverage of peptides from the cClaspin protein two phosphosites were
identified on cClaspin purified from untreated cells (at Ser143 and Ser803)
indicating that this approach is indeed feasible. The first of these sites is a non-
conserved S residue but the S803 residue is contained with in a well conserved
SP motif indicating a potential role for Cdk’s in phosphorylation of Claspin.
Without knowing the kinase responsible it is difficult to speculate as to what role
phosphorylated cClaspin is playing following protein synthesis inhibition. DNA
replication is inhibited following protein synthesis inhibition suggesting that DNAConor Larkin Chapter 6 179
damage signalling might be involved – however testing this directly has ruled this
out. It is reasonable to suggest that inhibition of protein translation would
affect the translation of histones during S phase and lead to a perturbation of
chromatin formation during S phase. However in this case it would be
reasonable to assume that only cClaspin in S phase cell would be modified.
However as the entire cClaspin band shifts it is reasonable to assume that
cClaspin is modified in every cell no matter what phase of the cell cycle it is in.
Another issue that remains to be resolved is what the cell is actually responding
to? It doesn’t appear to be the loss of a specific protein as the modification still
occurs when protein degradation is inhibited. It also does not appear to be
amino acid levels as the modification is apparent either when amino acid levels
are increased (by treating with CHX for example) or when they are removed.
Protein synthesis inhibitors may affect the structure of the ribosome but
inhibiting protein synthesis by removing amino acids or inducing ER stress also
induces the cClaspin modification arguing against this as a mechanism. Finally
by inhibiting protein synthesis in multiple ways rules out that a particular
protein synthesis inhibitor is also capable of activating a signalling pathway
independent of its role in inhibiting protein synthesis.
In summary a novel modification of a cell cycle checkpoint protein has been
identified. However the fundamental significance of this and the mechanism
behind it remains to be elucidated.Chapter 7.Conclusions and Future DirectionsConor Larkin Chapter 7 181
7.1. Chicken Claspin Homologue
The chicken orthologue of Claspin has been cloned and characterised during this
study. At the amino acid level cClaspin share significant similarity across its full
length with human and xenopus Claspin but especially in the C-terminus which
has been shown to mediate Chk1 activation through direct binding (Lee et al,
2005). The residues of Claspin that are important for this function are the
phospho S/T sites located within the Chk1 binding domain (Clarke & Clarke,
2005; Kumagai & Dunphy, 2003) and these sites are conserved in the chicken
Claspin orthologue.
Although the N-terminus of Claspin is not as highly conserved as the C-terminus
the overall structure appears similar. Lee et al have described that there are
basic patches in the N-terminus of the protein that mediate binding of cClaspin
to chromatin (Lee et al, 2005). We have identified another conserved basic
patch in the N-terminus of the protein which could also play a role in this
process.
Claspin has also been shown to interact with another mediator protein – Brca1 in
order to facilitate Chk1 activation. Claspin and Brca1 appear to work together
in the activation of Chk1 (Lin et al, 2004; Yoo et al, 2006). Nothing is known
about where Claspin and Brca1 interact. As discussed previously it is interesting
to note that the Chk1 binding motif itself provides the perfect BRCT consensus
interaction motif once the Ser residues are phosphorylated. However Chk1 has
been shown to bind to this region and the binding is dependent on
phosphorylation which leads to the speculation that Chk1 itself binds these
phospho-residues (Jeong et al, 2003). It would be interesting to see whether the
Claspin-Brca1 interaction is also compromised upon mutation of the critical S/T
residues.
Some confusion exists in the literature about where Claspin migrates in SDS-
PAGE. The predicted molecular mass of Claspin is approximately 150kDa but it
has been reported previously to run above 200kDa, possibly due to its low pI
(Kumagai & Dunphy, 2000; Sar et al, 2004). Despite this some authors refer to a
band migrating at 150-160kDa as Claspin (Brondello et al, 2007; Collis et al,
2007). Whether this band is a non-specific cross reaction with an unrelatedConor Larkin Chapter 7 182
protein or a Claspin related protein is unknown. However from the in-vitro
translation experiments carried out using the cClaspin cDNA isolated, cClaspin
clearly migrates with an apparent molecular mass of >250kDa. In addition the
antibody raised against cClaspin also recognises a band at >250kDa in cell
extracts. Interestingly it also recognises a band around 150kDa. The identity of
this protein was not determined.
7.2. cClaspin plays an essential role in DT40 cells
Although heritable mutations in many proteins involved in the DNA damage
response have been identified and implicated in human disease, such mutations
in the ATR-Chk1 pathway are relatively very uncommon (Marsh et al, 2007;
Zhang et al, 2009). Any mutations that do arise are generally not complete loss
of function mutations. Coupled with this information is the fact that both ATR
knock-out and Chk1 knock-out mice are embryonic lethal showing that this
pathway is critical for cell survival (Brown & Baltimore, 2000; Takai et al, 2000).
DT40 cells however tolerate loss of Chk1 but not of ATR (Zachos et al, 2003), N
Lowndes, Personal Communication). Work presented in this thesis strongly
indicates that DT40 cells do not tolerate loss of Claspin either. Given this, it is
reasonable to assume that Claspin plays role in the normal cell cycle which is
distinct from its role as a facilitator of Chk1 activation. What this role is has yet
to be determined but given that the yeast homologue of Claspin plays a role
during replication is it reasonable to speculate that vertebrate Claspin also plays
an intrinsic role in DNA replication.
Due to time constraints and technical difficulties it was not possible to generate
a conditional knock-out of cClaspin. However a cClaspin
On/Off cell line would be
a useful tool to study the essential function of Claspin. Such a cell line would
permit characterisation of how cells die following removal of cClaspin. If, as
might be expected, cClaspin plays an essential role in DNA replication then one
might expect that the cells would accumulate in S phase before they die.
cClaspin depletion could also be carried out simultaneously with cell cycle
synchronisation in either early S phase or in mitosis. Releasing the cells into
back into cycle in the absence of cClaspin might reveal unknown functions of
cClaspin in other phases of the cell cycle.Conor Larkin Chapter 7 183
A cClaspin
On/Off cell line can also be used to carry out structure-function studies
on the protein. The cells could be stably transfected with portions of the
protein expressed from a constitutive promoter. Once the WT cClaspin protein
is repressed the function of the fragment could be assessed. Indeed taking this
approach a screen could be carried out in order to determine the regions of
Claspin that are essential for cell survival. It could also allow the identification
of separation of function mutants that can support cell viability but may be
defective in checkpoint activation for example.
One disadvantage of the Tet-system is that repression of the protein expression
depends both on the stability of the transgene mRNA and on the stability of the
final protein. This means that it may take up to 24 hours for the protein levels
to be reduced enough in order to reveal the null phenotype. A way around this
would be to express an N-degron tagged version of cClaspin in the cells (Labib et
al, 2000). This degron is temperature sensitive and once the cells are shifted to
a higher temperature the protein is actively degraded in the cells. In this
manner the protein can be cleared from the cells in between 60-90 minutes
allowing characterisation of the consequences of immediate loss of the protein
from the cell. This has successfully been used in DT40 cells to further probe the
functions of Rad51, knock-out of which also proves lethal (Su et al, 2008).
Coupling this rapid loss with cell cycle synchronisation could reveal cell cycle
phase specific functions of the protein.
7.3. Phosphorylation of cClaspin is complex
It is clear from the literature that Claspin is a highly phosphorylated protein.
Large scale proteomics analyses frequently report the identification of
phosphorylated Claspin residues (Bodenmiller et al, 2007; Dephoure et al, 2008;
Gauci et al, 2009; Olsen et al, 2006; Zhai et al, 2008). Indeed simply examining
the primary structure of the protein reveals that 15% of the protein consists of
potentially phosphorylatable residues (S/T/Y). Given this information it is
reasonable to expect that many kinases and phosphatases are involved in
regulating its function. (See Figure 7.1)
Phosphorylation of Claspin following two different stresses was examined in this
thesis, by examining phosphorylation induced mobility shifts. In agreement withConor Larkin Chapter 7 184
Figure 7.1 Claspin Phosphorylation is regulated by multiple kinases
Claspin has been shown to be phosphorylated by multiple kinases, however the kinases that
phosphorylate Claspin following replication stress remain unknown.
work already published, cClaspin was shown to be phosphorylated in an
ATM/ATR dependent manner during replication stress. Chk1 was also shown to
be required for this phosphorylation. An important issue not addressed in this
study is which sites on cClaspin are required for the phosphorylation induced
mobility shift. A reasonable assumption would be that cClaspin, like xClaspin
and hClaspin, would also be phosphorylated on S911 and S930 (which correspond
to T916 and S945 in hClaspin). But given the nature of a phosphorylation
induced mobility shift other sites of phosphorylation are probably also going to
be involved.
The regulation of cClaspin phosphorylation by Chk1 appears complex. Work
presented here has shown that Chk1 kinase activity is required for cClaspin
phosphorylation during replication stress however when tested directly it
appears that cClaspin is not a direct substrate of Chk1, at least under the in
vitro conditions tested. Work reported by Bennett et al expanded on this
observation and showed that in the absence of Chk1 only a partial inhibition of
Claspin phosphorylation was seen; in the absence of Chk1, cClaspin could still be
phosphorylated on S911 (T916 in hClaspin), one of the SG sites in the CKBD
(Bennett et al, 2008). Further work will need to be carried out in order to
clarify why Chk1 is required for certain cClaspin phosphorylation events. TheConor Larkin Chapter 7 185
Chk1-/- DT40 cells provide the ideal system in which this can be analysed. Once
optimised the TAP purification method for cClaspin coupled with mass
spectrometry should provide a valuable insight into the cClaspin phosphorylation
pattern regulated by Chk1. Indeed by using this approach 2 phosphorylation
sites were identified at S143 and S803 by mass spectrometry, showing that this
approach is feasible. An important issue that remains unresolved is why Chk1
would be required to phosphorylate its own upstream activator. Whether this
forms part of a positive amplification loop is unknown. Phosphosite mapping will
be the next critical step in understanding this phenomenon.
Furthermore a novel cClaspin phosphorylation pattern was discovered following
protein synthesis inhibition. Inhibiting protein synthesis through multiple
mechanisms led to the phosphorylation of cClaspin, potentially uncovering an
undiscovered link between the protein synthesis and DNA replication. The next
step in this project will be to identify which sites are being phosphorylated and
by which kinases. With this knowledge intervention studies, where only the
modification in response to protein synthesis inhibition is inhibited, will be
possible. This should provide a valuable insight into what the functional
significance of this phosphorylation is. Inhibition of protein synthesis only has a
mild effect on DNA replication, at least at early time points. Perhaps Claspin is
required to allow replication to proceed under these conditions. The key to
further investigation of this novel modification will be identifying a way to
inhibit it in order to address its functional significance.AppendicesConor Larkin Appendix A                                                              187
Appendix A cCLSPN mRNA Sequence Isoform 1
 
 
     
 
 
   Conor Larkin Appendix A                                                              188
NCBI Accession No - GU248360Conor Larkin Appendix B                                                              189
Appendix B cCLSPN mRNA Sequence Isoform 2Conor Larkin Appendix B                                                              190
NCBI Accession No - GU248361Conor Larkin Appendix C                                                              191
Appendix C cClaspin Amino Acid SequenceConor Larkin Appendix D                                                              192
Appendix D Multiple Sequence Alignment of
Claspin OrthologuesConor Larkin Appendix D                                                              193Conor Larkin Appendix D                                                              194Conor Larkin Appendix D                                                              195Conor Larkin Appendix D                                                              196Conor Larkin Appendix E                                                              197
Appendix E Identity Table from Multiple Sequence
AlignmentConor Larkin Appendix F                                                              198
Appendix F Conservation Table from Multiple
Sequence AlignmentConor Larkin Appendix G                                                              199
Appendix G Potential cClaspin Interacting
Partners
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SF.cClaspin following the tandem affinity purification method described in
section 2.2.2.9. Data has been curated to remove proteins that were identified
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the SF.cClaspin protein. The background (+/- Chk1) and treatment is indicated.
Table G-1 Chk1-/- Flp-In:SF.cClaspin Cells - UntreatedConor Larkin Appendix G                                                              200
Table G-2 Chk1-/- Flp-In:SF.cClaspin Cells - CHX treated
Table G-3 Chk1-/- Flp-In:SF.cClaspin Cells - APH treatedConor Larkin Appendix G                                                              201
Table G-4 Chk1 Revertant Flp-In:SF.cClaspin Cells - CHX treated
Table G-5 Chk1 Revertant Flp-In:SF.cClaspin Cells - APH treated202
List of References
Abdrakhmanov I, Lodygin D, Geroth P, Arakawa H, Law A, Plachy J, Korn B,
Buerstedde JM (2000) A large database of chicken bursal ESTs as a
resource for the analysis of vertebrate gene function. Genome Res 10:
2062-2069
Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR
kinases. Genes & Development 15: 2177-2196
Adachi N, Ishino T, Ishii Y, Takeda S, Koyama H (2001) DNA ligase IV-deficient
cells are more resistant to ionizing radiation in the absence of Ku70:
Implications for DNA double-strand break repair. Proc Natl Acad Sci U S A
98: 12109-12113
Alcasabas AA, Osborn AJ, Bachant J, Hu F, Werler PJH, Bousset K, Furuya K,
Diffley JFX, Carr AM, Elledge SJ (2001) Mrc1 transduces signals of DNA
replication stress to activate Rad53. 3: 958-965
Arakawa H, Buerstedde JM (2006) DT40 gene disruptions: a how-to for the design
and the construction of targeting vectors. Subcell Biochem 40: 1-9
Arakawa H, Moldovan GL, Saribasak H, Saribasak NN, Jentsch S, Buerstedde JM
(2006) A role for PCNA ubiquitination in immunoglobulin hypermutation.
PLoS Biol 4: e366
Arakawa H, D. Buerstedde, JM. (2001) Mutant loxP vectors for selectable marker
recycle and conditional knock-outs. BMC Biotechnology 1
Ayoub N, Rajendra E, Su X, Jeyasekharan AD, Mahen R, Venkitaraman AR (2009)
The carboxyl terminus of Brca2 links the disassembly of Rad51 complexes
to mitotic entry. Curr Biol 19: 1075-1085
Baba TW, Giroir BP, Humphries EH (1985) Cell lines derived from avian
lymphomas exhibit two distinct phenotypes. Virology 144: 139-151
Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur
JS, Alessi DR, Cohen P (2007) The selectivity of protein kinase inhibitors: a
further update. Biochem J 408: 297-315
Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through
intermolecular autophosphorylation and dimer dissociation. Nature 421:
499-506
Ball HL, Myers JS, Cortez D (2005) ATRIP Binding to Replication Protein A-Single-
stranded DNA Promotes ATR-ATRIP Localization but Is Dispensable for
Chk1 Phosphorylation. Mol Biol Cell 16: 2372-2381
Bando M, Katou YM, Komata M, Tanaka H, Itoh T, Sutani T, Shirahige K (2009)
Csm3, Tof1, and Mrc1 form a heterotrimeric mediator complex that
associates with DNA replication forks. Journal of Biological Chemistry
284: 34355-34365
Bartek J, Lukas C, Lukas J (2004) Checking on DNA damage in S phase. Nat Rev
Mol Cell Biol 5: 792-804
Bartek J, Lukas J (2001) Mammalian G1- and S-phase checkpoints in response to
DNA damage. Current Opinion in Cell Biology 13: 738-747
Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M
(2008) The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response
Checkpoint. Cell 134: 256-267
Bennett LN, Clarke PR (2006) Regulation of Claspin degradation by the ubiquitin-
proteosome pathway during the cell cycle and in response to ATR-
dependent checkpoint activation. FEBS Letters 580: 4176-4181203
Bennett LN, Larkin C, Gillespie DA, Clarke PR (2008) Claspin is phosphorylated in
the Chk1-binding domain by a kinase distinct from Chk1. Biochem Biophys
Res Commun 369: 973-976
Bezzubova O, Silbergleit A, Yamaguchi-Iwai Y, Takeda S, Buerstedde JM (1997)
Reduced X-ray resistance and homologous recombination frequencies in a
RAD54-/- mutant of the chicken DT40 cell line. Cell 89: 185-193
Boardman PE, Sanz-Ezquerro J, Overton IM, Burt DW, Bosch E, Fong WT, Tickle
C, Brown WR, Wilson SA, Hubbard SJ (2002) A comprehensive collection of
chicken cDNAs. Curr Biol 12: 1965-1969
Bodenmiller B, Mueller LN, Pedrioli PGA, Pflieger D, Junger MA, Eng JK,
Aebersold R, Tao WA (2007) An integrated chemical, mass spectrometric
and computational strategy for (quantitative) phosphoproteomics:
application to Drosophila melanogaster Kc167 cells. Molecular BioSystems
3: 275-286
Bourke E, Brown JA, Takeda S, Hochegger H, Morrison CG (2009) DNA damage
induces Chk1-dependent threonine-160 phosphorylation and activation of
Cdk2. Oncogene
Branzei D, Foiani M (2009) The checkpoint response to replication stress. DNA
Repair 8: 1038-1046
Bree RT, Lai XY, Canavan LE, Lowndes NF (2007) Comparisons between DT40
wildtype and DT40-Cre1 cells as suitable model systems for studying the
DNA damage response. Cell Cycle 6: 2310-2313
Bridge WL, Vandenberg CJ, Franklin RJ, Hiom K (2005) The BRIP1 helicase
functions independently of BRCA1 in the Fanconi anemia pathway for DNA
crosslink repair. Nat Genet 37: 953-957
Broderick R, Nasheuer H-P (2009) Regulation of Cdc45 in the cell cycle and after
DNA damage. Biochemical Society Transactions 37: 926-930
Brondello J-M, Ducommun B, Fernandez A, Lamb NJ (2007) Linking PCNA-
dependent replication and ATR by human Claspin. Biochemical and
Biophysical Research Communications 354: 1028-1033
Brostrom CO, Brostrom MA, Kivie M (1997) Regulation of Translational Initiation
during Cellular Responses to Stress. In Progress in Nucleic Acid Research
and Molecular Biology Vol. Volume 58, pp 79-125. Academic Press
Brown EJ, Baltimore D (2000) ATR disruption leads to chromosomal
fragmentation and early embryonic lethality. Genes & Development 14:
397-402
Brown WR, Hubbard SJ, Tickle C, Wilson SA (2003) The chicken as a model for
large-scale analysis of vertebrate gene function. Nat Rev Genet 4: 87-98
Brummer T, Naegele H, Reth M, Misawa Y (2003) Identification of novel ERK-
mediated feedback phosphorylation sites at the C-terminus of B-Raf.
Oncogene 22: 8823-8834
Brummer T, Shaw PE, Reth M, Misawa Y (2002) Inducible gene deletion reveals
different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling.
Embo J 21: 5611-5622
Buerstedde JM, Takeda S (1991) Increased ratio of targeted to random
integration after transfection of chicken B cell lines. Cell 67: 179-188
Buerstedde JM, Reynaud CA, Humphries EH, Olson W, Ewert DL, Weill JC (1990)
Light chain gene conversion continues at high rate in an ALV-induced cell
line. Embo J 9: 921-927
Canman CE (2001) Replication checkpoint: Preventing mitotic catastrophe.
Current Biology 11: R121-R124204
Cano E, Hazzalin CA, Mahadevan LC (1994) Anisomycin-activated protein kinases
p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are
implicated in the induction of c-fos and c-jun. Mol Cell Biol 14: 7352-7362
Capasso H, Palermo C, Wan S, Rao H, John UP, O'Connell MJ, Walworth NC
(2002) Phosphorylation activates Chk1 and is required for checkpoint-
mediated cell cycle arrest. J Cell Sci 115: 4555 - 4564
Casper AM, Nghiem P, Arlt MF, Glover TW (2002) ATR Regulates Fragile Site
Stability. Cell 111: 779-789
Cejka P, Stojic L, Mojas N, Russell AM, Heinimann K, Cannavo E, di Pietro M,
Marra G, Jiricny J (2003) Methylation-induced G2/M arrest requires a full
complement of the mismatch repair protein hMLH1. EMBO J 22: 2245-
2254
Chang H, Delany ME (2004) Karyotype stability of the DT40 chicken B cell line:
macrochromosome variation and cytogenetic mosaicism. Chromosome Res
12: 299-307
Chen P, Luo C, Deng Y, Ryan K, Register J, Margosiak S, Tempczyk-Russell A,
Nguyen B, Myers P, Lundgren K (2000) The 1.7 A crystal structure of
human cell cycle checkpoint kinase Chk1: implications for Chk1
regulation. Cell 100: 681 - 692
Chen S-h, Zhou H (2009) Reconstitution of Rad53 Activation by Mec1 through
Adaptor Protein Mrc1. Journal of Biological Chemistry 284: 18593-18604
Chen Y, Caldwell JM, Pereira E, Baker RW, Sanchez Y (2009) ATRMec1
Phosphorylation-independent Activation of Chk1 in Vivo. Journal of
Biological Chemistry 284: 182-190
Chen Y, Sanchez Y (2004) Chk1 in the DNA damage response: conserved roles
from yeasts to mammals. DNA Repair 3: 1025-1032
Chini CC, Chen J (2003) Human claspin is required for replication checkpoint
control. J Biol Chem 278: 30057-30062
Chini CC, Chen J (2004) Claspin, a regulator of Chk1 in DNA replication stress
pathway. DNA Repair (Amst) 3: 1033-1037
Chini CCS, Chen J (2006) Repeated Phosphopeptide Motifs in Human Claspin Are
Phosphorylated by Chk1 and Mediate Claspin Function. J Biol Chem 281:
33276-33282
Chini CCS, Wood J, Chen J (2006) Chk1 is required to maintain Claspin stability.
Oncogene 25: 4165-4171
Churikov D, Price CM (2008) Pot1 and cell cycle progression cooperate in
telomere length regulation. Nat Struct Mol Biol 15: 79-84
Cimprich KA, Cortez D (2008) ATR: an essential regulator of genome integrity.
Nat Rev Mol Cell Biol 9: 616-627
Clarke CA, Clarke PR (2005) DNA-dependent phosphorylation of Chk1 and Claspin
in a human cell-free system. Biochem J 388: 705-712
Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD, Boulton SJ (2007) HCLK2 is
essential for the mammalian S-phase checkpoint and impacts on Chk1
stability. Nat Cell Biol 9: 391-401
Crooijmans RP, Vrebalov J, Dijkhof RJ, van der Poel JJ, Groenen MA (2000) Two-
dimensional screening of the Wageningen chicken BAC library. Mamm
Genome 11: 360-363
Cuadrado M, Martinez-Pastor B, Murga M, Toledo LI, Gutierrez-Martinez P, Lopez
E, Fernandez-Capetillo O (2006) ATM regulates ATR chromatin loading in
response to DNA double-strand breaks. J Exp Med 203: 297-303
Daniel JA, Pellegrini M, Lee J-H, Paull TT, Feigenbaum L, Nussenzweig A (2008)
Multiple autophosphorylation sites are dispensable for murine ATM
activation in vivo. J Cell Biol 183: 777-783205
Daub H (2005) Characterisation of kinase-selective inhibitors by chemical
proteomics. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics
1754: 183-190
Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of
action of some commonly used protein kinase inhibitors. Biochem J 351:
95-105
de Laat WL, Jaspers NGJ, Hoeijmakers JHJ (1999) Molecular mechanism of
nucleotide excision repair. Genes & Development 13: 768-785
Dephoure N, Zhou C, VillÃ©n J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP
(2008) A quantitative atlas of mitotic phosphorylation. Proceedings of the
National Academy of Sciences 105: 10762-10767
Dhar PK, Sonoda E, Fujimori A, Yamashita YM, Takeda S (2001) DNA repair
studies: experimental evidence in support of chicken DT40 cell line as a
unique model. J Environ Pathol Toxicol Oncol 20: 273-283
Doetschman T, Gregg RG, Maeda N, Hooper ML, Melton DW, Thompson S,
Smithies O (1987) Targetted correction of a mutant HPRT gene in mouse
embryonic stem cells. Nature 330: 576-578
Downs JA, Jackson SP (2004) A means to a DNA end: the many roles of Ku. Nat
Rev Mol Cell Biol 5: 367-378
Erkko H, Pylkäs K, Karppinen S-M, Winqvist R (2008) Germline alterations in the
CLSPN gene in breast cancer families. Cancer Letters 261: 93-97
Errico A, Costanzo V, Hunt T (2007) Tipin is required for stalled replication forks
to resume DNA replication after removal of aphidicolin in Xenopus egg
extracts. Proceedings of the National Academy of Sciences 104: 14929-
14934
Faustrup H, Bekker-Jensen S, Bartek J, Lukas J, Mailand N (2009) USP7
counteracts SCF{beta}TrCP- but not APCCdh1-mediated proteolysis of
Claspin. J Cell Biol 184: 13-19
Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, Smythe C (2001)
Activation of mammalian Chk1 during DNA replication arrest: a role for
Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J
Cell Biol 154: 913-923
Flavio M, Arianna Donella D, Maria R, Anna MB, Luca C, Barbara G, Thomas M,
Helmut M, Doriano F, Pascal F, Grazyna D, Lorenzo AP (1995) Different
Susceptibility of Protein Kinases to Staurosporine Inhibition. European
Journal of Biochemistry 234: 317-322
Focarelli ML, Soza S, Mannini L, Paulis M, Montecucco A, Musio A (2009) Claspin
inhibition leads to fragile site expression. Genes, Chromosomes and
Cancer 48: 1083-1090
Fortini P, Pascucci B, Parlanti E, D'Errico M, Simonelli V, Dogliotti E (2003) The
base excision repair: mechanisms and its relevance for cancer
susceptibility. Biochimie 85: 1053-1071
Franklin R, Sale JE (2006) 2D cell cycle analysis. Subcell Biochem 40: 405-408
Fukushima T, Takata M, Morrison C, Araki R, Fujimori A, Abe M, Tatsumi K, Jasin
M, Dhar PK, Sonoda E, Chiba T, Takeda S (2001) Genetic analysis of the
DNA-dependent protein kinase reveals an inhibitory role of Ku in late S-G2
phase DNA double-strand break repair. J Biol Chem 276: 44413-44418
Furnari B, Rhind N, Russell P (1997) Cdc25 mitotic inducer targeted by chk1 DNA
damage checkpoint kinase. Science 277: 1495-1497
Gao D, Inuzuka H, Korenjak M, Tseng A, Wu T, Wan L, Kirschner M, Dyson N, Wei
W (2009) Cdh1 Regulates Cell Cycle through Modulating the Claspin/Chk1
and the Rb/E2F1 Pathways. Mol Biol Cell 20: 3305-3316206
Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJR, Mohammed S (2009) Lys-N
and Trypsin Cover Complementary Parts of the Phosphoproteome in a
Refined SCX-Based Approach. Analytical Chemistry 81: 4493-4501
Gilbert CS, Green CM, Lowndes NF (2001) Budding Yeast Rad9 Is an ATP-
Dependent Rad53 Activating Machine. Molecular Cell 8: 129-136
Gillespie DA, Henriques C (2006) Centrifugal elutriation as a means of cell cycle
phase separation and synchronisation. Subcell Biochem 40: 359-361
Gillespie DA, Walker M (2006) Mitotic index determination by flow cytometry.
Subcell Biochem 40: 355-358
Goodarzi AA, Noon AT, Deckbar D, Ziv Y, Shiloh Y, Löbrich M, Jeggo PA (2008)
ATM Signaling Facilitates Repair of DNA Double-Strand Breaks Associated
with Heterochromatin. Molecular Cell 31: 167-177
Groenen MA, Cheng HH, Bumstead N, Benkel BF, Briles WE, Burke T, Burt DW,
Crittenden LB, Dodgson J, Hillel J, Lamont S, de Leon AP, Soller M,
Takahashi H, Vignal A (2000) A consensus linkage map of the chicken
genome. Genome Res 10: 137-147
Grollman AP (1967) Inhibitors of protein biosynthesis. II. Mode of action of
anisomycin. J Biol Chem 242: 3226-3233
Grollman AP (1968) Inhibitors of protein biosynthesis. V. Effects of emetine on
protein and nucleic acid biosynthesis in HeLa cells. J Biol Chem 243:
4089-4094
Groth AC, Olivares EC, Thyagarajan B, Calos MP (2000) A phage integrase directs
efficient site-specific integration in human cells. Proceedings of the
National Academy of Sciences of the United States of America 97: 5995-
6000
Guo C, Kosarek-Stancel J, Tang T-S, Friedberg E (2009) Y-family DNA
polymerases in mammalian cells. Cellular and Molecular Life Sciences 66:
2363-2381
Hartlerode AJ, Scully R (2009) Mechanisms of double-strand break repair in
somatic mammalian cells. Biochemical Journal 423: 157-168
Hartwell LH (1967) Macromolecule synthesis in temperature-sensitive mutants of
yeast. J Bacteriol 93: 1662-1670
Hazzalin CA, Cano E, Cuenda A, Barratt MJ, Cohen P, Mahadevan LC (1996)
p38/RK is essential for stress-induced nuclear responses: JNK/SAPKs and
c-Jun/ATF-2 phosphorylation are insufficient. Current Biology 6: 1028-
1031
Hein J, Boichuk S, Wu J, Cheng Y, Freire R, Jat PS, Roberts TM, Gjoerup OV
(2009) Simian Virus 40 Large T Antigen Disrupts Genome Integrity and
Activates a DNA Damage Response via Bub1 Binding. J Virol 83: 117-127
Hillen W, Klock G, Kaffenberger I, Wray LV, Reznikoff WS (1982) Purification of
the TET repressor and TET operator from the transposon Tn10 and
characterization of their interaction. J Biol Chem 257: 6605-6613
Hillier LW, Miller W, Birney W, Warren W, Hardison R, Ponting C, Bork P, Burt D,
Groenen M, Delany M, Dodgson J, Chinwall A, Cliften P, Clifton S,
Delehaunty K, Fronick C, Fulton R, Graves T, Kremitzki C, Layman D,
Magrini V, McPherson J, Miner T, Minx P, Nash W, Nhan M, Nelson J, Oddy
L, Pohl C, Randall-Maher J, Smith S, Wallis J, Yang S, Romanov M, Rondelli
C, Paton B, Smith J, Morrice D, Daniels L, Tempest H, Robertson L,
Masabanda J, Griffin D, Vignal A, Fillon V, Jacobbson L, Kerje S,
Andersson L, Crooijmans R, Aerts J, van der Poel J, Ellegren H, Caldwell
R, Hubbard S, Grafham D, Kierzek A, McLaren S, Overton I, Arakawa H,
Beattie K, Bezzubov Y, Boardman P, Bonfield J, Croning M, Davies R,
Francis M, Humphray S, Scott C, Taylor R, Tickle C, Brown W, Rogers J,207
Buerstedde J, Wilson S, Stubbs L, Ovcharenko I, Gordon L, Lucas S, Miller
M, Inoko H, Shiina T, Kaufman J, Salomonsen J, K. S, Wong G, Wang J, Liu
B, Wang J, Yu J, Yang H, Nefedov M, Koriabine M, deJong P, Goodstadt L,
Webber C, Dickens N, Letunic I, Suyama M, Torrents D, von Mering C,
Zdobnov E, Makova K, Nekrutenko A, Elnitski L, Eswara P, King D, Yang S,
Tyekucheva S, Radakrishnan A, Harris R, Chiaromonte F, Taylor J, He J,
Rijnkels M, Griffiths-Jones S, Ureta-Vidal S, Hoffman M, Severin JS, SMJ.
Law A, Speed D, Waddington D, Cheng Z, Tuzun E, Eichler E, Bao Z, Flicek
P, Shteynberg D, Brent M, Bye J, Huckle E, Chatterji S, Dewey C, Pachter
L, Kouranov A, Mourelatos Z, Hatzigeorgiou A, Paterson A, Ivarie R,
Brandstrom M, Axelsson E, Backstrom N, Berlin S, Webster M, Pourquie O,
Reymond A, Ucla C, Antonarakis S, Long M, Emerson J, Betrán E,
Dupanloup I, Kaessmann H, Hinrichs A, Bejerano G, Furey T, Harte R,
Raney B, Siepel A, Kent W, Haussler D, Eyras E, Castelo R, Abril J,
Castellano S, Camara F, Parra G, Guigo R, Bourque G, Tesler G, Pevzner
P, Smit A, Fulton L, Mardis E, Wilson R (2004) Sequence and comparative
analysis of the chicken genome provide unique perspectives on vertebrate
evolution. Nature 432: 695-716
Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK (1998) The DF-1 Chicken
Fibroblast Cell Line: Transformation Induced by Diverse Oncogenes and
Cell Death Resulting from Infection by Avian Leukosis Viruses. Virology
248: 295-304
Hirano S, Yamamoto K, Ishiai M, Yamazoe M, Seki M, Matsushita N, Ohzeki M,
Yamashita YM, Arakawa H, Buerstedde JM, Enomoto T, Takeda S,
Thompson LH, Takata M (2005) Functional relationships of FANCC to
homologous recombination, translesion synthesis, and BLM. Embo J 24:
418-427
Hochegger H, Dejsuphong D, Fukushima T, Morrison C, Sonoda E, Schreiber V,
Zhao GY, Saberi A, Masutani M, Adachi N, Koyama H, de Murcia G, Takeda
S (2006) Parp-1 protects homologous recombination from interference by
Ku and Ligase IV in vertebrate cells. Embo J 25: 1305-1314
Hochegger H, Dejsuphong D, Sonoda E, Saberi A, Rajendra E, Kirk J, Hunt T,
Takeda S (2007) An essential role for Cdk1 in S phase control is revealed
via chemical genetics in vertebrate cells. J Cell Biol 178: 257-268
Hodgson B, Calzada A, Labib K (2007) Mrc1 and Tof1 Regulate DNA Replication
Forks in Different Ways during Normal S Phase. Mol Biol Cell 18: 3894-
3902
Hudson DF, Morrison C, Ruchaud S, Earnshaw WC (2002) Reverse genetics of
essential genes in tissue-culture cells: 'dead cells talking'. Trends in Cell
Biology 12: 281-287
Imamura O, Fujita K, Itoh C, Takeda S, Furuichi Y, Matsumoto T (2002) Werner
and Bloom helicases are involved in DNA repair in a complementary
fashion. Oncogene 21: 954-963
Ishiai M, Kimura M, Namikoshi K, Yamazoe M, Yamamoto K, Arakawa H,
Agematsu K, Matsushita N, Takeda S, Buerstedde JM, Takata M (2004) DNA
cross-link repair protein SNM1A interacts with PIAS1 in nuclear focus
formation. Mol Cell Biol 24: 10733-10741
Iwabuchi K, Hashimoto M, Matsui T, Kurihara T, Shimizu H, Adachi N, Ishiai M,
Yamamoto K, Tauchi H, Takata M, Koyama H, Date T (2006) 53BP1
contributes to survival of cells irradiated with X-ray during G1 without
Ku70 or Artemis. Genes Cells 11: 935-948208
Iwanaga R, Komori H, Ishida S, Okamura N, Nakayama K, Nakayama KI, Ohtani K
(2006) Identification of novel E2F1 target genes regulated in cell cycle-
dependent and independent manners. Oncogene 25: 1786-1798
Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A (2000) An
indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates
cell cycle arrest caused by DNA damage. Cancer Res 60: 566-572
Jeong S-Y, Kumagai A, Lee J, Dunphy WG (2003) Phosphorylated Claspin
Interacts with a Phosphate-binding Site in the Kinase Domain of Chk1
during ATR-mediated Activation. Journal of Biological Chemistry 278:
46782-46788
Jiricny J (2006) The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol
7: 335-346
Johnson M, Phua HH, Bennett SC, Spence JM, Farr CJ (2009) Studying vertebrate
topoisomerase 2 function using a conditional knockdown system in DT40
cells. Nucleic Acids Res 37: e98
Jorgensen RA, Reznikoff WS (1979) Organization of structural and regulatory
genes that mediate tetracycline resistance in transposon Tn10. J Bacteriol
138: 705-714
Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432: 316-
323
Katou Y, Kanoh Y, Bando M, Noguchi H, Tanaka H, Ashikari T, Sugimoto K,
Shirahige K (2003) S-phase checkpoint proteins Tof1 and Mrc1 form a
stable replication-pausing complex. Nature 424: 1078-1083
Kawamoto T, Araki K, Sonoda E, Yamashita YM, Harada K, Kikuchi K, Masutani C,
Hanaoka F, Nozaki K, Hashimoto N, Takeda S (2005) Dual roles for DNA
polymerase eta in homologous DNA recombination and translesion DNA
synthesis. Mol Cell 20: 793-799
Kelley LA, Sternberg MJ (2009) Protein structure prediction on the Web: a case
study using the Phyre server. Nat Protoc 4: 363-371
Kia-Ki H, Martinage A (1992) Post-translational chemical modification(S) of
proteins. International Journal of Biochemistry 24: 19-28
Kikuchi K, Taniguchi Y, Hatanaka A, Sonoda E, Hochegger H, Adachi N, Matsuzaki
Y, Koyama H, van Gent DC, Jasin M, Takeda S (2005) Fen-1 facilitates
homologous recombination by removing divergent sequences at DNA break
ends. Mol Cell Biol 25: 6948-6955
Kim JM, Kakusho N, Yamada M, Kanoh Y, Takemoto N, Masai H (2008) Cdc7
kinase mediates Claspin phosphorylation in DNA replication checkpoint.
Oncogene 27: 3475-3482
Kimball SR, Do AN, Kutzler L, Cavener DR, Jefferson LS (2008) Rapid turnover of
the mTOR complex 1 (mTORC1) repressor REDD1 and activation of
mTORC1 signaling following inhibition of protein synthesis. J Biol Chem
283: 3465-3475
Kobayashi M, Hirano A, Kumano T, Xiang SL, Mihara K, Haseda Y, Matsui O,
Shimizu H, Yamamoto K (2004) Critical role for chicken Rad17 and Rad9 in
the cellular response to DNA damage and stalled DNA replication. Genes
Cells 9: 291-303
Kobayashi M, Ono H, Mihara K, Tauchi H, Komatsu K, Shibata T, Shimizu H,
Uchida K, Yamamoto K (2006) ATM activation by a sulfhydryl-reactive
inflammatory cyclopentenone prostaglandin. Genes Cells 11: 779-789
Kohzaki M, Hatanaka A, Sonoda E, Yamazoe M, Kikuchi K, Vu Trung N, Szuts D,
Sale JE, Shinagawa H, Watanabe M, Takeda S (2007) Cooperative roles of
vertebrate Fbh1 and Blm DNA helicases in avoidance of crossovers during209
recombination initiated by replication fork collapse. Mol Cell Biol 27:
2812-2820
Kosoy A, O'Connell MJ (2008) Regulation of Chk1 by its C-terminal domain. Mol
Biol Cell 19: 4546 - 4553
Kozak M (1987) An analysis of 5'-noncoding sequences from 699 vertebrate
messenger RNAs. Nucl Acids Res 15: 8125-8148
Kumagai A, Dunphy WG (2000) Claspin, a novel protein required for the
activation of Chk1 during a DNA replication checkpoint response in
Xenopus egg extracts. Mol Cell 6: 839-849
Kumagai A, Dunphy WG (2003) Repeated phosphopeptide motifs in Claspin
mediate the regulated binding of Chk1. Nat Cell Biol 5: 161-165
Kumagai A, Guo Z, Emami KH, Wang SX, Dunphy WG (1998) The Xenopus Chk1
protein kinase mediates a caffeine-sensitive pathway of checkpoint
control in cell-free extracts. J Cell Biol 142: 1559-1569
Kumagai A, Kim SM, Dunphy WG (2004) Claspin and the activated form of ATR-
ATRIP collaborate in the activation of Chk1. J Biol Chem 279: 49599-
49608
Kumagai A, Lee J, Yoo HY, Dunphy WG (2006) TopBP1 activates the ATR-ATRIP
complex. Cell 124: 943-955
Labib K, Tercero JA, Diffley JF (2000) Uninterrupted MCM2-7 Function Required
for DNA Replication Fork Progression. Science 288: 1643-1647
Lane D, Harlow E (1988) Antibodies, A Laboratory Manual: Cold Spring Harbor
Laboratory.
Lavin MF, Kozlov S (2007) ATM activation and DNA damage response. Cell Cycle
6: 931-942
Lazzaro F, Giannattasio M, Puddu F, Granata M, Pellicioli A, Plevani P, Muzi-
Falconi M (2009) Checkpoint mechanisms at the intersection between DNA
damage and repair. DNA Repair 8: 1055-1067
Lee J, Gold DA, Shevchenko A, Dunphy WG (2005) Roles of replication fork-
interacting and Chk1-activating domains from Claspin in a DNA replication
checkpoint response. Mol Biol Cell 16: 5269-5282
Lee J, Kumagai A, Dunphy WG (2001) Positive regulation of Wee1 by Chk1 and
14-3-3 proteins. Mol Biol Cell 12: 551-563
Lee J, Kumagai A, Dunphy WG (2003) Claspin, a Chk1-regulatory protein,
monitors DNA replication on chromatin independently of RPA, ATR, and
Rad17. Mol Cell 11: 329-340
Lee J, Kumagai A, Dunphy WG (2007) The Rad9-Hus1-Rad1 checkpoint clamp
regulates interaction of TopBP1 with ATR. J Biol Chem 282: 28036-28044
Lieber MR (2008) The Mechanism of Human Nonhomologous DNA End Joining.
Journal of Biological Chemistry 283: 1-5
Lin SY, Li K, Stewart GS, Elledge SJ (2004) Human Claspin works with BRCA1 to
both positively and negatively regulate cell proliferation. Proc Natl Acad
Sci U S A 101: 6484-6489
Lindsey-Boltz LA, SerÃ§in Ãz, Choi J-H, Sancar A (2009) Reconstitution of Human
Claspin-mediated Phosphorylation of Chk1 by the ATR (Ataxia
Telangiectasia-mutated and Rad3-related) Checkpoint Kinase. Journal of
Biological Chemistry 284: 33107-33114
Lisby M, Rothstein R (2009) Choreography of recombination proteins during the
DNA damage response. DNA Repair 8: 1068-1076
Liu S, Bekker-Jensen S, Mailand N, Lukas C, Bartek J, Lukas J (2006) Claspin
Operates Downstream of TopBP1 To Direct ATR Signaling towards Chk1
Activation. Mol Cell Biol 26: 6056-6064210
Liu Y, Jiang N, Wu J, Dai W, Rosenblum JS (2007) Polo-like Kinases Inhibited by
Wortmannin. Journal of Biological Chemistry 282: 2505-2511
Loeb LA, Bielas JH, Beckman RA, Bodmer IW (2008) Cancers Exhibit a Mutator
Phenotype: Clinical Implications. Cancer Res 68: 3551-3557
Lou H, Komata M, Katou Y, Guan Z, Reis CC, Budd M, Shirahige K, Campbell JL
(2008) Mrc1 and DNA Polymerase [var epsilon] Function Together in
Linking DNA Replication and the S Phase Checkpoint. Molecular Cell 32:
106-117
Lupardus PJ, Cimprich KA (2006) Phosphorylation of Xenopus Rad1 and Hus1
Defines a Readout for ATR Activation That Is Independent of Claspin and
the Rad9 Carboxy Terminus. Mol Biol Cell 17: 1559-1569
Mailand N, Bekker-Jensen S, Bartek J, Lukas J (2006) Destruction of Claspin by
SCF[beta]TrCP Restrains Chk1 Activation and Facilitates Recovery from
Genotoxic Stress. Molecular Cell 23: 307-318
Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, Lukas J (2000)
Rapid destruction of human Cdc25A in response to DNA damage. Science
288: 1425-1429
Mamely I, van Vugt MA, Smits VA, Semple JI, Lemmens B, Perrakis A, Medema
RH, Freire R (2006) Polo-like kinase-1 controls proteasome-dependent
degradation of Claspin during checkpoint recovery. Curr Biol 16: 1950-
1955
Manke IA, Lowery DM, Nguyen A, Yaffe MB (2003) BRCT Repeats As
Phosphopeptide-Binding Modules Involved in Protein Targeting. Science
302: 636-639
Mansour SL, Thomas KR, Capecchi MR (1988) Disruption of the proto-oncogene
int-2 in mouse embryo-derived stem cells: a general strategy for targeting
mutations to non-selectable genes. Nature 336: 348-352
Marsh A, Healey S, Lewis A, Spurdle A, Kedda M, Khanna K, kConFab, Mann G,
Pupo G, Lakhani S, Chenevix-Trench G (2007) Mutation analysis of five
candidate genes in familial breast cancer. Breast Cancer Research and
Treatment 105: 377-389
Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, Bishop DK (2007) RAD51
up-regulation bypasses BRCA1 function and is a common feature of BRCA1-
deficient breast tumors. Cancer Res 67: 9658-9665
Masabanda JS, Burt DW, O'Brien PCM, Vignal A, Fillon V, Walsh PS, Cox H,
Tempest HG, Smith J, Habermann F, Schmid M, Matsuda Y, Ferguson-
Smith MA, Crooijmans RPMA, Groenen MAM, Griffin DK (2004) Molecular
Cytogenetic Definition of the Chicken Genome: The First Complete Avian
Karyotype. Genetics 166: 1367-1373
McCarrick JW, 3rd, Parnes JR, Seong RH, Solter D, Knowles BB (1993) Positive-
negative selection gene targeting with the diphtheria toxin A-chain gene
in mouse embryonic stem cells. Transgenic Res 2: 183-190
McVey M, Lee SE (2008) MMEJ repair of double-strand breaks (director's cut):
deleted sequences and alternative endings. Trends Genet 24: 529-538
Mikhailov A, Cole RW, Rieder CL (2002) DNA damage during mitosis in human
cells delays the metaphase/anaphase transition via the spindle-assembly
checkpoint. Curr Biol 12: 1797-1806
Mohammad DH, Yaffe MB (2009) 14-3-3 proteins, FHA domains and BRCT domains
in the DNA damage response. DNA Repair 8: 1009-1017
Nakamura K, Sakai W, Kawamoto T, Bree RT, Lowndes NF, Takeda S, Taniguchi Y
(2006) Genetic dissection of vertebrate 53BP1: a major role in non-
homologous end joining of DNA double strand breaks. DNA Repair (Amst)
5: 741-749211
Namiki Y, Zou L (2006) ATRIP associates with replication protein A-coated ssDNA
through multiple interactions. Proceedings of the National Academy of
Sciences of the United States of America 103: 580-585
Naylor ML, Li J-m, Osborn AJ, Elledge SJ (2009) Mrc1 phosphorylation in response
to DNA replication stress is required for Mec1 accumulation at the stalled
fork. Proceedings of the National Academy of Sciences 106: 12765-12770
Ng CP, Lee HC, Ho CW, Arooz T, Siu WY, Lau A, Poon RY (2004) Differential
mode of regulation of the checkpoint kinases CHK1 and CHK2 by their
regulatory domains. J Biol Chem 279: 8808-8819
Nitani N, Nakamura K, Nakagawa C, Masukata H, Nakagawa T (2006) Regulation
of DNA replication machinery by Mrc1 in fission yeast. Genetics 174: 155-
165
Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M, Orelli
BJ, Bishop DK, Hirano S, Ohzeki M, Ishiai M, Yamamoto K, Takata M,
Arakawa H, Buerstedde JM, Yamazoe M, Kawamoto T, Araki K, Takahashi
JA, Hashimoto N, Takeda S, Sonoda E (2005) Multiple repair pathways
mediate tolerance to chemotherapeutic cross-linking agents in vertebrate
cells. Cancer Res 65: 11704-11711
Nurse P, Thuriaux P, Nasmyth K (1976) Genetic control of the cell division cycle
in the fission yeast Schizosaccharomyces pombe. Mol Gen Genet 146: 167-
178
O'Brien V, Brown R (2006) Signalling cell cycle arrest and cell death through the
MMR System. Carcinogenesis 27: 682-692
O'Connell MJ, Raleigh JM, Verkade HM, Nurse P (1997) Chk1 is a wee1 kinase in
the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation.
Embo J 16: 545-554
Oehler V (2008) Role of Chk1 and Chk2 in mitotic checkpoint control in
vertebrate cells. PhD Thesis. University of Glasgow,
Okada T, Sonoda E, Yamashita YM, Koyoshi S, Tateishi S, Yamaizumi M, Takata
M, Ogawa O, Takeda S (2002) Involvement of vertebrate polkappa in
Rad18-independent postreplication repair of UV damage. J Biol Chem
277: 48690-48695
Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M (2006)
Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling
Networks. Cell 127: 635-648
Osborn AJ, Elledge SJ (2003) Mrc1 is a replication fork component whose
phosphorylation in response to DNA replication stress activates Rad53.
Genes Dev 17: 1755-1767
Pellegrini M, Celeste A, Difilippantonio S, Guo R, Wang W, Feigenbaum L,
Nussenzweig A (2006) Autophosphorylation at serine 1987 is dispensable
for murine Atm activation in vivo. Nature 443: 222-225
Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H (1997) Mitotic
and G2 checkpoint control: regulation of 14-3-3 protein binding by
phosphorylation of Cdc25C on serine-216. Science 277: 1501-1505
Pereira E, Chen Y, Sanchez Y (2009) Conserved ATRMec1 phosphorylation-
independent activation of Chk1 by single amino acid substitution in the
GD domain. Cell Cycle 8: 1788-1793
Peschiaroli A, Dorrello NV, Guardavaccaro D, Venere M, Halazonetis T, Sherman
NE, Pagano M (2006) SCF[beta]TrCP-Mediated Degradation of Claspin
Regulates Recovery from the DNA Replication Checkpoint Response.
Molecular Cell 23: 319-329
Petermann E, Helleday T, Caldecott KW (2008) Claspin Promotes Normal
Replication Fork Rates in Human Cells. Mol Biol Cell 19: 2373-2378212
Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott
KW (2006) Chk1 requirement for high global rates of replication fork
progression during normal vertebrate S phase. Mol Cell Biol 26: 3319-3326
Rainey MD, Black EJ, Zachos G, Gillespie DA (2008) Chk2 is required for optimal
mitotic delay in response to irradiation-induced DNA damage incurred in
G2 phase. Oncogene 27: 896-906
Rao PN, Johnson RT (1970) Mammalian cell fusion: studies on the regulation of
DNA synthesis and mitosis. Nature 225: 159-164
Resnitzky D, Gossen M, Bujard H, Reed SI (1994) Acceleration of the G1/S phase
transition by expression of cyclins D1 and E with an inducible system. Mol
Cell Biol 14: 1669-1679
Rhind N, Furnari B, Russell P (1997) Cdc2 tyrosine phosphorylation is required for
the DNA damage checkpoint in fission yeast. Genes Dev 11: 504-511
Saka Y, Esashi F, Matsusaka T, Mochida S, Yanagida M (1997) Damage and
replication checkpoint control in fission yeast is ensured by interactions of
Crb2, a protein with BRCT motif, with Cut5 andâ€‰Chk1. Genes &
Development 11: 3387-3400
Salghetti SE, Young Kim S, Tansey WP (1999) Destruction of Myc by ubiquitin-
mediated proteolysis: cancer-associated and transforming mutations
stabilize Myc. EMBO J 18: 717-726
Samejima K, Ogawa H, Cooke CA, Hudson DF, Macisaac F, Ribeiro SA, Vagnarelli
P, Cardinale S, Kerr A, Lai F, Ruchaud S, Yue Z, Earnshaw WC (2008) A
promoter-hijack strategy for conditional shutdown of multiply spliced
essential cell cycle genes. Proc Natl Acad Sci U S A 105: 2457-2462
San Filippo J, Sung P, Klein H (2008) Mechanism of Eukaryotic Homologous
Recombination. Annual Review of Biochemistry 77: 229-257
Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ
(1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage
of DNA damage to Cdk regulation through Cdc25. Science 277: 1497-1501
Sar F, Lindsey-Boltz LA, Subramanian D, Croteau DL, Hutsell SQ, Griffith JD,
Sancar A (2004) Human claspin is a ring-shaped DNA-binding protein with
high affinity to branched DNA structures. J Biol Chem 279: 39289-39295
Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT
(1999) Inhibition of ATM and ATR Kinase Activities by the Radiosensitizing
Agent, Caffeine. Cancer Res 59: 4375-4382
Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT (1998)
Inhibition of phosphoinositide 3-kinase related kinases by the
radiosensitizing agent wortmannin. Cancer Res 58: 4375-4382
Sato Y, Kasai T, Nakagawa S, Tanabe K, Watanabe T, Kawakami K, Takahashi Y
(2007) Stable integration and conditional expression of electroporated
transgenes in chicken embryos. Developmental Biology 305: 616-624
Schwartz MF, Duong JK, Sun Z, Morrow JS, Pradhan D, Stern DF (2002) Rad9
Phosphorylation Sites Couple Rad53 to the Saccharomyces cerevisiae DNA
Damage Checkpoint. Molecular Cell 9: 1055-1065
Scorah J, Dong MQ, Yates JR, 3rd, Scott M, Gillespie D, McGowan CH (2008) A
conserved proliferating cell nuclear antigen-interacting protein sequence
in Chk1 is required for checkpoint function. J Biol Chem 283: 17250-17259
Scorah J, McGowan CH (2009) Claspin and Chk1 regulate replication fork stability
by different mechanisms. Cell Cycle 8: 1036-1043
Seki S, Ohzeki M, Uchida A, Hirano S, Matsushita N, Kitao H, Oda T, Yamashita T,
Kashihara N, Tsubahara A, Takata M, Ishiai M (2007) A requirement of
FancL and FancD2 monoubiquitination in DNA repair. Genes Cells 12: 299-
310213
Shikata M, Ishikawa F, Kanoh J (2007) Tel2 Is Required for Activation of the
Mrc1-mediated Replication Checkpoint. Journal of Biological Chemistry
282: 5346-5355
Shimmoto M, Matsumoto S, Odagiri Y, Noguchi E, Russell P, Masai H (2009)
Interactions between Swi1-Swi3, Mrc1 and S phase kinase, Hsk1 may
regulate cellular responses to stalled replication forks in fission yeast.
Genes Cells 14: 669-682
Shiotani B, Zou L (2009) ATR signaling at a glance. J Cell Sci 122: 301-304
Simpson LJ, Sale JE (2003) Rev1 is essential for DNA damage tolerance and non-
templated immunoglobulin gene mutation in a vertebrate cell line. Embo
J 22: 1654-1664
Skoufias DA, Lacroix FB, Andreassen PR, Wilson L, Margolis RL (2004) Inhibition
of DNA decatenation, but not DNA damage, arrests cells at metaphase.
Mol Cell 15: 977-990
Sonoda E, Matsusaka T, Morrison C, Vagnarelli P, Hoshi O, Ushiki T, Nojima K,
Fukagawa T, Waizenegger IC, Peters JM, Earnshaw WC, Takeda S (2001a)
Scc1/Rad21/Mcd1 is required for sister chromatid cohesion and
kinetochore function in vertebrate cells. Dev Cell 1: 759-770
Sonoda E, Morrison C, Yamashita YM, Takata M, Takeda S (2001b) Reverse
genetic studies of homologous DNA recombination using the chicken B-
lymphocyte line, DT40. Philos Trans R Soc Lond B Biol Sci 356: 111-117
Sonoda E, Okada T, Zhao GY, Tateishi S, Araki K, Yamaizumi M, Yagi T, Verkaik
NS, van Gent DC, Takata M, Takeda S (2003) Multiple roles of Rev3, the
catalytic subunit of polzeta in maintaining genome stability in
vertebrates. Embo J 22: 3188-3197
Sonoda E, Sasaki MS, Buerstedde J-M, Bezzubova O, Shinohara A, Ogawa H,
Takata M, Yamaguchi-Iwai Y, Takeda S (1998) Rad51-deficient vertebrate
cells accumulate chromosomal breaks prior to cell death. EMBO J 17: 598-
608
Sonoda E, Zhao GY, Kohzaki M, Dhar PK, Kikuchi K, Redon C, Pilch DR, Bonner
WM, Nakano A, Watanabe M, Nakayama T, Takeda S, Takami Y (2007)
Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in
homologous recombinational repair. DNA Repair (Amst) 6: 280-292
Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J,
Helleday T (2005) The cell-cycle checkpoint kinase Chk1 is required for
mammalian homologous recombination repair. Nat Cell Biol 7: 195-201
Spardy N, Covella K, Cha E, Hoskins EE, Wells SI, Duensing A, Duensing S (2009)
Human Papillomavirus 16 E7 Oncoprotein Attenuates DNA Damage
Checkpoint Control by Increasing the Proteolytic Turnover of Claspin.
Cancer Res 69: 7022-7029
Su X, Bernal JA, Venkitaraman AR (2008) Cell-cycle coordination between DNA
replication and recombination revealed by a vertebrate N-end rule
degron-Rad51. Nat Struct Mol Biol 15: 1049-1058
Sui G, Affar el B, Shi Y, Brignone C, Wall NR, Yin P, Donohoe M, Luke MP, Calvo
D, Grossman SR (2004) Yin Yang 1 is a negative regulator of p53. Cell 117:
859-872
Sun Y, Xu Y, Roy K, Price BD (2007) DNA damage-induced acetylation of lysine
3016 of ATM activates ATM kinase activity. Mol Cell Biol 27: 8502-8509
Sung P, Klein H (2006) Mechanism of homologous recombination: mediators and
helicases take on regulatory functions. Nat Rev Mol Cell Biol 7: 739-750
Szyjka SJ, Viggiani CJ, Aparicio OM (2005) Mrc1 Is Required for Normal
Progression of Replication Forks throughout Chromatin in S. cerevisiae.
Molecular Cell 19: 691-697214
Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T,
Ikeda K, Nakayama K, Nakanishi M, Nakayama K-i (2000) Aberrant cell
cycle checkpoint function and early embryonic death in Chk1‐/‐
mice. Genes & Development 14: 1439-1447
Takao N, Kato H, Mori R, Morrison C, Sonada E, Sun X, Shimizu H, Yoshioka K,
Takeda S, Yamamoto K (1999) Disruption of ATM in p53-null cells causes
multiple functional abnormalities in cellular response to ionizing
radiation. Oncogene 18: 7002-7009
Takata M, Sasaki MS, Sonoda E, Fukushima T, Morrison C, Albala JS,
Swagemakers SM, Kanaar R, Thompson LH, Takeda S (2000) The Rad51
paralog Rad51B promotes homologous recombinational repair. Mol Cell
Biol 20: 6476-6482
Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, Yamaguchi-
Iwai Y, Shinohara A, Takeda S (1998) Homologous recombination and non-
homologous end-joining pathways of DNA double-strand break repair have
overlapping roles in the maintenance of chromosomal integrity in
vertebrate cells. Embo J 17: 5497-5508
Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, Schild D, Thompson LH,
Takeda S (2001) Chromosome instability and defective recombinational
repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 21:
2858-2866
Tanaka K, Hirota T (2009) Chromosome segregation machinery and cancer.
Cancer Sci 100: 1158-1165
Tanaka K, Russell P (2001) Mrc1 channels the DNA replication arrest signal to
checkpoint kinase Cds1. 3: 966-972
Tanaka K, Russell P (2004) Cds1 Phosphorylation by Rad3-Rad26 Kinase Is
Mediated by Forkhead-associated Domain Interaction with Mrc1. Journal
of Biological Chemistry 279: 32079-32086
Tanikawa J, Ichikawa-Iwata E, Kanei-Ishii C, Nakai A, Matsuzawa S-i, Reed JC,
Ishii S (2000) p53 Suppresses the c-Myb-induced Activation of Heat Shock
Transcription Factor 3. Journal of Biological Chemistry 275: 15578-15585
Tano K, Nakamura J, Asagoshi K, Arakawa H, Sonoda E, Braithwaite EK, Prasad
R, Buerstedde JM, Takeda S, Watanabe M, Wilson SH (2007) Interplay
between DNA polymerases beta and lambda in repair of oxidation DNA
damage in chicken DT40 cells. DNA Repair (Amst) 6: 869-875
Tauchi H, Kobayashi J, Morishima K, van Gent DC, Shiraishi T, Verkaik NS,
vanHeems D, Ito E, Nakamura A, Sonoda E, Takata M, Takeda S, Matsuura
S, Komatsu K (2002) Nbs1 is essential for DNA repair by homologous
recombination in higher vertebrate cells. Nature 420: 93-98
Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T,
Sabatini DM, Gray NS (2009) An ATP-competitive mammalian target of
rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J
Biol Chem 284: 8023-8032
Thoreen CC, Sabatini DM (2009) Rapamycin inhibits mTORC1, but not
completely. Autophagy 5: 725-726
Tsimaratou K, Kletsas D, Kastrinakis NG, Tsantoulis PK, Evangelou K, Sideridou
M, Liontos M, Poulias I, Venere M, Salmas M, Kittas C, Halazonetis TD,
Gorgoulis VG (2007) Evaluation of claspin as a proliferation marker in
human cancer and normal tissues. The Journal of Pathology 211: 331-339
Unsal-Kacmaz K, Chastain PD, Qu P-P, Minoo P, Cordeiro-Stone M, Sancar A,
Kaufmann WK (2007) The Human Tim/Tipin Complex Coordinates an Intra-
S Checkpoint Response to UV That Slows Replication Fork Displacement.
Mol Cell Biol 27: 3131-3142215
Verbeek B, Southgate TD, Gilham DE, Margison GP (2008) O6-Methylguanine-DNA
methyltransferase inactivation and chemotherapy. Br Med Bull 85: 17-33
Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K,
De Wolf-Peeters C, Christiaens M-R, Michiels L, Bouillon R, Verstuyf A
(2007) The E2F-Regulated Gene Chk1 Is Highly Expressed in Triple-
Negative Estrogen Receptor /Progesterone Receptor /HER-2 Breast
Carcinomas. Cancer Res 67: 6574-6581
Wakasugi M, Matsuura K, Nagasawa A, Fu D, Shimizu H, Yamamoto K-i, Takeda S,
Matsunaga T (2007) DDB1 gene disruption causes a severe growth defect
and apoptosis in chicken DT40 cells. Biochemical and Biophysical Research
Communications 364: 771-777
Walker M, Black EJ, Oehler V, Gillespie DA, Scott MT (2009) Chk1 C-terminal
regulatory phosphorylation mediates checkpoint activation by de-
repression of Chk1 catalytic activity. Oncogene 28: 2314-2323
Walworth N, Davey S, Beach D (1993) Fission yeast chk1 protein kinase links the
rad checkpoint pathway to cdc2. Nature 363: 368-371
Wang SX, Dunphy WG (2000) Activation of Xenopus Chk1 by mutagenesis of
threonine-377. FEBS Letters 487: 277-281
Wang W, Seki M, Narita Y, Sonoda E, Takeda S, Yamada K, Masuko T, Katada T,
Enomoto T (2000) Possible association of BLM in decreasing DNA double
strand breaks during DNA replication. Embo J 19: 3428-3435
Wang X, Zou L, Lu T, Bao S, Hurov KE, Hittelman WN, Elledge SJ, Li L (2006)
Rad17 Phosphorylation Is Required for Claspin Recruitment and Chk1
Activation in Response to Replication Stress. Molecular Cell 23: 331-341
Winding P, Berchtold MW (2001) The chicken B cell line DT40: a novel tool for
gene disruption experiments. J Immunol Methods 249: 1-16
Xu Y-j, Kelly TJ (2009) Autoinhibition and Autoactivation of the DNA Replication
Checkpoint Kinase Cds1. Journal of Biological Chemistry 284: 16016-
16027
Xu Y, Davenport M, Kelly TJ (2006) Two-stage mechanism for activation of the
DNA replication checkpoint kinase Cds1 in fission yeast. Genes &
Development 20: 990-1003
Yamaguchi-Iwai Y, Sonoda E, Buerstedde JM, Bezzubova O, Morrison C, Takata
M, Shinohara A, Takeda S (1998) Homologous recombination, but not DNA
repair, is reduced in vertebrate cells deficient in RAD52. Mol Cell Biol 18:
6430-6435
Yamaguchi-Iwai Y, Sonoda E, Sasaki MS, Morrison C, Haraguchi T, Hiraoka Y,
Yamashita YM, Yagi T, Takata M, Price C, Kakazu N, Takeda S (1999)
Mre11 is essential for the maintenance of chromosomal DNA in vertebrate
cells. Embo J 18: 6619-6629
Yamamoto K, Hirano S, Ishiai M, Morishima K, Kitao H, Namikoshi K, Kimura M,
Matsushita N, Arakawa H, Buerstedde JM, Komatsu K, Thompson LH,
Takata M (2005) Fanconi anemia protein FANCD2 promotes
immunoglobulin gene conversion and DNA repair through a mechanism
related to homologous recombination. Mol Cell Biol 25: 34-43
Yamamoto K, Ishiai M, Matsushita N, Arakawa H, Lamerdin JE, Buerstedde JM,
Tanimoto M, Harada M, Thompson LH, Takata M (2003) Fanconi anemia
FANCG protein in mitigating radiation- and enzyme-induced DNA double-
strand breaks by homologous recombination in vertebrate cells. Mol Cell
Biol 23: 5421-5430
Yamashita YM, Okada T, Matsusaka T, Sonoda E, Zhao GY, Araki K, Tateishi S,
Yamaizumi M, Takeda S (2002) RAD18 and RAD54 cooperatively contribute216
to maintenance of genomic stability in vertebrate cells. Embo J 21: 5558-
5566
Yamazoe M, Sonoda E, Hochegger H, Takeda S (2004) Reverse genetic studies of
the DNA damage response in the chicken B lymphocyte line DT40. DNA
Repair (Amst) 3: 1175-1185
Yan S, Lindsay HD, Michael WM (2006) Direct requirement for Xmus101 in ATR-
mediated phosphorylation of Claspin bound Chk1 during checkpoint
signaling. J Cell Biol
Yang XH, Shiotani B, Classon M, Zou L (2008) Chk1 and Claspin potentiate PCNA
ubiquitination. Genes Dev 22: 1147-1152
Yoo HY, Jeong S-Y, Dunphy WG (2006) Site-specific phosphorylation of a
checkpoint mediator protein controls its responses to different DNA
structures. Genes & Development 20: 772-783
Yoo HY, Kumagai A, Shevchenko A, Dunphy WG (2004) Adaptation of a DNA
replication checkpoint response depends upon inactivation of Claspin by
the Polo-like kinase. Cell 117: 575-588
Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG (2007) Ataxia-
telangiectasia Mutated (ATM)-dependent Activation of ATR Occurs through
Phosphorylation of TopBP1 by ATM. Journal of Biological Chemistry 282:
17501-17506
Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG (2009) The Mre11-
Rad50-Nbs1 Complex Mediates Activation of TopBP1 by ATM. Mol Biol Cell
20: 2351-2360
Yoshimura M, Kohzaki M, Nakamura J, Asagoshi K, Sonoda E, Hou E, Prasad R,
Wilson SH, Tano K, Yasui A, Lan L, Seki M, Wood RD, Arakawa H,
Buerstedde JM, Hochegger H, Okada T, Hiraoka M, Takeda S (2006)
Vertebrate POLQ and POLbeta cooperate in base excision repair of
oxidative DNA damage. Mol Cell 24: 115-125
Yoshizawa-Sugata N, Masai H (2007) Human Tim/Timeless-interacting Protein,
Tipin, Is Required for Efficient Progression of S Phase and DNA Replication
Checkpoint. Journal of Biological Chemistry 282: 2729-2740
Yuan J, Wang X, Zhang Y, Hu X, Fei J, Li N (2006) Mammalian Pol III Promoter H1
can Transcribe shRNA Inducing RNAi in Chicken Cells. Molecular Biology
Reports 33: 33-41
Yun MH, Hiom K (2009) CtIP-BRCA1 modulates the choice of DNA double-strand-
break repair pathway throughout the cell cycle. Nature 459: 460-463
Zachos G, Rainey MD, Gillespie DA (2003) Chk1-deficient tumour cells are viable
but exhibit multiple checkpoint and survival defects. Embo J 22: 713-723
Zachos G, Rainey MD, Gillespie DA (2005) Chk1-dependent S-M checkpoint delay
in vertebrate cells is linked to maintenance of viable replication
structures. Mol Cell Biol 25: 563-574
Zhai B, VillÃ©n J, Beausoleil SA, Mintseris J, Gygi SP (2008) Phosphoproteome
Analysis of Drosophila melanogaster Embryos. Journal of Proteome
Research 7: 1675-1682
Zhang D, Zaugg K, Mak TW, Elledge SJ (2006) A Role for the Deubiquitinating
Enzyme USP28 in Control of the DNA-Damage Response. Cell 126: 529-542
Zhang J, Song Y-H, Brannigan BW, Wahrer DCR, Schiripo TA, Harris PL, Haserlat
SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L,
Sgroi DC, Haber DA, Bell DW (2009) Prevalence and Functional Analysis of
Sequence Variants in the ATR Checkpoint Mediator Claspin. Molecular
Cancer Research 7: 1510-1516217
Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, Reth M (1996)
Inducible site-directed recombination in mouse embryonic stem cells.
Nucleic Acids Res 24: 543-548
Zhao H, Piwnica-Worms H (2001) ATR-mediated checkpoint pathways regulate
phosphorylation and activation of human Chk1. Mol Cell Biol 21: 4129 -
4139
Zhao H, Russell P (2004) DNA binding domain in the replication checkpoint
protein Mrc1 of Schizosaccharomyces pombe. J Biol Chem 279: 53023-
53027
Zhao H, Tanaka K, Nogochi E, Nogochi C, Russell P (2003) Replication Checkpoint
Protein Mrc1 Is Regulated by Rad3 and Tel1 in Fission Yeast. Mol Cell Biol
23: 8395-8403